{
 "cells": [
  {
   "cell_type": "code",
   "id": "initial_id",
   "metadata": {
    "collapsed": true,
    "ExecuteTime": {
     "end_time": "2024-11-09T15:28:25.322165Z",
     "start_time": "2024-11-09T15:28:13.888972Z"
    }
   },
   "source": [
    "import pandas as pd\n",
    "\n",
    "df = pd.read_excel('drug_df.xlsx')\n",
    "df.columns"
   ],
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['Unnamed: 0', '@type', '@created', '@updated', 'drugbank-id', 'name',\n",
       "       'description', 'cas-number', 'unii', 'state', 'groups',\n",
       "       'general-references', 'synthesis-reference', 'indication',\n",
       "       'pharmacodynamics', 'mechanism-of-action', 'toxicity', 'metabolism',\n",
       "       'absorption', 'half-life', 'protein-binding', 'route-of-elimination',\n",
       "       'volume-of-distribution', 'clearance', 'classification', 'salts',\n",
       "       'synonyms', 'products', 'international-brands', 'mixtures', 'packagers',\n",
       "       'manufacturers', 'prices', 'categories', 'affected-organisms',\n",
       "       'dosages', 'atc-codes', 'ahfs-codes', 'pdb-entries', 'patents',\n",
       "       'food-interactions', 'drug-interactions', 'sequences',\n",
       "       'experimental-properties', 'external-identifiers', 'external-links',\n",
       "       'pathways', 'reactions', 'snp-effects', 'snp-adverse-drug-reactions',\n",
       "       'targets', 'enzymes', 'carriers', 'transporters', 'fda-label', 'msds',\n",
       "       'average-mass', 'monoisotopic-mass', 'calculated-properties'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "execution_count": 1
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-11-09T15:30:27.076305Z",
     "start_time": "2024-11-09T15:30:27.039938Z"
    }
   },
   "cell_type": "code",
   "source": [
    "pd.set_option('display.max_columns', None)\n",
    "pd.set_option('display.max_colwidth', None)  # Increase to 200 characters per column\n",
    "\n",
    "for col in df.columns:\n",
    "    print(df[col].head())"
   ],
   "id": "74d437129e4f51e7",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0    0\n",
      "1    1\n",
      "2    2\n",
      "3    3\n",
      "4    4\n",
      "Name: Unnamed: 0, dtype: int64\n",
      "0    biotech\n",
      "1    biotech\n",
      "2    biotech\n",
      "3    biotech\n",
      "4    biotech\n",
      "Name: @type, dtype: object\n",
      "0    2005-06-13\n",
      "1    2005-06-13\n",
      "2    2005-06-13\n",
      "3    2005-06-13\n",
      "4    2005-06-13\n",
      "Name: @created, dtype: object\n",
      "0    2024-01-02\n",
      "1    2024-01-02\n",
      "2    2024-03-13\n",
      "3    2024-01-02\n",
      "4    2024-02-02\n",
      "Name: @updated, dtype: object\n",
      "0    [{'@primary': 'true', '#text': 'DB00001'}, 'BTD00024', 'BIOD00024']\n",
      "1    [{'@primary': 'true', '#text': 'DB00002'}, 'BTD00071', 'BIOD00071']\n",
      "2    [{'@primary': 'true', '#text': 'DB00003'}, 'BTD00001', 'BIOD00001']\n",
      "3    [{'@primary': 'true', '#text': 'DB00004'}, 'BTD00084', 'BIOD00084']\n",
      "4    [{'@primary': 'true', '#text': 'DB00005'}, 'BTD00052', 'BIOD00052']\n",
      "Name: drugbank-id, dtype: object\n",
      "0              Lepirudin\n",
      "1              Cetuximab\n",
      "2           Dornase alfa\n",
      "3    Denileukin diftitox\n",
      "4             Etanercept\n",
      "Name: name, dtype: object\n",
      "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end).[A246609] \\r\\n\\r\\nLepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]\n",
      "1    Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF).[A227973] EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and homeostasis.[A228083] EGFR has been implicated in various types of cancer, as it is often overexpressed in malignant cells [A227973] and EGFR overexpression has been linked to more advanced disease and poor prognosis.[A227963] EGFR is often mutated in certain types of cancer and serves as a driver of tumorigenesis.[A228083] _In vitro_, cetuximab was shown to mediate anti-tumour effects in numerous cancer cell lines and human tumour xenografts.[A227963]\\r\\n\\r\\nApproved by the FDA in February 2004 under the brand name ERBITUX, cetuximab is used for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.[A227963,L39045] It has also been investigated in advanced colorectal cancer, EGFR-expressing non-small cell lung cancer (NSCLC), and unresectable squamous cell skin cancer.[L31418] Cetuximab is administered via intravenous infusion and is used as monotherapy or in combination with other chemotherapies, including platinum agents, radiation therapy, [leucovorin], [fluorouracil], and [irinotecan].[L30448]\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections. Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity.\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.\n",
      "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).\n",
      "Name: description, dtype: object\n",
      "0    138068-37-8\n",
      "1    205923-56-4\n",
      "2    143831-71-4\n",
      "3    173146-27-5\n",
      "4    185243-69-0\n",
      "Name: cas-number, dtype: object\n",
      "0    Y43GF64R34\n",
      "1    PQX0D8J21J\n",
      "2    953A26OA1Y\n",
      "3    25E79B5CTM\n",
      "4    OP401G7OJC\n",
      "Name: unii, dtype: object\n",
      "0     solid\n",
      "1    liquid\n",
      "2    liquid\n",
      "3    liquid\n",
      "4    liquid\n",
      "Name: state, dtype: object\n",
      "0          {'group': ['approved', 'withdrawn']}\n",
      "1                         {'group': 'approved'}\n",
      "2                         {'group': 'approved'}\n",
      "3    {'group': ['approved', 'investigational']}\n",
      "4    {'group': ['approved', 'investigational']}\n",
      "Name: groups, dtype: object\n",
      "0                                                                                                                                                                                                                                                                                                                                                                                                                                                      {'articles': {'article': [{'ref-id': 'A1', 'pubmed-id': '16244762', 'citation': 'Smythe MA, Stephens JL, Koerber JM, Mattson JC: A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost. 2005 Oct;11(4):371-4.'}, {'ref-id': 'A2', 'pubmed-id': '16690967', 'citation': 'Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, Francois D, Racadot E, Camarasa P, Blouch MT, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, de Maistre E, Grunebaum L, Mouton C, Huisse MG, Gouault-Heilmann M, Lucke V: Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006 Sep 1;108(5):1492-6. Epub 2006 May 11.'}, {'ref-id': 'A3', 'pubmed-id': '16241940', 'citation': 'Lubenow N, Eichler P, Lietz T, Greinacher A: Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005 Nov;3(11):2428-36.'}, {'ref-id': 'A246609', 'pubmed-id': '19707378', 'citation': 'Petros S: Lepirudin in the management of patients with heparin-induced thrombocytopenia. Biologics. 2008 Sep;2(3):481-90. doi: 10.2147/btt.s3415.'}, {'ref-id': 'A246624', 'pubmed-id': '25294122', 'citation': 'Chapin JC, Hajjar KA: Fibrinolysis and the control of blood coagulation. Blood Rev. 2015 Jan;29(1):17-24. doi: 10.1016/j.blre.2014.09.003. Epub 2014 Sep 16.'}]}, 'textbooks': None, 'links': {'link': [{'ref-id': 'L48', 'title': 'Google books', 'url': 'http://books.google.com/books?id=iadLoXoQkWEC&pg=PA440'}, {'ref-id': 'L41539', 'title': 'Health Canada Approved Drug Products: Refludan (lepirudin) lyophilized powder for intravenous injection', 'url': 'https://pdf.hres.ca/dpd_pm/00004023.PDF'}, {'ref-id': 'L41544', 'title': 'FDA Clinical Pharmacology and Biopharmaceutics Review: Refludan (lepirudin) lyophilized powder for intravenous injection', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20807_Refludan_biopharmr.pdf'}, {'ref-id': 'L41569', 'title': 'EMA Summary of Product Characteristics: Refludan (lepirudin) powder for intravenous injection or infusion', 'url': 'https://www.ema.europa.eu/en/documents/product-information/refludan-epar-product-information_en.pdf'}, {'ref-id': 'L41574', 'title': 'Bayer HealthCare: Discontinuation of Refludan [lepirudin (rDNA) for injection]', 'url': 'https://www.hrsa.gov/sites/default/files/opa/programrequirements/manufacturerletters/2012/refludan05312012.pdf'}]}, 'attachments': None}\n",
      "1    {'articles': {'article': [{'ref-id': 'A9', 'pubmed-id': '11752352', 'citation': 'Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.'}, {'ref-id': 'A11', 'pubmed-id': '16336752', 'citation': 'Snyder LC, Astsaturov I, Weiner LM: Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80.'}, {'ref-id': 'A227963', 'pubmed-id': '16117976', 'citation': 'Wong SF: Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther. 2005 Jun;27(6):684-94. doi: 10.1016/j.clinthera.2005.06.003.'}, {'ref-id': 'A227973', 'pubmed-id': '15821783', 'citation': 'Harding J, Burtness B: Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc). 2005 Feb;41(2):107-27. doi: 10.1358/dot.2005.41.2.882662.'}, {'ref-id': 'A227978', 'pubmed-id': '16428506', 'citation': 'Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, Myers JN: Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res. 2006 Jan 15;12(2):600-7. doi: 10.1158/1078-0432.CCR-05-1325.'}, {'ref-id': 'A40006', 'pubmed-id': '28653357', 'citation': 'Ryman JT, Meibohm B: Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588. doi: 10.1002/psp4.12224. Epub 2017 Jul 29.'}, {'ref-id': 'A228003', 'pubmed-id': '18218786', 'citation': 'Dirks NL, Nolting A, Kovar A, Meibohm B: Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol. 2008 Mar;48(3):267-78. doi: 10.1177/0091270007313393. Epub 2008 Jan 24.'}, {'ref-id': 'A228078', 'pubmed-id': '20088790', 'citation': 'Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S: Cetuximab: from bench to bedside. Curr Cancer Drug Targets. 2010 Feb;10(1):80-95. doi: 10.2174/156800910790980241.'}, {'ref-id': 'A228083', 'pubmed-id': '29124875', 'citation': 'Sigismund S, Avanzato D, Lanzetti L: Emerging functions of the EGFR in cancer. Mol Oncol. 2018 Jan;12(1):3-20. doi: 10.1002/1878-0261.12155. Epub 2017 Nov 27.'}]}, 'textbooks': None, 'links': {'link': [{'ref-id': 'L31408', 'title': 'Bristol-Myers Squibb Company: Cetuximab Safety Data Sheet', 'url': 'https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/SDS_9BRMY_ERBITUX.pdf'}, {'ref-id': 'L30448', 'title': 'FDA Approved Drug Products: ERBITUX (cetuximab) injection, for intravenous use', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125084s275lbl.pdf'}, {'ref-id': 'L31418', 'title': 'StatPearls: Cetuximab', 'url': 'https://www.ncbi.nlm.nih.gov/books/NBK459293/'}, {'ref-id': 'L39045', 'title': 'FDA Approved Drug Products: ERBITUX (cetuximab) injection, for intravenous use', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf'}]}, 'attachments': None}\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   {'articles': {'article': [{'ref-id': 'A12', 'pubmed-id': '8792953', 'citation': 'Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61.'}, {'ref-id': 'A13', 'pubmed-id': '20238314', 'citation': 'Jones AP, Wallis C: Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD001127. doi: 10.1002/14651858.CD001127.pub2.'}, {'ref-id': 'A14', 'pubmed-id': '19255515', 'citation': 'Riethmueller J, Kumpf M, Borth-Bruhns T, Brehm W, Wiskirchen J, Sieverding L, Ankele C, Hofbeck M, Baden W: Clinical and in vitro effect of dornase alfa in mechanically ventilated pediatric non-cystic fibrosis patients with atelectases. Cell Physiol Biochem. 2009;23(1-3):205-10. doi: 10.1159/000204109. Epub 2009 Feb  18.'}]}, 'textbooks': None, 'links': None, 'attachments': None}\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        {'articles': {'article': [{'ref-id': 'A15', 'pubmed-id': '17187516', 'citation': 'Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7.'}, {'ref-id': 'A16', 'pubmed-id': '17454642', 'citation': 'Park M, Liu GT, Piltz-Seymour J, Wisda CL, Rook AH, Junkins-Hopkins JM, Nasta SD, Kim EJ: Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy. Leuk Lymphoma. 2007 Apr;48(4):808-11.'}]}, 'textbooks': None, 'links': None, 'attachments': None}\n",
      "4                                                                                                                                                                                                                              {'articles': {'article': [{'ref-id': 'A202010', 'pubmed-id': '27463856', 'citation': 'Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.'}, {'ref-id': 'A215352', 'pubmed-id': '20852002', 'citation': 'Zhou SY, Shu C, Korth-Bradley J, Raible D, Palmisano M, Wadjula J, Fatenejad S, Bjornsson T: Integrated population pharmacokinetics of etanercept in healthy subjects and in patients with rheumatoid arthritis and ankylosing spondylitis. J Clin Pharmacol. 2011 Jun;51(6):864-75. doi: 10.1177/0091270010375961. Epub 2010 Sep 17.'}, {'ref-id': 'A215357', 'pubmed-id': '15703360', 'citation': 'Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H: Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol. 2005 Mar;45(3):246-56. doi: 10.1177/0091270004271945.'}, {'ref-id': 'A215657', 'pubmed-id': '10676822', 'citation': 'Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME: The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother. 2000 Feb;34(2):161-4. doi: 10.1345/aph.19126.'}, {'ref-id': 'A216522', 'pubmed-id': '17916444', 'citation': 'Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, Gjertson D, Braun J, Reed E, Singh RR: TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008 Feb;126(2):121-36. doi: 10.1016/j.clim.2007.08.013. Epub 2007 Oct 3.'}, {'ref-id': 'A77626', 'pubmed-id': '8387891', 'citation': \"Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, Loetscher H, Lesslauer W: Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell. 1993 May 7;73(3):431-45.\"}]}, 'textbooks': None, 'links': {'link': [{'ref-id': 'L14862', 'title': 'FDA Approved Drug Products: Enbrel (etanercept) injection solution', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103795s5574s5577lbl.pdf'}, {'ref-id': 'L45523', 'title': 'Health Canada Approved Drug Products: RYMTI (etanercept) solution for injection (August 2022)', 'url': 'https://pdf.hres.ca/dpd_pm/00068678.PDF'}, {'ref-id': 'L48526', 'title': 'FDA Approved Drug Products: ENBREL® (etanercept) injection, for subcutaneous use (October 2023)', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103795s5595lbl.pdf'}, {'ref-id': 'L12948', 'title': 'FDA Approved Drug Products: Erelzi (etanercept) injection', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761042s010lbl.pdf'}]}, 'attachments': None}\n",
      "Name: general-references, dtype: object\n",
      "0    Recombinant hirudin expressed by using yeast secretary (China Patent No. CN1371994A, 2001). China National Intellectual Property Administration. https://patents.google.com/patent/CN1371994A/en\n",
      "1                                                                                                                                                                                                 NaN\n",
      "2                                                                                                                                                                                                 NaN\n",
      "3                                                                                                                                                                                                 NaN\n",
      "4                Timothy D. Osslund, Christi L. Clogston, Shon Lee Crampton, Randal B. Bass, \"Crystals of etanercept and methods of making thereof.\" U.S. Patent US07276477, issued October 02, 2007.\n",
      "Name: synthesis-reference, dtype: object\n",
      "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Lepirudin is indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation. In patients with ACS, lepirudin is intended for use with [aspirin].[L41539] Lepirudin is also indicated for anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease in order to prevent further thromboembolic complications.[L41539]\n",
      "1    Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.[L30448]\\r\\n\\r\\nCetuximab is also indicated for K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI, a chemotherapy combination that includes [leucovorin], [fluorouracil], and [irinotecan]; in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy; or as monotherapy in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.[L30448]\\r\\n\\r\\nAdditionally, cetuximab is also indicated for metastatic colorectal cancer that is BRAF V600E mutation-positive (as determined by an FDA-approved test) in combination with [encorafenib] but only after prior therapy.[L39045]\\r\\n\\r\\nCetuximab is not indicated for the treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown.[L30448]\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Used as adjunct therapy in the treatment of cystic fibrosis.\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 For treatment of cutaneous T-cell lymphoma\n",
      "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older.[L14862,L45523] It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis.[L48526]\n",
      "Name: indication, dtype: object\n",
      "0    Lepirudin is a recombinant hirudin that acts as a highly specific thrombin inhibitor. Its activity is measured by anti-thrombin units (ATUs) that correspond to the amount of lepirudin required to neutralize a unit of the World Health Organization α-thrombin (89/588) standard. The activity of lepirudin is 16,000 ATU/mg.[L41539,L41569] A single molecule of lepirudin binds to a molecule of thrombin, blocking its thrombogenic activity. This drug increases activated partial thromboplastin time (aPTT)  and PT (INR) values in a dose-dependent manner, and its mode of action is independent of antithrombin III.[L41539,L41569] Platelet factor 4 does not inhibit lepirudin.[L41539,L41569]\\r\\n\\r\\nThe pharmacodynamic effect of lepirudin was evaluated by measuring an increase in aPTT. No saturable effect was observed at the highest tested dose (0.5 mg/kg, IV bolus).[L41539] Thrombin time was considered an unsuitable routine test for lepirudin monitoring due to the high values detected (200 seconds) even at low doses.[L41539] The concomitant use of thrombolytic therapy and lepirudin is not recommended due to the high risk of bleeding that may be life-threatening. In patients with a risk of bleeding, a physician should weigh the risks of lepirudin administration against its benefits.  There is also an especially high risk of bleeding in patients who weigh less than 50 kg, and a lower dosage is required. Patients with renal impairment have a higher risk of hemorrhagic adverse events.[L41539]\n",
      "1                                                                                                                                                                                                                                                                 Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.[L31418] Cetuximab works by inhibiting the growth and survival of EGFR-positive tumours.[A227963] _In vitro_, it promotes antibody-dependent cellular cytotoxicity (ADCC) against certain human tumour types. On the contrary, cetuximab does not exert its anti-tumour effects on human tumour xenografts lacking EGFR expression.[A227963, L30448]\\r\\n\\r\\nCetuximab potentiates the cytotoxic effects of chemotherapeutics and radiation therapy when used in combination.[L30448] In human tumour xenograft models in mice, cetuximab and irinotecan synergistically inhibited the growth of orthotopic anaplastic thyroid carcinoma xenografts _in vitro_ and _in vivo_. Cetuximab potentiated the _in vitro_ anti-proliferative and pro-apoptotic effect of irinotecan and achieved 93% _in vivo_ inhibition of tumour growth when combined with irinotecan, compared to 77% and 79% inhibition when cetuximab and irinotecan were used alone, respectively.[A227978]\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Cystic fibrosis (CF) is a disease characterized by the retention of viscous purulent secretions in the airways. These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to these infections. Dornase alfa hydrolyzes the DNA in sputum of CF patients and reduces sputum viscosity and viscoelasticity. The enzyme does not appear to affect sputum in the absence of an inflammatory response to infection, nor does it affect the sputum of healthy individuals.\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Denileukin diftitox (Ontak) directs the cytocidal action of diphtheria toxin to cells which express the IL-2 receptor. The human IL-2 receptor exists in three forms, low (CD25), intermediate (CD122/CD132) and high (CD25/CD122/CD132) affinity. Malignant cells expressing one or more of the subunits of the IL-2 receptor are found in certain leukemias and lymphomas including cutaneous T-cell lymphoma (CTCL). Ontak interacts with the high affinity IL-2 receptor on the cell surface and inhibits cellular protein synthesis, resulting in cell death within hours.\n",
      "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Etanercept binds specifically to tumor necrosis factor (TNF) and thereby modulates biological processes that are induced or regulated by TNF.[L14862,A216522] Such processes or molecules affected include the level of adhesion molecules expressed, as well as serum levels of cytokines and matrix metalloproteinases.\n",
      "Name: pharmacodynamics, dtype: object\n",
      "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Lepirudin is a direct thrombin inhibitor used as an anticoagulant in patients for whom heparin is contraindicated.[L41539,A3] Thrombin is a serine protease that participates in the blood-clotting cascade, and it is formed by the cleavage of pro-thrombin. Active thrombin cleaves fibrinogen and generates fibrin monomers that polymerize to form fibrin clots.[A246624]\\r\\n\\r\\nLepirudin binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex.[A246609] This blocks the protease activity of thrombin and inhibits the coagulation process. Each molecule of lepirudin binds to a single molecule of thrombin,[L41539] and unlike [heparin], it is able to inhibit thrombin in both its clot-bound or free states.[A246609]\n",
      "1    The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a type I receptor tyrosine kinase expressed on both normal and malignant cells. It has been investigated as a therapeutic target for anticancer treatment, as it is often upregulated in cancer types, including head and neck, colon, and rectal cancers.[L30448] When activated by its ligand, EGFR undergoes a conformational change and dimerization to form homodimers or heterodimers with another member of the ErbB family of receptors. Dimerization of EGFR activates the intracellular tyrosine kinase region of EGFR and promotes autophosphorylation, initiating a series of downstream signalling cascades, including cell differentiation, proliferation, migration, angiogenesis, and apoptosis. This EGFR signalling pathway is often dysregulated in cancer cells, leading to aberrant cell growth and enhanced cell survival.[L31418]\\r\\n\\r\\nCetuximab is a monoclonal antibody that binds specifically to the EGFR on both normal and tumour cells to competitively inhibit the binding of epidermal growth factor (EGF) and other ligands that are produced by normal and tumour tissue epithelial cells.[A11, L30448] Upon binding to domain III of EGFR - which is the binding site for its growth factor ligands - cetuximab prevents the receptor from adopting an extended conformation and thereby inhibits EGFR activation, as well as phosphorylation and activation of receptor-associated kinases (MAPK, PI3K/Akt, Jak/Stat).[A11, A228078] Inhibition of the EGFR signalling pathway ultimately leads to inhibition of cell cycle progression, cell survival pathways, and tumour cell motility and invasion.[A227963] Cetuximab also induces cell apoptosis and decreases matrix metalloproteinase and vascular endothelial growth factor (VEGF) production.[A228078, L30448] _In vitro_, cetuximab was shown to inhibit tumour angiogenesis.[A227978] Binding of cetuximab to EGFR also results in internalization of the antibody-receptor complex, leading to an overall downregulation of EGFR expression.[A227973]\\r\\n\\r\\nK-ras is a small G-protein downstream of EGFR that plays an important role in promoting the EGFR signalling cascade: in some malignant cells, K-ras can acquire activating mutations in exon 2 [L31418] and thus be continuously active regardless of EGFR regulation.[L30448] Since mutant Ras proteins can isolate the pathway from the effect of EGFR, K-Ras mutations can render EGFR inhibitors like cetuximab ineffective in exerting anti-tumour effects.[L30448, L31418] Cetuximab is thus only limited in its use for K-Ras wild-type, EGFR-expressing cancers.[L30448]\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Extracellular DNA is a viscous anionic polymer and its breakdown appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction. Dornase alfa does not seem to have any effect on non-purulent sputum.\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.\n",
      "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55).[A216522] Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. Notably, etancerpt is only capable of binding to the active trimeric form of TNF as its binding site is located in the cleft between subunits.[A77626]TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.[A216522] Increased levels of TNF are found in tissues and fluids of those with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.\n",
      "Name: mechanism-of-action, dtype: object\n",
      "0    The acute toxicity of intravenous lepirudin was evaluated in mice (0.1-1000 mg/kg), rats (1-1000 mg/kg), and monkeys (1-100 mg/kg), and toxicity was not detected at the doses investigated.[L41539] The acute toxicity of lepirudin administered subcutaneously was also evaluated in mice (1-1250 mg/kg) and rats (1-500 mg/kg), and no toxicity was detected.[L41539] One rat (100 mg/kg) died of rapid blood loss after the subcutaneous administration of lepirudin. Reactions to local injections such as hemorrhages, hematomas and/or nodules were detected in mice and rats given subcutaneous doses of lepirudin equal or higher than 500 mg/kg and 10 mg/kg, respectively.[L41539] \\r\\n\\r\\nChronic toxicity was evaluated in rats and monkeys given lepirudin for up to 3 months. Most of the effects observed were due to the antithrombotic action of lepirudin. After 3 months, hemosiderin deposits in the spleen and moderate sinus histiocytosis in the lymph node were observed in rats. In monkeys, external and internal hemorrhages and hematomas were detected.[L41539] Lepidurin was reported as not mutagenic.[L41539]\\r\\n\\r\\nRelative overdose may occur in patients with renal impairment, therefore, bolus dose and rate of infusion must be reduced in case of known or suspected renal insufficiency.[L41539] Excessively high activated partial thromboplastin time (aPTT) values suggest an overdose and a risk of bleeding. Lepirudin has no known antidote. In case of life-threatening bleeding and if excessive plasma levels of lepirudin are suspected: 1)stop the administration of lepirudin immediately, 2) determine aPTT and coagulation parameters, 3) determine hemoglobin, and prepare for a transfusion, 4) follow the treatment guidelines for patients with shock.[L41539] Hemofiltration or hemodialysis may be useful in case of overdose, based in single case reports and animal data.[L41539]\n",
      "1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           The intravenous LD<sub>50</sub> is > 300 mg/kg in mice and > 200 mg/kg in rats.[L31408] There is limited information on the overdose from cetuximab.\\r\\n\\r\\nIn clinical trials, cetuximab was associated with serious and fatal infusion reactions, cardiopulmonary arrest or sudden death, and serious dermatologic toxicities. Pulmonary toxicities, such as interstitial lung disease, interstitial pneumonitis with non-cardiogenic pulmonary edema, and exacerbation of pre-existing fibrotic lung disease have been reported.[L30448]\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Adverse reactions occur at a frequency of < 1/1000 and are usually mild and transient in nature. Reported adverse effects include chest pain (pleuritic/non-cardiac), fever, dyspepsia, voice alteration (hoarseness), pharyngitis, dyspnea, laryngitis, rhinitis, decreased lung function, rash, urticaria, and conjunctivitis. There is no evidence of carcinogenic or mutagenic properties. The safety of dornase alfa has not been studied in pregnant women, nursing women and children under the age of 5 years old.\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   NaN\n",
      "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   NaN\n",
      "Name: toxicity, dtype: object\n",
      "0    As a polypeptide, lepirudin is expected to be metabolized by the sequential cleavage of amino acids by kidney exoproteases, which have carboxypeptidase and dipeptidase-like activity.[L41539,L41544] The C-terminal cleavage of lepirudin aminoacids (aminoacids 1 to 65) produces four metabolites with anti-thrombotic activity: M1 (aminoacids 1 to 64), M2 (aminoacids 1 to 63), M3 (aminoacids 1 to 62), and M4 (aminoacids 1 to 61).[L41544]\n",
      "1                                                                                                                                                                                                                                                    Like other monoclonal antibodies, cetuximab is expected to undergo lysosomal degradation by the reticuloendothelial system and protein catabolism by a target‐mediated disposition pathway.[A40006]\n",
      "2                                                                                                                                                                                                                                                                                                                             While no conclusive studies have yet been published, dornase alfa is expected to be metabolized by proteases in biofluids.\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                    NaN\n",
      "4                                                                                                                                                                                                                                                                                                                          As etanercept is a fusion protein antibody, it is assumed to be metabolized via proteinases similarly to endogenous proteins.\n",
      "Name: metabolism, dtype: object\n",
      "0    Lepirudin administered as a single intravenous bolus injection of 0.4 mg/kg in 9 healthy volunteers (male and female) resulted in a C<sub>max</sub> of 2924 ng/mL, a t<sub>max</sub> of 0.17 h and an AUC<sub>0-∞</sub> of 2500 ng•h/mL.[L41539] When 0.1, 0.15 and 0.2 mg/kg of lepirudin was administered as a single intravenous infusion over 6 hours in healthy male volunteers, lepirudin had a corresponding C<sub>max</sub> of 111, 203, and 2446 ng/mL and a corresponding AUC of 612, 1184, and 1446 ng•h/mL.[L41544] Bioavailability is 100% following injection. Also, it has been reported that following subcutaneous (sc) administration, the bioavailability of lepirudin is almost 100%.[A246609]\n",
      "1                                                                                                                                                                                                                                                                                                                                      After administration of a 400 mg/m<sup>2</sup> initial dose followed by a 250 mg/m<sup>2</sup> weekly dose, the steady-state levels of cetuximab was reached by the third weekly infusion with mean peak and trough concentrations across studies ranging from 168 µg/mL to 235 µg/mL and 41 µg/mL to 85 µg/mL, respectively.[L30448] T<sub>max</sub> is about 3 hours.[A227963]\n",
      "2                                                                                                                                                                       Studies in rats and monkeys after inhalation of dornase alfa shows very little systemic absorption (less than 15% for rats and less than 2% for monkeys). The results were also witnessed in patients. Dornase alfa is also associated with very low accumulation with no serum concentration greater than 10ng/mL observed no matter the dose administered. Bioavailability: mean sputum concentrations of dornase alfa can be measured after 15 minutes. Onset is achieved within 3 to 7 days. Peak concentrations are achieved after 9 days.\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   NaN\n",
      "4                                                                                                         Population pharmacokinetic modeling in adults with RA, AS, or who were healthy showed a subcutaneous bioavailability of 56.9% with a Ka of 0.0223/h.[A215352] Another model in pediatric JIA patients showed an increased Ka of 0.05/h with a high mean interindividual variability of 215%.[A215357] Cmax after a single 25 mg subcutaneous dose of Enbrel is reported as 1.1 mcg/L with a Tmax of 69 h.[L14862] Cmax after repeated dosing is reported as 2.4 mcg/L in adult RA patients with a dosage of 25 mg twice weekly and 2.1 mcg in pediatric JIA patients with a dosage of 0.4 mg/kg twice weekly.\n",
      "Name: absorption, dtype: object\n",
      "0    Lepirudin has an initial half-life of approximately 10 minutes, and in young healthy volunteers, it has a terminal half-time of 1.3 hours.[L41539] Lepirudin has a first-order elimination kinetic; plasma concentration increases proportionally as the lepirudin intravenous dose is increased. Elimination half-life values of up to 2 days were detected in patients with marked renal insufficiency (creatinine clearance < 15 mL/min).[L41539]\n",
      "1                                                                                                                                                                                                                                      After administration of a 400 mg/m<sup>2</sup> initial dose followed by a 250 mg/m<sup>2</sup> weekly dose, the mean half-life for cetuximab was approximately 112 hours, with a range of 63 to 230 hours.[L30448]\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                     NaN\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                               70-80 min\n",
      "4                                                                                                                                                                                                                         Etanercept has a mean half-life of elimination of 102 hours in RA patients.[L14862] Population models have shown a mean half-life of 68 hours in healthy adults and 70.7-94.8 hours in pediatric JIA patients.[A215657,A215357]\n",
      "Name: half-life, dtype: object\n",
      "0    In human plasma, the protein binding of lepirudin was approximately 3%.[L41539]\n",
      "1                                                 There is no information available.\n",
      "2                                                                                NaN\n",
      "3                                                                                NaN\n",
      "4                                No significant protein binding has been identified.\n",
      "Name: protein-binding, dtype: object\n",
      "0    Lepirudin is mostly excreted through urine (48.3%). About 35% of lepirudin is excreted unchanged, while metabolites are found in a smaller proportion (2.5% of M1, 5.4% of M2, 3.9% of M3 and 1.6% of M4).[L41544]\n",
      "1                                                                                                                                                                               There is limited information available.\n",
      "2                                                                                                                                                                                                                   NaN\n",
      "3                                                                                                                                                                                                                   NaN\n",
      "4                                                                                                                                                                                                                   NaN\n",
      "Name: route-of-elimination, dtype: object\n",
      "0    The volume of distribution of lepirudin at steady state was 12.2 L in healthy young subjects (n=18, 18-60 years), 18.7 L in healthy elderly subjects (n=10, 65-80 years), 18.0 L in renally impaired subjects (n=16, creatinine clearance < 80 mL/min, and 32.1 L in heparin-induced thrombocytopenia patients (n=73).[L41539] The distribution of lepirudin is mainly restricted to extracellular fluids.[L41539]\n",
      "1                                                                                                                                                                                                                                                                                                                       The volume of the distribution is about 2-3 L/m<sup>2</sup> and is independent of dose.[L30448]\n",
      "2                                                                                                                                                                                                                                                         In studies in rats and monkeys, the initial volume of distribution is similar to the serum volume. Concentrations in sputum decline rapidly after inhalation.\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                   * 0.06 to 0.09 L/kg\n",
      "4                                                                                                                                                                                 Population pharmacokinetic modeling predicts a total Vd of 5.49 L with a peripheral compartment of 1.24 L in adults with RA and an apparent Vd with subcutaneous administration in pediatric JIA patients of 7.88 L.[A215352,A215357]\n",
      "Name: volume-of-distribution, dtype: object\n",
      "0    The clearance of lepirudin is proportional to the glomerular filtration rate. On average, lepirudin clearance was 164 mL/min in healthy young subjects (n=18, 18-60 years) and 25% lower in women than in men. In healthy elderly subjects (n=10, 65-80 years), clearance was 139 mL/min, about 20% lower than in younger patients.[L41539] This is possibly due to the lower creatinine clearance in elderly patients. In renally impaired subjects (n=16, creatinine clearance < 80 mL/min), clearance was 61 mL/min, and in heparin-induced thrombocytopenia patients (n=73), it was 114 mL/min.[L41539]\n",
      "1                                                                                                                                   In patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck, the estimated clearance rate was 0.103 L/h.[A228003] At doses ranging from 200 to 400 mg/m<sup>2</sup>, complete saturation of systemic clearance was observed. In a population pharmacokinetic study,  female patients had a 25% lower intrinsic cetuximab clearance than male patients, although there was no evidence of the need for dose modification based on sex.[A227963]\n",
      "2                                                                                                                                                                                                                                                                                         Studies in rats indicate that, following aerosol administration, the disappearance half-life of dornase alfa from the lungs is 11 hours. In humans, sputum DNase levels declined below half of those detected immediately post-administration within 2 hours but effects on sputum rheology persisted beyond 12 hours.\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               * 0.6 - 2.0 mL/min/kg [Lymphoma]\n",
      "4                                                                                                                                                                                                                                                                                                                                                                                      Etanercept has a mean apparent clearance of 160 mL/h in RA patients.[L14862] Population models predict a mean apparent clearance of 132 mL/h in healthy adults and 0.0576 L/h in pediatric JIA patients.[A215657,A215357]\n",
      "Name: clearance, dtype: object\n",
      "0    {'description': None, 'direct-parent': 'Peptides', 'kingdom': 'Organic Compounds', 'superclass': 'Organic Acids', 'class': 'Carboxylic Acids and Derivatives', 'subclass': 'Amino Acids, Peptides, and Analogues'}\n",
      "1    {'description': None, 'direct-parent': 'Peptides', 'kingdom': 'Organic Compounds', 'superclass': 'Organic Acids', 'class': 'Carboxylic Acids and Derivatives', 'subclass': 'Amino Acids, Peptides, and Analogues'}\n",
      "2    {'description': None, 'direct-parent': 'Peptides', 'kingdom': 'Organic Compounds', 'superclass': 'Organic Acids', 'class': 'Carboxylic Acids and Derivatives', 'subclass': 'Amino Acids, Peptides, and Analogues'}\n",
      "3    {'description': None, 'direct-parent': 'Peptides', 'kingdom': 'Organic Compounds', 'superclass': 'Organic Acids', 'class': 'Carboxylic Acids and Derivatives', 'subclass': 'Amino Acids, Peptides, and Analogues'}\n",
      "4    {'description': None, 'direct-parent': 'Peptides', 'kingdom': 'Organic Compounds', 'superclass': 'Organic Acids', 'class': 'Carboxylic Acids and Derivatives', 'subclass': 'Amino Acids, Peptides, and Analogues'}\n",
      "Name: classification, dtype: object\n",
      "0    NaN\n",
      "1    NaN\n",
      "2    NaN\n",
      "3    NaN\n",
      "4    NaN\n",
      "Name: salts, dtype: object\n",
      "0                                                                 {'synonym': [{'@language': 'english', '@coder': '', '#text': '[Leu1, Thr2]-63-desulfohirudin'}, {'@language': 'english', '@coder': '', '#text': 'Desulfatohirudin'}, {'@language': 'english', '@coder': '', '#text': 'Hirudin variant-1'}, {'@language': 'english', '@coder': 'inn', '#text': 'Lepirudin'}, {'@language': 'english', '@coder': '', '#text': 'Lepirudin recombinant'}, {'@language': 'english', '@coder': '', '#text': 'R-hirudin'}]}\n",
      "1                                                                                                                                                                                                                                                                                  {'synonym': [{'@language': 'english/spanish/german', '@coder': 'inn/usan', '#text': 'Cetuximab'}, {'@language': 'french', '@coder': 'inn', '#text': 'Cétuximab'}, {'@language': 'latin', '@coder': 'inn', '#text': 'Cetuximabum'}]}\n",
      "2        {'synonym': [{'@language': 'english', '@coder': '', '#text': 'Deoxyribonuclease (human clone 18-1 protein moiety)'}, {'@language': 'spanish', '@coder': '', '#text': 'Dornasa alfa'}, {'@language': 'english', '@coder': 'inn/jan/usan', '#text': 'Dornase alfa'}, {'@language': 'english', '@coder': '', '#text': 'Dornase alfa, recombinant'}, {'@language': 'english', '@coder': '', '#text': 'Dornase alpha'}, {'@language': 'english', '@coder': '', '#text': 'Recombinant deoxyribonuclease (DNAse)'}]}\n",
      "3                                                                                                                                                                                                                                                        {'synonym': [{'@language': 'english', '@coder': '', '#text': 'Denileukin'}, {'@language': 'english', '@coder': 'inn/usan', '#text': 'Denileukin diftitox'}, {'@language': 'english', '@coder': '', '#text': 'Interleukin-2/diptheria toxin fusion protein'}]}\n",
      "4    {'synonym': [{'@language': 'english', '@coder': 'inn/ban/usan', '#text': 'Etanercept'}, {'@language': 'english', '@coder': '', '#text': 'etanercept-szzs'}, {'@language': 'english', '@coder': '', '#text': 'etanercept-ykro'}, {'@language': 'english', '@coder': '', '#text': 'Recombinant human TNF'}, {'@language': 'english', '@coder': '', '#text': 'rhu TNFR:Fc'}, {'@language': 'english', '@coder': '', '#text': 'rhu-TNFR:Fc'}, {'@language': 'english', '@coder': '', '#text': 'TNFR-Immunoadhesin'}]}\n",
      "Name: synonyms, dtype: object\n",
      "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           {'product': [{'name': 'Refludan', 'labeller': 'Bayer', 'ndc-id': None, 'ndc-product-code': '50419-150', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '1998-03-06', 'ended-marketing-on': '2013-06-30', 'dosage-form': 'Powder', 'strength': '50 mg/1mL', 'route': 'Intravenous', 'fda-application-number': 'NDA020807', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Refludan', 'labeller': 'Bayer', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': '02240996', 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2000-01-31', 'ended-marketing-on': '2013-07-26', 'dosage-form': 'Powder, for solution', 'strength': '50 mg / vial', 'route': 'Intravenous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'Canada', 'source': 'DPD'}, {'name': 'Refludan', 'labeller': 'Celgene Europe Limited', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000122', 'ema-ma-number': 'EU/1/97/035/001', 'started-marketing-on': '2016-09-08', 'ended-marketing-on': '2012-07-27', 'dosage-form': 'Injection, solution, concentrate', 'strength': '50 mg', 'route': 'Intravenous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'false', 'country': 'EU', 'source': 'EMA'}, {'name': 'Refludan', 'labeller': 'Celgene Europe Limited', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000122', 'ema-ma-number': 'EU/1/97/035/002', 'started-marketing-on': '2016-09-08', 'ended-marketing-on': '2012-07-27', 'dosage-form': 'Injection, solution, concentrate', 'strength': '50 mg', 'route': 'Intravenous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'false', 'country': 'EU', 'source': 'EMA'}, {'name': 'Refludan', 'labeller': 'Celgene Europe Limited', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000122', 'ema-ma-number': 'EU/1/97/035/003', 'started-marketing-on': '2016-09-08', 'ended-marketing-on': '2012-07-27', 'dosage-form': 'Injection, solution, concentrate', 'strength': '20 mg', 'route': 'Intravenous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'false', 'country': 'EU', 'source': 'EMA'}, {'name': 'Refludan', 'labeller': 'Celgene Europe Limited', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000122', 'ema-ma-number': 'EU/1/97/035/004', 'started-marketing-on': '2016-09-08', 'ended-marketing-on': '2012-07-27', 'dosage-form': 'Injection, solution, concentrate', 'strength': '20 mg', 'route': 'Intravenous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'false', 'country': 'EU', 'source': 'EMA'}]}\n",
      "1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       {'product': [{'name': 'Erbitux', 'labeller': 'ImClone LLC', 'ndc-id': None, 'ndc-product-code': '66733-948', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2004-02-12', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '2 mg/1mL', 'route': 'Intravenous', 'fda-application-number': 'BLA125084', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Erbitux', 'labeller': 'ImClone LLC', 'ndc-id': None, 'ndc-product-code': '66733-958', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2007-10-02', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '2 mg/1mL', 'route': 'Intravenous', 'fda-application-number': 'BLA125084', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Erbitux', 'labeller': 'Imclone, Llc', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': '02271249', 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2008-10-28', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '2 mg / mL', 'route': 'Intravenous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'Canada', 'source': 'DPD'}, {'name': 'Erbitux', 'labeller': 'Merck Europe B.V.', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000558', 'ema-ma-number': 'EU/1/04/281/003', 'started-marketing-on': '2016-09-08', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '5 mg/ml', 'route': 'Intravenous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Erbitux', 'labeller': 'Merck Europe B.V.', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000558', 'ema-ma-number': 'EU/1/04/281/005', 'started-marketing-on': '2016-09-08', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '5 mg/ml', 'route': 'Intravenous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}]}\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            {'product': [{'name': 'Pulmozyme', 'labeller': 'Genentech, Inc.', 'ndc-id': None, 'ndc-product-code': '50242-100', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '1993-12-30', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '1 mg/1mL', 'route': 'Respiratory (inhalation)', 'fda-application-number': 'BLA103532', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Pulmozyme 1mg/ml', 'labeller': 'Hoffmann La Roche', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': '02046733', 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '1994-12-31', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '1 mg / mL', 'route': 'Respiratory (inhalation)', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'Canada', 'source': 'DPD'}]}\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  {'product': {'name': 'Ontak', 'labeller': 'Eisai Limited', 'ndc-id': None, 'ndc-product-code': '62856-603', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2013-11-01', 'ended-marketing-on': '2013-11-01', 'dosage-form': 'Injection, solution', 'strength': '150 ug/1mL', 'route': 'Intravenous', 'fda-application-number': 'BLA103767', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}}\n",
      "4    {'product': [{'name': 'Benepali', 'labeller': 'Samsung Bioepis Nl B.V.', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004007', 'ema-ma-number': 'EU/1/15/1074/001', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Benepali', 'labeller': 'Samsung Bioepis Nl B.V.', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004007', 'ema-ma-number': 'EU/1/15/1074/002', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Benepali', 'labeller': 'Samsung Bioepis Nl B.V.', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004007', 'ema-ma-number': 'EU/1/15/1074/003', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Benepali', 'labeller': 'Samsung Bioepis Nl B.V.', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004007', 'ema-ma-number': 'EU/1/15/1074/004', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Benepali', 'labeller': 'Samsung Bioepis Nl B.V.', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004007', 'ema-ma-number': 'EU/1/15/1074/005', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Benepali', 'labeller': 'Samsung Bioepis Nl B.V.', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004007', 'ema-ma-number': 'EU/1/15/1074/006', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Benepali', 'labeller': 'Samsung Bioepis Nl B.V.', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004007', 'ema-ma-number': 'EU/1/15/1074/007', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Brenzys', 'labeller': 'Samsung Bioepis Co., Ltd.', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': '02455323', 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2016-09-23', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '50 mg / mL', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'Canada', 'source': 'DPD'}, {'name': 'Brenzys', 'labeller': 'Samsung Bioepis Co., Ltd.', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': '02455331', 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2016-09-13', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '50 mg / mL', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'Canada', 'source': 'DPD'}, {'name': 'Enbrel', 'labeller': 'Physicians Total Care, Inc.', 'ndc-id': None, 'ndc-product-code': '54868-5444', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2005-10-06', 'ended-marketing-on': '2012-06-30', 'dosage-form': 'Solution', 'strength': '50 mg/1mL', 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'Physicians Total Care, Inc.', 'ndc-id': None, 'ndc-product-code': '54868-4782', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2003-04-30', 'ended-marketing-on': '2012-06-30', 'dosage-form': 'Kit', 'strength': None, 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'A-S Medication Solutions', 'ndc-id': None, 'ndc-product-code': '50090-3531', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2005-11-10', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '50 mg/1mL', 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'A-S Medication Solutions', 'ndc-id': None, 'ndc-product-code': '50090-4490', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2005-11-10', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '50 mg/1mL', 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'Immunex Corporation', 'ndc-id': None, 'ndc-product-code': '58406-435', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2005-10-06', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '50 mg/1mL', 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'Immunex Corporation', 'ndc-id': None, 'ndc-product-code': '58406-445', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2005-11-10', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '50 mg/1mL', 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'Immunex Corporation', 'ndc-id': None, 'ndc-product-code': '58406-425', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2003-01-02', 'ended-marketing-on': None, 'dosage-form': 'Injection, powder, lyophilized, for solution; Kit', 'strength': '25 mg/1mL', 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'Immunex Corporation', 'ndc-id': None, 'ndc-product-code': '58406-455', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2005-11-10', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '25 mg/0.5mL', 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'Immunex Corporation', 'ndc-id': None, 'ndc-product-code': '58406-456', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2017-09-29', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '50 mg/1mL', 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'Immunex Corporation', 'ndc-id': None, 'ndc-product-code': '58406-446', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2017-10-20', 'ended-marketing-on': '2019-09-11', 'dosage-form': 'Solution', 'strength': '50 mg/1mL', 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'Immunex Corporation', 'ndc-id': None, 'ndc-product-code': '58406-021', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2019-06-07', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '50 mg/1mL', 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'Immunex Corporation', 'ndc-id': None, 'ndc-product-code': '58406-032', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2019-06-07', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '50 mg/1mL', 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'Immunex Corporation', 'ndc-id': None, 'ndc-product-code': '58406-010', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2019-06-07', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '25 mg/0.5mL', 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'Immunex Corporation', 'ndc-id': None, 'ndc-product-code': '58406-044', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2019-06-07', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '50 mg/1mL', 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'Immunex Corporation', 'ndc-id': None, 'ndc-product-code': '58406-055', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2020-03-05', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '25 mg/0.5mL', 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'A-S Medication Solutions', 'ndc-id': None, 'ndc-product-code': '50090-4590', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2019-06-07', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '50 mg/1mL', 'route': 'Subcutaneous', 'fda-application-number': 'BLA103795', 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'US', 'source': 'FDA NDC'}, {'name': 'Enbrel', 'labeller': 'Immunex Corporation', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': '02274728', 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2005-12-21', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '50 mg / mL', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'Canada', 'source': 'DPD'}, {'name': 'Enbrel', 'labeller': 'Immunex Corporation', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': '02242903', 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2001-03-14', 'ended-marketing-on': '2023-01-31', 'dosage-form': 'Kit; Liquid; Powder, for solution', 'strength': None, 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'Canada', 'source': 'DPD'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/001', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': '2018-07-16', 'dosage-form': 'Injection, powder, for solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/002', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': None, 'dosage-form': 'Injection, powder, for solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/003', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': None, 'dosage-form': 'Injection, powder, for solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/004', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': None, 'dosage-form': 'Injection, powder, for solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/005', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': None, 'dosage-form': 'Injection, powder, for solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/006', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': '2018-07-16', 'dosage-form': 'Injection, powder, for solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/007', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': '2018-07-16', 'dosage-form': 'Injection, powder, for solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/008', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': '2018-07-16', 'dosage-form': 'Injection, powder, for solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/009', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': '2018-07-16', 'dosage-form': 'Injection, powder, for solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/010', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': '2018-07-16', 'dosage-form': 'Injection, powder, for solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/011', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': '2018-07-16', 'dosage-form': 'Injection, powder, for solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/013', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/014', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/015', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/016', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/017', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/018', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/019', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/020', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/021', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/022', 'started-marketing-on': '2016-09-20', 'ended-marketing-on': None, 'dosage-form': 'Injection, powder, for solution', 'strength': '10 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/023', 'started-marketing-on': '2021-03-01', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/024', 'started-marketing-on': '2021-03-01', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/025', 'started-marketing-on': '2021-03-01', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Enbrel', 'labeller': 'Pfizer Europe Ma Eeig', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/000262', 'ema-ma-number': 'EU/1/99/126/026', 'started-marketing-on': '2021-03-01', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Erelzi', 'labeller': 'Sandoz Canada Incorporated', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': '02462850', 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2017-08-04', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '50 mg / mL', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'Canada', 'source': 'DPD'}, {'name': 'Erelzi', 'labeller': 'Sandoz Canada Incorporated', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': '02462869', 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2017-08-04', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '50 mg / mL', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'Canada', 'source': 'DPD'}, {'name': 'Erelzi', 'labeller': 'Sandoz Canada Incorporated', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': '02462877', 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2017-12-08', 'ended-marketing-on': None, 'dosage-form': 'Solution', 'strength': '25 mg / 0.5 mL', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'Canada', 'source': 'DPD'}, {'name': 'Erelzi', 'labeller': 'Sandoz', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004192', 'ema-ma-number': 'EU/1/17/1195/001', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Erelzi', 'labeller': 'Sandoz', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004192', 'ema-ma-number': 'EU/1/17/1195/002', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Erelzi', 'labeller': 'Sandoz', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004192', 'ema-ma-number': 'EU/1/17/1195/003', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Erelzi', 'labeller': 'Sandoz', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004192', 'ema-ma-number': 'EU/1/17/1195/004', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Erelzi', 'labeller': 'Sandoz', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004192', 'ema-ma-number': 'EU/1/17/1195/005', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Erelzi', 'labeller': 'Sandoz', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004192', 'ema-ma-number': 'EU/1/17/1195/006', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Erelzi', 'labeller': 'Sandoz', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004192', 'ema-ma-number': 'EU/1/17/1195/007', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Erelzi', 'labeller': 'Sandoz', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004192', 'ema-ma-number': 'EU/1/17/1195/008', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Erelzi', 'labeller': 'Sandoz', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004192', 'ema-ma-number': 'EU/1/17/1195/009', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Erelzi', 'labeller': 'Sandoz', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004192', 'ema-ma-number': 'EU/1/17/1195/010', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Erelzi', 'labeller': 'Sandoz', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004192', 'ema-ma-number': 'EU/1/17/1195/011', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Erelzi', 'labeller': 'Sandoz', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004192', 'ema-ma-number': 'EU/1/17/1195/012', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '50 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Erelzi', 'labeller': 'Sandoz', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004192', 'ema-ma-number': 'EU/1/17/1195/013', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Erelzi', 'labeller': 'Sandoz', 'ndc-id': None, 'ndc-product-code': None, 'dpd-id': None, 'ema-product-code': 'EMEA/H/C/004192', 'ema-ma-number': 'EU/1/17/1195/014', 'started-marketing-on': '2020-12-16', 'ended-marketing-on': None, 'dosage-form': 'Injection, solution', 'strength': '25 mg', 'route': 'Subcutaneous', 'fda-application-number': None, 'generic': 'false', 'over-the-counter': 'false', 'approved': 'true', 'country': 'EU', 'source': 'EMA'}, {'name': 'Eticovo', 'labeller': 'Samsung Bioepis Co., Ltd.', 'ndc-id': None, 'ndc-product-code': '71202-004', 'dpd-id': None, 'ema-product-code': None, 'ema-ma-number': None, 'started-marketing-on': '2020-10-31', 'ended-m\n",
      "Name: products, dtype: object\n",
      "0                                                                                                      NaN\n",
      "1                                                                                                      NaN\n",
      "2                               {'international-brand': {'name': 'Viscozyme', 'company': 'Roche (Chile)'}}\n",
      "3                                                                                                      NaN\n",
      "4    {'international-brand': [{'name': 'Davictrel', 'company': None}, {'name': 'Tunex', 'company': None}]}\n",
      "Name: international-brands, dtype: object\n",
      "0                                                                                                                NaN\n",
      "1                                                                                                                NaN\n",
      "2                                                                                                                NaN\n",
      "3                                                                                                                NaN\n",
      "4    {'mixture': [{'name': 'Enbrel', 'ingredients': 'Etanercept'}, {'name': 'Enbrel', 'ingredients': 'Etanercept'}]}\n",
      "Name: mixtures, dtype: object\n",
      "0                                                                                                                                                                                                                                                                                             {'packager': [{'name': 'Bayer Healthcare', 'url': 'http://www.bayerhealthcare.com'}, {'name': 'Berlex Labs', 'url': 'http://www.berlex.com'}]}\n",
      "1                                                                                                                                               {'packager': [{'name': 'Cardinal Health', 'url': 'http://www.cardinal.com'}, {'name': 'Catalent Pharma Solutions', 'url': 'http://www.catalent.com'}, {'name': 'ImClone Systems Inc.', 'url': 'http://www.imclone.com'}, {'name': 'Oso Biopharmaceuticals Manufacturing LLC', 'url': None}]}\n",
      "2                                                {'packager': [{'name': 'Cardinal Health', 'url': 'http://www.cardinal.com'}, {'name': 'Catalent Pharma Solutions', 'url': 'http://www.catalent.com'}, {'name': 'F Hoffmann-La Roche Ltd.', 'url': 'http://www.roche.com'}, {'name': 'Genentech Inc.', 'url': 'http://www.gene.com'}, {'name': 'Meda AB', 'url': 'http://www.meda.se'}, {'name': 'Medpointe Pharmaceuticals', 'url': None}]}\n",
      "3                                                                                                                                                                                                       {'packager': [{'name': 'Eisai Inc.', 'url': 'http://www.eisai.com'}, {'name': 'Hollister-Stier Laboratories LLC', 'url': 'http://www.hollisterstier.com'}, {'name': 'Ligand Pharmaceuticals Inc.', 'url': 'http://www.ligand.com'}]}\n",
      "4    {'packager': [{'name': 'Amgen Inc.', 'url': 'http://www.amgen.com'}, {'name': 'Boehringer Ingelheim Ltd.', 'url': 'http://www.boehringer-ingelheim.com'}, {'name': 'DSM Corp.', 'url': 'http://www.dsm.com'}, {'name': 'Immunex Corp.', 'url': None}, {'name': 'Physicians Total Care Inc.', 'url': 'http://www.physicianstotalcare.com'}, {'name': 'Vetter Pharma Fertigung GmbH and Co. KG', 'url': 'http://www.vetter-pharma.com'}]}\n",
      "Name: packagers, dtype: object\n",
      "0    {'manufacturer': {'@generic': 'false', '@url': '', '#text': 'Bayer healthcare pharmaceuticals inc'}}\n",
      "1                                                                                                     NaN\n",
      "2                          {'manufacturer': {'@generic': 'false', '@url': '', '#text': 'Genentech, Inc'}}\n",
      "3                                                                                                     NaN\n",
      "4             {'manufacturer': {'@generic': 'false', '@url': '', '#text': 'Amgen Inc. + Wyeth + Takeda'}}\n",
      "Name: manufacturers, dtype: object\n",
      "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                {'price': {'description': 'Refludan 50 mg vial', 'cost': {'@currency': 'USD', '#text': '273.19'}, 'unit': 'vial'}}\n",
      "1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               NaN\n",
      "2    {'price': [{'description': 'Lufyllin 200 mg tablet', 'cost': {'@currency': 'USD', '#text': '3.21'}, 'unit': 'tablet'}, {'description': 'Lufyllin-gg tablet', 'cost': {'@currency': 'USD', '#text': '3.84'}, 'unit': 'tablet'}, {'description': 'Lufyllin-GG 200-200 mg tablet', 'cost': {'@currency': 'USD', '#text': '3.99'}, 'unit': 'tablet'}, {'description': 'Lufyllin-400 tablet', 'cost': {'@currency': 'USD', '#text': '4.62'}, 'unit': 'tablet'}, {'description': 'Lufyllin 400 mg tablet', 'cost': {'@currency': 'USD', '#text': '4.81'}, 'unit': 'tablet'}, {'description': 'Pulmozyme 1 mg/ml ampul', 'cost': {'@currency': 'USD', '#text': '37.05'}, 'unit': 'ml'}, {'description': 'Pulmozyme 1 mg/ml Solution 2.5ml Plastic Container', 'cost': {'@currency': 'USD', '#text': '77.06'}, 'unit': 'plastic'}, {'description': 'Lufyllin-GG 100-100 mg/15ml Elixir', 'cost': {'@currency': 'USD', '#text': '0.6'}, 'unit': 'ml'}]}\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 {'price': {'description': 'Ontak 150 mcg/ml vial', 'cost': {'@currency': 'USD', '#text': '878.4'}, 'unit': 'ml'}}\n",
      "4                                                                                                                                                                                                                                                         {'price': [{'description': 'Enbrel 25 mg kit', 'cost': {'@currency': 'USD', '#text': '250.37'}, 'unit': 'each'}, {'description': 'Enbrel 50 mg/ml sureclick syr', 'cost': {'@currency': 'USD', '#text': '488.74'}, 'unit': 'syringe'}, {'description': 'Enbrel 4 25 mg Kit (1 Box = 1 Kit = Four 25 mg Vials)', 'cost': {'@currency': 'USD', '#text': '1016.57'}, 'unit': 'box'}, {'description': 'Enbrel (1 Box = 1 Kit = Four 50 mg Syringes) 3.92ml Box', 'cost': {'@currency': 'USD', '#text': '2033.14'}, 'unit': 'box'}, {'description': 'Enbrel SureClick (1 Box Contains Four 50 mg Prefilled Autoinjectors)', 'cost': {'@currency': 'USD', '#text': '2033.14'}, 'unit': 'box'}]}\n",
      "Name: prices, dtype: object\n",
      "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      {'category': [{'category': 'Amino Acids, Peptides, and Proteins', 'mesh-id': 'D000602'}, {'category': 'Anticoagulants', 'mesh-id': 'D000925'}, {'category': 'Antithrombin Proteins', 'mesh-id': 'D058833'}, {'category': 'Antithrombins', 'mesh-id': 'D000991'}, {'category': 'Blood and Blood Forming Organs', 'mesh-id': None}, {'category': 'Cardiovascular Agents', 'mesh-id': 'D002317'}, {'category': 'Enzyme Inhibitors', 'mesh-id': 'D004791'}, {'category': 'Fibrin Modulating Agents', 'mesh-id': 'D050299'}, {'category': 'Hematologic Agents', 'mesh-id': 'D006401'}, {'category': 'Peptides', 'mesh-id': 'D010455'}, {'category': 'Protease Inhibitors', 'mesh-id': 'D011480'}, {'category': 'Proteins', 'mesh-id': 'D011506'}, {'category': 'Serine Protease Inhibitors', 'mesh-id': 'D015842'}, {'category': 'Serpins', 'mesh-id': 'D015843'}, {'category': 'Thrombin Inhibitors', 'mesh-id': None}]}\n",
      "1                                                                                            {'category': [{'category': 'Amino Acids, Peptides, and Proteins', 'mesh-id': 'D000602'}, {'category': 'Antibodies', 'mesh-id': 'D000906'}, {'category': 'Antibodies, Monoclonal', 'mesh-id': 'D000911'}, {'category': 'Antibodies, Monoclonal, Humanized', 'mesh-id': 'D061067'}, {'category': 'Antineoplastic Agents', 'mesh-id': 'D000970'}, {'category': 'Antineoplastic Agents, Immunological', 'mesh-id': 'D000074322'}, {'category': 'Antineoplastic and Immunomodulating Agents', 'mesh-id': None}, {'category': 'Blood Proteins', 'mesh-id': 'D001798'}, {'category': 'Cancer immunotherapy', 'mesh-id': None}, {'category': 'EGFR (Epidermal Growth Factor Receptor) inhibitors', 'mesh-id': None}, {'category': 'Epidermal Growth Factor Receptor Antagonist', 'mesh-id': None}, {'category': 'Globulins', 'mesh-id': 'D005916'}, {'category': 'HER1 Antagonists', 'mesh-id': None}, {'category': 'Immunoglobulins', 'mesh-id': 'D007136'}, {'category': 'Immunoproteins', 'mesh-id': 'D007162'}, {'category': 'Immunotherapy', 'mesh-id': 'D007167'}, {'category': 'MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES', 'mesh-id': None}, {'category': 'Narrow Therapeutic Index Drugs', 'mesh-id': None}, {'category': 'Proteins', 'mesh-id': 'D011506'}, {'category': 'Serum Globulins', 'mesh-id': 'D012712'}]}\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               {'category': [{'category': 'Amino Acids, Peptides, and Proteins', 'mesh-id': 'D000602'}, {'category': 'Cough and Cold Preparations', 'mesh-id': None}, {'category': 'Decreased Respiratory Secretion Viscosity', 'mesh-id': None}, {'category': 'Deoxyribonucleases', 'mesh-id': 'D003851'}, {'category': 'Endodeoxyribonucleases', 'mesh-id': 'D004706'}, {'category': 'Endonucleases', 'mesh-id': 'D004720'}, {'category': 'Enzymes', 'mesh-id': 'D004798'}, {'category': 'Enzymes and Coenzymes', 'mesh-id': 'D045762'}, {'category': 'Esterases', 'mesh-id': 'D004950'}, {'category': 'Expectorants', 'mesh-id': 'D005100'}, {'category': 'Hydrolases', 'mesh-id': 'D006867'}, {'category': 'Proteins', 'mesh-id': 'D011506'}, {'category': 'Recombinant Human Deoxyribonuclease 1', 'mesh-id': None}]}\n",
      "3    {'category': [{'category': 'ADP Ribose Transferases', 'mesh-id': 'D036002'}, {'category': 'Amino Acids, Peptides, and Proteins', 'mesh-id': 'D000602'}, {'category': 'Antineoplastic Agents', 'mesh-id': 'D000970'}, {'category': 'Antineoplastic and Immunomodulating Agents', 'mesh-id': None}, {'category': 'Bacterial Toxins', 'mesh-id': 'D001427'}, {'category': 'Biological Factors', 'mesh-id': 'D001685'}, {'category': 'Cancer immunotherapy', 'mesh-id': None}, {'category': 'CD25-directed Cytotoxin', 'mesh-id': None}, {'category': 'Cytokines', 'mesh-id': 'D016207'}, {'category': 'Enzymes', 'mesh-id': 'D004798'}, {'category': 'Enzymes and Coenzymes', 'mesh-id': 'D045762'}, {'category': 'Glycosyltransferases', 'mesh-id': 'D016695'}, {'category': 'Immunotherapy', 'mesh-id': 'D007167'}, {'category': 'Intercellular Signaling Peptides and Proteins', 'mesh-id': 'D036341'}, {'category': 'Interleukins', 'mesh-id': 'D007378'}, {'category': 'Lymphokines', 'mesh-id': 'D008222'}, {'category': 'Narrow Therapeutic Index Drugs', 'mesh-id': None}, {'category': 'Pentosyltransferases', 'mesh-id': 'D010430'}, {'category': 'Peptides', 'mesh-id': 'D010455'}, {'category': 'Proteins', 'mesh-id': 'D011506'}, {'category': 'Recombinant Proteins', 'mesh-id': 'D011994'}, {'category': 'Toxins, Biological', 'mesh-id': 'D014118'}, {'category': 'Transferases', 'mesh-id': 'D014166'}]}\n",
      "4                      {'category': [{'category': 'Agents reducing cytokine levels', 'mesh-id': None}, {'category': 'Amino Acids, Peptides, and Proteins', 'mesh-id': 'D000602'}, {'category': 'Anti-Inflammatory Agents', 'mesh-id': 'D000893'}, {'category': 'Antibodies', 'mesh-id': 'D000906'}, {'category': 'Antirheumatic Agents', 'mesh-id': 'D018501'}, {'category': 'Biological Products', 'mesh-id': 'D001688'}, {'category': 'Biologics for Rheumatoid Arthritis Treatment', 'mesh-id': None}, {'category': 'Dermatologicals', 'mesh-id': 'D003879'}, {'category': 'Disease-modifying Antirheumatic Agents', 'mesh-id': None}, {'category': 'Immunoglobulin Constant Regions', 'mesh-id': 'D007127'}, {'category': 'Immunoglobulin Fc Fragments', 'mesh-id': 'D007141'}, {'category': 'Immunoglobulin Fragments', 'mesh-id': 'D007128'}, {'category': 'Immunoglobulin Isotypes', 'mesh-id': 'D007132'}, {'category': 'Immunologic Factors', 'mesh-id': 'D007155'}, {'category': 'Immunoproteins', 'mesh-id': 'D007162'}, {'category': 'Immunosuppressive Agents', 'mesh-id': 'D007166'}, {'category': 'Membrane Proteins', 'mesh-id': 'D008565'}, {'category': 'Peptides', 'mesh-id': 'D010455'}, {'category': 'Proteins', 'mesh-id': 'D011506'}, {'category': 'Tumor necrosis factor alpha (TNF-alpha) inhibitors', 'mesh-id': None}, {'category': 'Tumor Necrosis Factor Blockers', 'mesh-id': 'D000079424'}]}\n",
      "Name: categories, dtype: object\n",
      "0    {'affected-organism': 'Humans and other mammals'}\n",
      "1    {'affected-organism': 'Humans and other mammals'}\n",
      "2    {'affected-organism': 'Humans and other mammals'}\n",
      "3    {'affected-organism': 'Humans and other mammals'}\n",
      "4    {'affected-organism': 'Humans and other mammals'}\n",
      "Name: affected-organisms, dtype: object\n",
      "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       {'dosage': [{'form': 'Injection, powder, for suspension', 'route': 'Intravenous', 'strength': '50 mg'}, {'form': 'Injection, solution, concentrate', 'route': 'Intravenous', 'strength': '20 mg'}, {'form': 'Injection, solution, concentrate', 'route': 'Intravenous', 'strength': '50 mg'}, {'form': 'Powder', 'route': 'Intravenous', 'strength': None}, {'form': 'Powder', 'route': 'Intravenous', 'strength': '50 mg/1mL'}, {'form': 'Powder, for solution', 'route': 'Intravenous', 'strength': '50 mg / vial'}]}\n",
      "1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            {'dosage': [{'form': 'Injection', 'route': 'Intravenous', 'strength': None}, {'form': 'Injection, solution', 'route': 'Intravenous', 'strength': '5 mg/ml'}, {'form': 'Injection, solution', 'route': 'Intravenous; Parenteral', 'strength': '5 MG/ML'}, {'form': 'Solution', 'route': 'Intravenous', 'strength': '2 mg/1mL'}, {'form': 'Solution', 'route': 'Intravenous', 'strength': '2 mg / mL'}, {'form': 'Solution', 'route': 'Intravenous', 'strength': '5.000 mg'}, {'form': 'Solution', 'route': 'Intravenous', 'strength': '5 mg'}, {'form': 'Injection, solution', 'route': 'Intravenous', 'strength': '100 mg/20ml'}, {'form': 'Injection, solution', 'route': 'Intravenous', 'strength': '500 mg/100ml'}, {'form': 'Solution', 'route': 'Intravenous', 'strength': '5 mg/ml'}, {'form': 'Solution', 'route': 'Intravenous', 'strength': None}, {'form': 'Solution', 'route': 'Intravenous', 'strength': '5 mg/1ml'}]}\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       {'dosage': [{'form': 'Aerosol, spray', 'route': 'Respiratory (inhalation)', 'strength': '2.5 mg'}, {'form': 'Solution', 'route': 'Respiratory (inhalation)', 'strength': '1 mg/1mL'}, {'form': 'Solution', 'route': 'Respiratory (inhalation)', 'strength': '1 mg / mL'}, {'form': 'Solution', 'route': 'Respiratory (inhalation)', 'strength': '2.5 mg/2.5ml'}, {'form': 'Solution', 'route': 'Respiratory (inhalation)', 'strength': None}, {'form': 'Solution', 'route': 'Respiratory (inhalation)', 'strength': '2500 E./2.5ml'}, {'form': 'Solution', 'route': 'Respiratory (inhalation)', 'strength': '2.5 mg'}]}\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 {'dosage': {'form': 'Injection, solution', 'route': 'Intravenous', 'strength': '150 ug/1mL'}}\n",
      "4    {'dosage': [{'form': 'Injection, solution', 'route': 'Parenteral', 'strength': '25 MG'}, {'form': 'Injection, solution', 'route': 'Parenteral', 'strength': '50 MG'}, {'form': 'Injection', 'route': 'Subcutaneous', 'strength': None}, {'form': 'Injection, powder, for solution', 'route': 'Subcutaneous', 'strength': '10 MG'}, {'form': 'Injection, powder, for solution', 'route': 'Subcutaneous', 'strength': '25 MG/ML'}, {'form': 'Injection, powder, for solution', 'route': 'Subcutaneous', 'strength': '50 MG'}, {'form': 'Injection, powder, lyophilized, for solution; kit', 'route': 'Subcutaneous', 'strength': '25 mg/1mL'}, {'form': 'Kit', 'route': 'Subcutaneous', 'strength': None}, {'form': 'Kit; liquid; powder, for solution', 'route': 'Subcutaneous', 'strength': None}, {'form': 'Powder', 'route': 'Subcutaneous', 'strength': '25 MG'}, {'form': 'Solution', 'route': 'Parenteral; Subcutaneous', 'strength': '50 MG'}, {'form': 'Solution', 'route': 'Subcutaneous', 'strength': '25 mg/0.5mL'}, {'form': 'Solution', 'route': 'Subcutaneous', 'strength': '25.000 mg'}, {'form': 'Solution', 'route': 'Subcutaneous', 'strength': '50 mg / mL'}, {'form': 'Solution', 'route': 'Subcutaneous', 'strength': '50 mg/1mL'}, {'form': 'Solution', 'route': None, 'strength': '25 mg/0.5ml'}, {'form': 'Injection, powder, lyophilized, for solution', 'route': 'Subcutaneous', 'strength': '50 mg'}, {'form': 'Injection', 'route': 'Subcutaneous', 'strength': '25 mg/0.5ml'}, {'form': 'Powder', 'route': 'Parenteral', 'strength': '25 MG'}, {'form': 'Injection, solution', 'route': 'Subcutaneous', 'strength': '25 MG'}, {'form': 'Injection, solution', 'route': 'Subcutaneous', 'strength': '50 MG'}, {'form': 'Injection', 'route': 'Subcutaneous', 'strength': '25 mg'}, {'form': 'Injection', 'route': 'Subcutaneous', 'strength': '50 mg'}, {'form': 'Injection, solution', 'route': 'Subcutaneous', 'strength': '50 mg/mL'}, {'form': 'Solution', 'route': 'Subcutaneous', 'strength': '25 mg'}, {'form': 'Solution', 'route': 'Subcutaneous', 'strength': '50 mg'}, {'form': 'Injection, solution', 'route': 'Parenteral; Subcutaneous', 'strength': '25 MG'}, {'form': 'Injection, solution', 'route': 'Parenteral; Subcutaneous', 'strength': '50 MG'}, {'form': 'Solution', 'route': 'Subcutaneous', 'strength': '25 mg / 0.5 mL'}, {'form': 'Solution', 'route': 'Subcutaneous', 'strength': '25.00 mg'}, {'form': 'Injection, powder, lyophilized, for solution', 'route': 'Subcutaneous', 'strength': '25 mg'}, {'form': 'Injection, powder, lyophilized, for solution', 'route': 'Subcutaneous', 'strength': None}, {'form': 'Injection, solution', 'route': 'Subcutaneous', 'strength': '25 mg/0.5mL'}, {'form': 'Injection, solution', 'route': 'Subcutaneous', 'strength': '50 mg/1mL'}, {'form': 'Injection, powder, for solution', 'route': 'Subcutaneous', 'strength': '25 mg'}, {'form': 'Solution', 'route': None, 'strength': '25 mg'}, {'form': 'Solution', 'route': None, 'strength': '50 mg'}, {'form': 'Solution', 'route': 'Subcutaneous', 'strength': '50 mg / 1 mL'}, {'form': 'Injection, powder, for solution', 'route': 'Intramuscular', 'strength': '25 mg/25mg'}, {'form': 'Injection, solution', 'route': None, 'strength': '50 mg'}, {'form': 'Powder', 'route': None, 'strength': '25 mg/1vial'}]}\n",
      "Name: dosages, dtype: object\n",
      "0                                                                     {'atc-code': {'@code': 'B01AE02', 'level': [{'@code': 'B01AE', '#text': 'Direct thrombin inhibitors'}, {'@code': 'B01A', '#text': 'ANTITHROMBOTIC AGENTS'}, {'@code': 'B01', '#text': 'ANTITHROMBOTIC AGENTS'}, {'@code': 'B', '#text': 'BLOOD AND BLOOD FORMING ORGANS'}]}}\n",
      "1    {'atc-code': {'@code': 'L01FE01', 'level': [{'@code': 'L01FE', '#text': 'EGFR (Epidermal Growth Factor Receptor) inhibitors'}, {'@code': 'L01F', '#text': 'MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES'}, {'@code': 'L01', '#text': 'ANTINEOPLASTIC AGENTS'}, {'@code': 'L', '#text': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS'}]}}\n",
      "2                                                        {'atc-code': {'@code': 'R05CB13', 'level': [{'@code': 'R05CB', '#text': 'Mucolytics'}, {'@code': 'R05C', '#text': 'EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS'}, {'@code': 'R05', '#text': 'COUGH AND COLD PREPARATIONS'}, {'@code': 'R', '#text': 'RESPIRATORY SYSTEM'}]}}\n",
      "3                                                  {'atc-code': {'@code': 'L01XX29', 'level': [{'@code': 'L01XX', '#text': 'Other antineoplastic agents'}, {'@code': 'L01X', '#text': 'OTHER ANTINEOPLASTIC AGENTS'}, {'@code': 'L01', '#text': 'ANTINEOPLASTIC AGENTS'}, {'@code': 'L', '#text': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS'}]}}\n",
      "4                                       {'atc-code': {'@code': 'L04AB01', 'level': [{'@code': 'L04AB', '#text': 'Tumor necrosis factor alpha (TNF-alpha) inhibitors'}, {'@code': 'L04A', '#text': 'IMMUNOSUPPRESSANTS'}, {'@code': 'L04', '#text': 'IMMUNOSUPPRESSANTS'}, {'@code': 'L', '#text': 'ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS'}]}}\n",
      "Name: atc-codes, dtype: object\n",
      "0   NaN\n",
      "1   NaN\n",
      "2   NaN\n",
      "3   NaN\n",
      "4   NaN\n",
      "Name: ahfs-codes, dtype: float64\n",
      "0    NaN\n",
      "1    NaN\n",
      "2    NaN\n",
      "3    NaN\n",
      "4    NaN\n",
      "Name: pdb-entries, dtype: object\n",
      "0                                                                                                                                                                                                                                                                    {'patent': {'number': '5180668', 'country': 'United States', 'approved': '1993-01-19', 'expires': '2010-01-19', 'pediatric-extension': 'false'}}\n",
      "1                                                                                                                                                                                                                                                                           {'patent': {'number': '1340417', 'country': 'Canada', 'approved': '1999-03-02', 'expires': '2016-03-02', 'pediatric-extension': 'false'}}\n",
      "2                                                                                                                                          {'patent': [{'number': '2184581', 'country': 'Canada', 'approved': '2005-02-22', 'expires': '2015-02-28', 'pediatric-extension': 'false'}, {'number': '2137237', 'country': 'Canada', 'approved': '2004-10-26', 'expires': '2013-05-28', 'pediatric-extension': 'false'}]}\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                 NaN\n",
      "4    {'patent': [{'number': '2476934', 'country': 'Canada', 'approved': '2009-06-16', 'expires': '2023-02-27', 'pediatric-extension': 'false'}, {'number': '2123593', 'country': 'Canada', 'approved': '2000-03-14', 'expires': '2013-09-14', 'pediatric-extension': 'false'}, {'number': '7276477', 'country': 'United States', 'approved': '2007-10-02', 'expires': '2024-07-29', 'pediatric-extension': 'false'}]}\n",
      "Name: patents, dtype: object\n",
      "0    {'food-interaction': 'Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include chamomile, garlic, ginger, ginkgo and ginseng.'}\n",
      "1                                                                                                                                                              NaN\n",
      "2                                                                                                                                                              NaN\n",
      "3                                                                                                                                                              NaN\n",
      "4                                                                                                                                                              NaN\n",
      "Name: food-interactions, dtype: object\n",
      "0    {'drug-interaction': [{'drugbank-id': 'DB06605', 'name': 'Apixaban', 'description': 'Apixaban may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB06695', 'name': 'Dabigatran etexilate', 'description': 'Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB01254', 'name': 'Dasatinib', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.'}, {'drugbank-id': 'DB01609', 'name': 'Deferasirox', 'description': 'The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox.'}, {'drugbank-id': 'DB01586', 'name': 'Ursodeoxycholic acid', 'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.'}, {'drugbank-id': 'DB02123', 'name': 'Glycochenodeoxycholic Acid', 'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Glycochenodeoxycholic Acid.'}, {'drugbank-id': 'DB02659', 'name': 'Cholic Acid', 'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Cholic Acid.'}, {'drugbank-id': 'DB02691', 'name': 'Glycocholic acid', 'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Glycocholic acid.'}, {'drugbank-id': 'DB03619', 'name': 'Deoxycholic acid', 'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Deoxycholic acid.'}, {'drugbank-id': 'DB04348', 'name': 'Taurocholic acid', 'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Taurocholic acid.'}, {'drugbank-id': 'DB05990', 'name': 'Obeticholic acid', 'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Obeticholic acid.'}, {'drugbank-id': 'DB06777', 'name': 'Chenodeoxycholic acid', 'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Chenodeoxycholic acid.'}, {'drugbank-id': 'DB08833', 'name': 'Taurochenodeoxycholic acid', 'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Taurochenodeoxycholic acid.'}, {'drugbank-id': 'DB08834', 'name': 'Tauroursodeoxycholic acid', 'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Tauroursodeoxycholic acid.'}, {'drugbank-id': 'DB08857', 'name': 'Bamet-UD2', 'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Bamet-UD2.'}, {'drugbank-id': 'DB11622', 'name': 'Dehydrocholic acid', 'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Dehydrocholic acid.'}, {'drugbank-id': 'DB11789', 'name': 'Hyodeoxycholic Acid', 'description': 'The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Hyodeoxycholic Acid.'}, {'drugbank-id': 'DB09075', 'name': 'Edoxaban', 'description': 'The risk or severity of bleeding can be increased when Edoxaban is combined with Lepirudin.'}, {'drugbank-id': 'DB09053', 'name': 'Ibrutinib', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Lepirudin.'}, {'drugbank-id': 'DB08935', 'name': 'Obinutuzumab', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Obinutuzumab.'}, {'drugbank-id': 'DB06228', 'name': 'Rivaroxaban', 'description': 'Lepirudin may increase the anticoagulant activities of Rivaroxaban.'}, {'drugbank-id': 'DB06206', 'name': 'Sugammadex', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Sugammadex.'}, {'drugbank-id': 'DB09070', 'name': 'Tibolone', 'description': 'Tibolone may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB00932', 'name': 'Tipranavir', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Lepirudin.'}, {'drugbank-id': 'DB00013', 'name': 'Urokinase', 'description': 'Urokinase may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB00163', 'name': 'Vitamin E', 'description': 'Vitamin E may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB09030', 'name': 'Vorapaxar', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Lepirudin.'}, {'drugbank-id': 'DB01381', 'name': 'Ginkgo biloba', 'description': 'Ginkgo biloba may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB01181', 'name': 'Ifosfamide', 'description': 'The risk or severity of bleeding can be increased when Ifosfamide is combined with Lepirudin.'}, {'drugbank-id': 'DB00468', 'name': 'Quinine', 'description': 'The therapeutic efficacy of Lepirudin can be increased when used in combination with Quinine.'}, {'drugbank-id': 'DB00908', 'name': 'Quinidine', 'description': 'The therapeutic efficacy of Lepirudin can be increased when used in combination with Quinidine.'}, {'drugbank-id': 'DB00675', 'name': 'Tamoxifen', 'description': 'The risk or severity of bleeding can be increased when Tamoxifen is combined with Lepirudin.'}, {'drugbank-id': 'DB00539', 'name': 'Toremifene', 'description': 'The risk or severity of bleeding can be increased when Toremifene is combined with Lepirudin.'}, {'drugbank-id': 'DB00806', 'name': 'Pentoxifylline', 'description': 'The therapeutic efficacy of Lepirudin can be increased when used in combination with Pentoxifylline.'}, {'drugbank-id': 'DB00686', 'name': 'Pentosan polysulfate', 'description': 'Pentosan polysulfate may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB00583', 'name': 'Levocarnitine', 'description': 'The therapeutic efficacy of Lepirudin can be increased when used in combination with Levocarnitine.'}, {'drugbank-id': 'DB00255', 'name': 'Diethylstilbestrol', 'description': 'Diethylstilbestrol may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB00269', 'name': 'Chlorotrianisene', 'description': 'Chlorotrianisene may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB00286', 'name': 'Conjugated estrogens', 'description': 'Conjugated estrogens may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB01357', 'name': 'Mestranol', 'description': 'The risk or severity of adverse effects can be increased when Mestranol is combined with Lepirudin.'}, {'drugbank-id': 'DB04574', 'name': 'Estrone sulfate', 'description': 'Estrone sulfate may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB04575', 'name': 'Quinestrol', 'description': 'Quinestrol may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB07931', 'name': 'Hexestrol', 'description': 'Hexestrol may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB09317', 'name': 'Synthetic Conjugated Estrogens, A', 'description': 'Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB09318', 'name': 'Synthetic Conjugated Estrogens, B', 'description': 'Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB09369', 'name': 'Polyestradiol phosphate', 'description': 'Polyestradiol phosphate may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB09381', 'name': 'Esterified estrogens', 'description': 'Esterified estrogens may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB11478', 'name': 'Zeranol', 'description': 'Zeranol may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB11674', 'name': 'Equol', 'description': 'Equol may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB13143', 'name': 'Methallenestril', 'description': 'Methallenestril may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB13386', 'name': 'Epimestrol', 'description': 'Epimestrol may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB13418', 'name': 'Moxestrol', 'description': 'Moxestrol may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB13952', 'name': 'Estradiol acetate', 'description': 'Estradiol acetate may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB13953', 'name': 'Estradiol benzoate', 'description': 'Estradiol benzoate may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB13954', 'name': 'Estradiol cypionate', 'description': 'Estradiol cypionate may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB13956', 'name': 'Estradiol valerate', 'description': 'Estradiol valerate may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB15334', 'name': 'Biochanin A', 'description': 'Biochanin A may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB15335', 'name': 'Formononetin', 'description': 'Formononetin may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB04573', 'name': 'Estriol', 'description': 'Estriol may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB09211', 'name': 'Limaprost', 'description': 'The risk or severity of adverse effects can be increased when Limaprost is combined with Lepirudin.'}, {'drugbank-id': 'DB00159', 'name': 'Icosapent', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Lepirudin.'}, {'drugbank-id': 'DB00244', 'name': 'Mesalazine', 'description': 'The risk or severity of bleeding can be increased when Mesalazine is combined with Lepirudin.'}, {'drugbank-id': 'DB00328', 'name': 'Indomethacin', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Lepirudin.'}, {'drugbank-id': 'DB00461', 'name': 'Nabumetone', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Lepirudin.'}, {'drugbank-id': 'DB00465', 'name': 'Ketorolac', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Lepirudin.'}, {'drugbank-id': 'DB00469', 'name': 'Tenoxicam', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Lepirudin.'}, {'drugbank-id': 'DB00482', 'name': 'Celecoxib', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Lepirudin.'}, {'drugbank-id': 'DB00500', 'name': 'Tolmetin', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Lepirudin.'}, {'drugbank-id': 'DB00533', 'name': 'Rofecoxib', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Lepirudin.'}, {'drugbank-id': 'DB00554', 'name': 'Piroxicam', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Lepirudin.'}, {'drugbank-id': 'DB00573', 'name': 'Fenoprofen', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Lepirudin.'}, {'drugbank-id': 'DB00580', 'name': 'Valdecoxib', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Lepirudin.'}, {'drugbank-id': 'DB00586', 'name': 'Diclofenac', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Lepirudin.'}, {'drugbank-id': 'DB00605', 'name': 'Sulindac', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Lepirudin.'}, {'drugbank-id': 'DB00712', 'name': 'Flurbiprofen', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Lepirudin.'}, {'drugbank-id': 'DB00749', 'name': 'Etodolac', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Lepirudin.'}, {'drugbank-id': 'DB00784', 'name': 'Mefenamic acid', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Lepirudin.'}, {'drugbank-id': 'DB00788', 'name': 'Naproxen', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Lepirudin.'}, {'drugbank-id': 'DB00795', 'name': 'Sulfasalazine', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Lepirudin.'}, {'drugbank-id': 'DB00812', 'name': 'Phenylbutazone', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Lepirudin.'}, {'drugbank-id': 'DB00814', 'name': 'Meloxicam', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Lepirudin.'}, {'drugbank-id': 'DB00821', 'name': 'Carprofen', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Lepirudin.'}, {'drugbank-id': 'DB00861', 'name': 'Diflunisal', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Lepirudin.'}, {'drugbank-id': 'DB00936', 'name': 'Salicylic acid', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Lepirudin.'}, {'drugbank-id': 'DB00939', 'name': 'Meclofenamic acid', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Lepirudin.'}, {'drugbank-id': 'DB00991', 'name': 'Oxaprozin', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Lepirudin.'}, {'drugbank-id': 'DB01009', 'name': 'Ketoprofen', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Lepirudin.'}, {'drugbank-id': 'DB01014', 'name': 'Balsalazide', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Lepirudin.'}, {'drugbank-id': 'DB01250', 'name': 'Olsalazine', 'description': 'The risk or severity of bleeding can be increased when Olsalazine is combined with Lepirudin.'}, {'drugbank-id': 'DB01283', 'name': 'Lumiracoxib', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Lepirudin.'}, {'drugbank-id': 'DB01397', 'name': 'Magnesium salicylate', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Lepirudin.'}, {'drugbank-id': 'DB01399', 'name': 'Salsalate', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Lepirudin.'}, {'drugbank-id': 'DB01401', 'name': 'Choline magnesium trisalicylate', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Lepirudin.'}, {'drugbank-id': 'DB01419', 'name': 'Antrafenine', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Lepirudin.'}, {'drugbank-id': 'DB01424', 'name': 'Aminophenazone', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Lepirudin.'}, {'drugbank-id': 'DB01435', 'name': 'Antipyrine', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Lepirudin.'}, {'drugbank-id': 'DB01600', 'name': 'Tiaprofenic acid', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Lepirudin.'}, {'drugbank-id': 'DB01628', 'name': 'Etoricoxib', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Lepirudin.'}, {'drugbank-id': 'DB02224', 'name': 'Taxifolin', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Lepirudin.'}, {'drugbank-id': 'DB03585', 'name': 'Oxyphenbutazone', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Lepirudin.'}, {'drugbank-id': 'DB04725', 'name': 'Licofelone', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Lepirudin.'}, {'drugbank-id': 'DB04812', 'name': 'Benoxaprofen', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Lepirudin.'}, {'drugbank-id': 'DB04828', 'name': 'Zomepirac', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Lepirudin.'}, {'drugbank-id': 'DB05095', 'name': 'Cimicoxib', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Lepirudin.'}, {'drugbank-id': 'DB06725', 'name': 'Lornoxicam', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Lepirudin.'}, {'drugbank-id': 'DB06736', 'name': 'Aceclofenac', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Lepirudin.'}, {'drugbank-id': 'DB06737', 'name': 'Zaltoprofen', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Lepirudin.'}, {'drugbank-id': 'DB07402', 'name': 'Azapropazone', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Lepirudin.'}, {'drugbank-id': 'DB08439', 'name': 'Parecoxib', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Lepirudin.'}, {'drugbank-id': 'DB08797', 'name': 'Salicylamide', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Lepirudin.'}, {'drugbank-id': 'DB08940', 'name': 'Kebuzone', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Lepirudin.'}, {'drugbank-id': 'DB08942', 'name': 'Isoxicam', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Lepirudin.'}, {'drugbank-id': 'DB08951', 'name': 'Indoprofen', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Lepirudin.'}, {'drugbank-id': 'DB08955', 'name': 'Ibuproxam', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Lepirudin.'}, {'drugbank-id': 'DB08976', 'name': 'Floctafenine', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Lepirudin.'}, {'drugbank-id': 'DB08981', 'name': 'Fenbufen', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Lepirudin.'}, {'drugbank-id': 'DB08984', 'name': 'Etofenamate', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Lepirudin.'}, {'drugbank-id': 'DB08991', 'name': 'Epirizole', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Lepirudin.'}, {'drugbank-id': 'DB09084', 'name': 'Benzydamine', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Lepirudin.'}, {'drugbank-id': 'DB09214', 'name': 'Dexketoprofen', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Lepirudin.'}, {'drugbank-id': 'DB09215', 'name': 'Droxicam', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Lepirudin.'}, {'drugbank-id': 'DB09216', 'name': 'Tolfenamic acid', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Lepirudin.'}, {'drugbank-id': 'DB09217', 'name': 'Firocoxib', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Lepirudin.'}, {'drugbank-id': 'DB09218', 'name': 'Clonixin', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Lepirudin.'}, {'drugbank-id': 'DB09285', 'name': 'Morniflumate', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Lepirudin.'}, {'drugbank-id': 'DB09288', 'name': 'Propacetamol', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Lepirudin.'}, {'drugbank-id': 'DB09295', 'name': 'Talniflumate', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Lepirudin.'}, {'drugbank-id': 'DB11455', 'name': 'Robenacoxib', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Lepirudin.'}, {'drugbank-id': 'DB11466', 'name': 'Tepoxalin', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Lepirudin.'}, {'drugbank-id': 'DB11518', 'name': 'Flunixin', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Lepirudin.'}, {'drugbank-id': 'DB12399', 'name': 'Polmacoxib', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Lepirudin.'}, {'drugbank-id': 'DB12610', 'name': 'Ebselen', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Lepirudin.'}, {'drugbank-id': 'DB13001', 'name': 'Tinoridine', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Lepirudin.'}, {'drugbank-id': 'DB13167', 'name': 'Alclofenac', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Lepirudin.'}, {'drugbank-id': 'DB13217', 'name': 'Fentiazac', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Lepirudin.'}, {'drugbank-id': 'DB13232', 'name': 'Suxibuzone', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Lepirudin.'}, {'drugbank-id': 'DB13286', 'name': 'Bumadizone', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Lepirudin.'}, {'drugbank-id': 'DB13314', 'name': 'Alminoprofen', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Lepirudin.'}, {'drugbank-id': 'DB13371', 'name': 'Difenpiramide', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Lepirudin.'}, {'drugbank-id': 'DB13407', 'name': 'Nifenazone', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Lepirudin.'}, {'drugbank-id': 'DB13432', 'name': 'Lonazolac', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Lepirudin.'}, {'drugbank-id': 'DB13481', 'name': 'Tenidap', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Lepirudin.'}, {'drugbank-id': 'DB13524', 'name': 'Propyphenazone', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Lepirudin.'}, {'drugbank-id': 'DB13527', 'name': 'Proglumetacin', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Lepirudin.'}, {'drugbank-id': 'DB13538', 'name': 'Guacetisal', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Lepirudin.'}, {'drugbank-id': 'DB13544', 'name': 'Ethenzamide', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Lepirudin.'}, {'drugbank-id': 'DB13612', 'name': 'Carbaspirin calcium', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Lepirudin.'}, {'drugbank-id': 'DB13629', 'name': 'Mofebutazone', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Lepirudin.'}, {'drugbank-id': 'DB13649', 'name': 'Proquazone', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Lepirudin.'}, {'drugbank-id': 'DB13657', 'name': 'Benorilate', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Lepirudin.'}, {'drugbank-id': 'DB13722', 'name': 'Pirprofen', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Lepirudin.'}, {'drugbank-id': 'DB13860', 'name': 'Imidazole salicylate', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Lepirudin.'}, {'drugbank-id': 'DB14059', 'name': 'SC-236', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Lepirudin.'}, {'drugbank-id': 'DB14060', 'name': 'NS-398', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Lepirudin.'}, {'drugbank-id': 'DB14938', 'name': 'Flurbiprofen axetil', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Lepirudin.'}, {'drugbank-id': 'DB09212', 'name': 'Loxoprofen', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Lepirudin.'}, {'drugbank-id': 'DB04552', 'name': 'Niflumic acid', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Lepirudin.'}, {'drugbank-id': 'DB04865', 'name': 'Omacetaxine mepesuccinate', 'description': 'The risk or severity of bleeding can be increased when Lepirudin is combined with Omacetaxine mepesuccinate.'}, {'drugbank-id': 'DB11133', 'name': 'Omega-3 fatty acids', 'description': 'Omega-3 fatty acids may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB00081', 'name': 'Tositumomab', 'description': 'The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Tositumomab.'}, {'drugbank-id': 'DB00048', 'name': 'Collagenase clostridium histolyticum', 'description': 'The risk or severity of adverse effects can be increased when Lepirudin is combined with Collagenase clostridium histolyticum.'}, {'drugbank-id': 'DB00389', 'name': 'Carbimazole', 'description': 'Carbimazole may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB00550', 'name': 'Propylthiouracil', 'description': 'Propylthiouracil may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB00763', 'name': 'Methimazole', 'description': 'Methimazole may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB03374', 'name': '3,5-Diiodotyrosine', 'description': '3,5-Diiodotyrosine may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB06715', 'name': 'Potassium Iodide', 'description': 'Potassium Iodide may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB07637', 'name': 'Dibromotyrosine', 'description': 'Dibromotyrosine may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB09418', 'name': 'Potassium perchlorate', 'description': 'Potassium perchlorate may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB13644', 'name': 'Methylthiouracil', 'description': 'Methylthiouracil may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB13804', 'name': 'Benzylthiouracil', 'description': 'Benzylthiouracil may increase the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB04066', 'name': 'p-Coumaric acid', 'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with p-Coumaric acid.'}, {'drugbank-id': 'DB04682', 'name': 'Octylphenoxy polyethoxyethanol', 'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Octylphenoxy polyethoxyethanol.'}, {'drugbank-id': 'DB05830', 'name': 'Trestolone', 'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Trestolone.'}, {'drugbank-id': 'DB06266', 'name': 'Lonidamine', 'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Lonidamine.'}, {'drugbank-id': 'DB08867', 'name': 'Ulipristal', 'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ulipristal.'}, {'drugbank-id': 'DB11507', 'name': 'Cloprostenol', 'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cloprostenol.'}, {'drugbank-id': 'DB12025', 'name': 'Triptolide', 'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Triptolide.'}, {'drugbank-id': 'DB13044', 'name': 'Gossypol', 'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gossypol.'}, {'drugbank-id': 'DB00294', 'name': 'Etonogestrel', 'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Etonogestrel.'}, {'drugbank-id': 'DB00378', 'name': 'Dydrogesterone', 'description': 'Dydrogesterone may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB00396', 'name': 'Progesterone', 'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Progesterone.'}, {'drugbank-id': 'DB01431', 'name': 'Allylestrenol', 'description': 'Allylestrenol may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB06713', 'name': 'Norelgestromin', 'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Norelgestromin.'}, {'drugbank-id': 'DB06789', 'name': 'Hydroxyprogesterone caproate', 'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydroxyprogesterone caproate.'}, {'drugbank-id': 'DB09124', 'name': 'Medrogestone', 'description': 'Medrogestone may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB11372', 'name': 'Altrenogest', 'description': 'Altrenogest may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB11636', 'name': 'Nomegestrol', 'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Nomegestrol.'}, {'drugbank-id': 'DB13230', 'name': 'Gestonorone', 'description': 'Gestonorone may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB13533', 'name': 'Methylestrenolone', 'description': 'Methylestrenolone may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB13602', 'name': 'Promegestone', 'description': 'Promegestone may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB13866', 'name': 'Etynodiol', 'description': 'The therapeutic efficacy of Lepirudin can be decreased when used in combination with Etynodiol.'}, {'drugbank-id': 'DB14570', 'name': 'Hydroxyprogesterone', 'description': 'Hydroxyprogesterone may decrease the anticoagulant activities of Lepirudin.'}, {'drugbank-id': 'DB14679', 'name': 'Quingestanol acetate', 'description': 'Quingestanol acetate ma\n",
      "1    {'drug-interaction': [{'drugbank-id': 'DB00255', 'name': 'Diethylstilbestrol', 'description': 'Diethylstilbestrol may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB00269', 'name': 'Chlorotrianisene', 'description': 'Chlorotrianisene may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB00286', 'name': 'Conjugated estrogens', 'description': 'Conjugated estrogens may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB00655', 'name': 'Estrone', 'description': 'Estrone may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB00783', 'name': 'Estradiol', 'description': 'Estradiol may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB00890', 'name': 'Dienestrol', 'description': 'Dienestrol may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB00977', 'name': 'Ethinylestradiol', 'description': 'Ethinylestradiol may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB01357', 'name': 'Mestranol', 'description': 'Mestranol may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB04573', 'name': 'Estriol', 'description': 'Estriol may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB04574', 'name': 'Estrone sulfate', 'description': 'Estrone sulfate may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB04575', 'name': 'Quinestrol', 'description': 'Quinestrol may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB07931', 'name': 'Hexestrol', 'description': 'Hexestrol may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB09070', 'name': 'Tibolone', 'description': 'Tibolone may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB09317', 'name': 'Synthetic Conjugated Estrogens, A', 'description': 'Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB09318', 'name': 'Synthetic Conjugated Estrogens, B', 'description': 'Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB09369', 'name': 'Polyestradiol phosphate', 'description': 'Polyestradiol phosphate may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB09381', 'name': 'Esterified estrogens', 'description': 'Esterified estrogens may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB11478', 'name': 'Zeranol', 'description': 'Zeranol may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB11674', 'name': 'Equol', 'description': 'Equol may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB12487', 'name': 'Promestriene', 'description': 'Promestriene may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB13143', 'name': 'Methallenestril', 'description': 'Methallenestril may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB13386', 'name': 'Epimestrol', 'description': 'Epimestrol may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB13418', 'name': 'Moxestrol', 'description': 'Moxestrol may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB13952', 'name': 'Estradiol acetate', 'description': 'Estradiol acetate may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB13953', 'name': 'Estradiol benzoate', 'description': 'Estradiol benzoate may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB13954', 'name': 'Estradiol cypionate', 'description': 'Estradiol cypionate may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB13956', 'name': 'Estradiol valerate', 'description': 'Estradiol valerate may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB15334', 'name': 'Biochanin A', 'description': 'Biochanin A may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB15335', 'name': 'Formononetin', 'description': 'Formononetin may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB12235', 'name': 'Estetrol', 'description': 'Estetrol may increase the thrombogenic activities of Cetuximab.'}, {'drugbank-id': 'DB00028', 'name': 'Human immunoglobulin G', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Human immunoglobulin G.'}, {'drugbank-id': 'DB00043', 'name': 'Omalizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Omalizumab.'}, {'drugbank-id': 'DB00051', 'name': 'Adalimumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Adalimumab.'}, {'drugbank-id': 'DB00054', 'name': 'Abciximab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Abciximab.'}, {'drugbank-id': 'DB00056', 'name': 'Gemtuzumab ozogamicin', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Gemtuzumab ozogamicin.'}, {'drugbank-id': 'DB00057', 'name': 'Indium In-111 satumomab pendetide', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Indium In-111 satumomab pendetide.'}, {'drugbank-id': 'DB00065', 'name': 'Infliximab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Infliximab.'}, {'drugbank-id': 'DB00072', 'name': 'Trastuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Trastuzumab.'}, {'drugbank-id': 'DB00073', 'name': 'Rituximab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Rituximab.'}, {'drugbank-id': 'DB00074', 'name': 'Basiliximab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Basiliximab.'}, {'drugbank-id': 'DB00075', 'name': 'Muromonab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Muromonab.'}, {'drugbank-id': 'DB00076', 'name': 'Digoxin Immune Fab (Ovine)', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Digoxin Immune Fab (Ovine).'}, {'drugbank-id': 'DB00078', 'name': 'Ibritumomab tiuxetan', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Ibritumomab tiuxetan.'}, {'drugbank-id': 'DB00081', 'name': 'Tositumomab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Tositumomab.'}, {'drugbank-id': 'DB00087', 'name': 'Alemtuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Alemtuzumab.'}, {'drugbank-id': 'DB00089', 'name': 'Capromab pendetide', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Capromab pendetide.'}, {'drugbank-id': 'DB00095', 'name': 'Efalizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Efalizumab.'}, {'drugbank-id': 'DB00098', 'name': 'Antithymocyte immunoglobulin (rabbit)', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Antithymocyte immunoglobulin (rabbit).'}, {'drugbank-id': 'DB00108', 'name': 'Natalizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Natalizumab.'}, {'drugbank-id': 'DB00110', 'name': 'Palivizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Palivizumab.'}, {'drugbank-id': 'DB00111', 'name': 'Daclizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Daclizumab.'}, {'drugbank-id': 'DB00112', 'name': 'Bevacizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Bevacizumab.'}, {'drugbank-id': 'DB00113', 'name': 'Technetium Tc-99m arcitumomab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Technetium Tc-99m arcitumomab.'}, {'drugbank-id': 'DB01257', 'name': 'Eculizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Eculizumab.'}, {'drugbank-id': 'DB01269', 'name': 'Panitumumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Panitumumab.'}, {'drugbank-id': 'DB01270', 'name': 'Ranibizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Ranibizumab.'}, {'drugbank-id': 'DB04901', 'name': 'Galiximab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Galiximab.'}, {'drugbank-id': 'DB04949', 'name': 'Pexelizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Pexelizumab.'}, {'drugbank-id': 'DB04956', 'name': 'Afelimomab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Afelimomab.'}, {'drugbank-id': 'DB04958', 'name': 'Epratuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Epratuzumab.'}, {'drugbank-id': 'DB04962', 'name': 'Bectumomab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Bectumomab.'}, {'drugbank-id': 'DB04964', 'name': 'Oregovomab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Oregovomab.'}, {'drugbank-id': 'DB04988', 'name': 'IGN311', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with IGN311.'}, {'drugbank-id': 'DB05006', 'name': 'Adecatumumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Adecatumumab.'}, {'drugbank-id': 'DB05097', 'name': 'Labetuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Labetuzumab.'}, {'drugbank-id': 'DB05101', 'name': 'Matuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Matuzumab.'}, {'drugbank-id': 'DB05111', 'name': 'Fontolizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Fontolizumab.'}, {'drugbank-id': 'DB05136', 'name': 'Bavituximab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Bavituximab.'}, {'drugbank-id': 'DB05139', 'name': 'CR002', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with CR002.'}, {'drugbank-id': 'DB05209', 'name': 'Rozrolimupab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Rozrolimupab.'}, {'drugbank-id': 'DB05304', 'name': 'Girentuximab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Girentuximab.'}, {'drugbank-id': 'DB05336', 'name': 'Obiltoxaximab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Obiltoxaximab.'}, {'drugbank-id': 'DB05405', 'name': 'XTL-001', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with XTL-001.'}, {'drugbank-id': 'DB05437', 'name': 'NAV 1800', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with NAV 1800.'}, {'drugbank-id': 'DB05459', 'name': 'Briakinumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Briakinumab.'}, {'drugbank-id': 'DB05496', 'name': 'Otelixizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Otelixizumab.'}, {'drugbank-id': 'DB05545', 'name': 'AMG 108', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with AMG 108.'}, {'drugbank-id': 'DB05550', 'name': 'Iratumumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Iratumumab.'}, {'drugbank-id': 'DB05555', 'name': 'Enokizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Enokizumab.'}, {'drugbank-id': 'DB05578', 'name': 'Ramucirumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Ramucirumab.'}, {'drugbank-id': 'DB05595', 'name': 'Farletuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Farletuzumab.'}, {'drugbank-id': 'DB05656', 'name': 'Veltuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Veltuzumab.'}, {'drugbank-id': 'DB05679', 'name': 'Ustekinumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Ustekinumab.'}, {'drugbank-id': 'DB05773', 'name': 'Trastuzumab emtansine', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Trastuzumab emtansine.'}, {'drugbank-id': 'DB05793', 'name': 'PRO-542', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with PRO-542.'}, {'drugbank-id': 'DB05797', 'name': 'TNX-901', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with TNX-901.'}, {'drugbank-id': 'DB05889', 'name': 'Inotuzumab ozogamicin', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Inotuzumab ozogamicin.'}, {'drugbank-id': 'DB05892', 'name': 'RI 624', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with RI 624.'}, {'drugbank-id': 'DB05915', 'name': 'Stamulumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with MYO-029.'}, {'drugbank-id': 'DB05916', 'name': 'CT-011', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with CT-011.'}, {'drugbank-id': 'DB05941', 'name': 'Leronlimab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Leronlimab.'}, {'drugbank-id': 'DB05996', 'name': 'Glembatumumab vedotin', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Glembatumumab vedotin.'}, {'drugbank-id': 'DB06043', 'name': 'Olaratumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Olaratumab.'}, {'drugbank-id': 'DB06049', 'name': 'IPH 2101', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with IPH 2101.'}, {'drugbank-id': 'DB06050', 'name': 'TB-402', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with TB-402.'}, {'drugbank-id': 'DB06081', 'name': 'Caplacizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Caplacizumab.'}, {'drugbank-id': 'DB06101', 'name': 'IMC-1C11', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with IMC-1C11.'}, {'drugbank-id': 'DB06116', 'name': 'Eldelumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Eldelumab.'}, {'drugbank-id': 'DB06162', 'name': 'Lumiliximab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Lumiliximab.'}, {'drugbank-id': 'DB06168', 'name': 'Canakinumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Canakinumab.'}, {'drugbank-id': 'DB06186', 'name': 'Ipilimumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Ipilimumab.'}, {'drugbank-id': 'DB06192', 'name': 'Nimotuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Nimotuzumab.'}, {'drugbank-id': 'DB06241', 'name': 'Clenoliximab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Clenoliximab.'}, {'drugbank-id': 'DB06273', 'name': 'Tocilizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Tocilizumab.'}, {'drugbank-id': 'DB06304', 'name': 'BIIB015', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with BIIB015.'}, {'drugbank-id': 'DB06305', 'name': 'Sonepcizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Sonepcizumab.'}, {'drugbank-id': 'DB06310', 'name': 'Motavizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Motavizumab.'}, {'drugbank-id': 'DB06317', 'name': 'Elotuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Elotuzumab.'}, {'drugbank-id': 'DB06318', 'name': 'AVE9633', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with AVE9633.'}, {'drugbank-id': 'DB06322', 'name': 'Carotuximab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Carotuximab.'}, {'drugbank-id': 'DB06324', 'name': 'XmAb 2513', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with XmAb 2513.'}, {'drugbank-id': 'DB06342', 'name': 'Coltuximab ravtansine', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Coltuximab ravtansine.'}, {'drugbank-id': 'DB06360', 'name': 'Lucatumumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Lucatumumab.'}, {'drugbank-id': 'DB06366', 'name': 'Pertuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Pertuzumab.'}, {'drugbank-id': 'DB06371', 'name': 'Siplizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Siplizumab.'}, {'drugbank-id': 'DB06467', 'name': 'Apolizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Apolizumab.'}, {'drugbank-id': 'DB06474', 'name': 'Sibrotuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Sibrotuzumab.'}, {'drugbank-id': 'DB06550', 'name': 'Bivatuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Bivatuzumab.'}, {'drugbank-id': 'DB06557', 'name': 'Lerdelimumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Lerdelimumab.'}, {'drugbank-id': 'DB06599', 'name': 'Lexatumumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Lexatumumab.'}, {'drugbank-id': 'DB06602', 'name': 'Reslizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Reslizumab.'}, {'drugbank-id': 'DB06606', 'name': 'Teplizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Teplizumab.'}, {'drugbank-id': 'DB06607', 'name': 'Catumaxomab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Catumaxomab.'}, {'drugbank-id': 'DB06612', 'name': 'Mepolizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Mepolizumab.'}, {'drugbank-id': 'DB06643', 'name': 'Denosumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Denosumab.'}, {'drugbank-id': 'DB06647', 'name': 'Volociximab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Volociximab.'}, {'drugbank-id': 'DB06650', 'name': 'Ofatumumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Ofatumumab.'}, {'drugbank-id': 'DB06674', 'name': 'Golimumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Golimumab.'}, {'drugbank-id': 'DB08870', 'name': 'Brentuximab vedotin', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Brentuximab vedotin.'}, {'drugbank-id': 'DB08879', 'name': 'Belimumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Belimumab.'}, {'drugbank-id': 'DB08902', 'name': 'Raxibacumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Raxibacumab.'}, {'drugbank-id': 'DB08935', 'name': 'Obinutuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Obinutuzumab.'}, {'drugbank-id': 'DB09029', 'name': 'Secukinumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Secukinumab.'}, {'drugbank-id': 'DB09033', 'name': 'Vedolizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Vedolizumab.'}, {'drugbank-id': 'DB09035', 'name': 'Nivolumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Nivolumab.'}, {'drugbank-id': 'DB09036', 'name': 'Siltuximab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Siltuximab.'}, {'drugbank-id': 'DB09037', 'name': 'Pembrolizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Pembrolizumab.'}, {'drugbank-id': 'DB09045', 'name': 'Dulaglutide', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Dulaglutide.'}, {'drugbank-id': 'DB09052', 'name': 'Blinatumomab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Blinatumomab.'}, {'drugbank-id': 'DB09057', 'name': 'Anthrax immune globulin human', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Anthrax immune globulin human.'}, {'drugbank-id': 'DB09077', 'name': 'Dinutuximab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Dinutuximab.'}, {'drugbank-id': 'DB09105', 'name': 'Asfotase alfa', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Asfotase alfa.'}, {'drugbank-id': 'DB09264', 'name': 'Idarucizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Idarucizumab.'}, {'drugbank-id': 'DB09302', 'name': 'Alirocumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Alirocumab.'}, {'drugbank-id': 'DB09303', 'name': 'Evolocumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Evolocumab.'}, {'drugbank-id': 'DB09312', 'name': 'Antilymphocyte immunoglobulin (horse)', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Antilymphocyte immunoglobulin (horse).'}, {'drugbank-id': 'DB09331', 'name': 'Daratumumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Daratumumab.'}, {'drugbank-id': 'DB09559', 'name': 'Necitumumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Necitumumab.'}, {'drugbank-id': 'DB11569', 'name': 'Ixekizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Ixekizumab.'}, {'drugbank-id': 'DB11580', 'name': 'Ravulizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Ravulizumab.'}, {'drugbank-id': 'DB11595', 'name': 'Atezolizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Atezolizumab.'}, {'drugbank-id': 'DB11604', 'name': 'Tetanus immune globulin, human', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Tetanus immune globulin, human.'}, {'drugbank-id': 'DB11608', 'name': 'Eftrenonacog alfa', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Eftrenonacog alfa.'}, {'drugbank-id': 'DB11621', 'name': 'Human varicella-zoster immune globulin', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Human varicella-zoster immune globulin.'}, {'drugbank-id': 'DB11646', 'name': 'Conatumumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Conatumumab.'}, {'drugbank-id': 'DB11657', 'name': 'Tabalumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Tabalumab.'}, {'drugbank-id': 'DB11680', 'name': 'Ficlatuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Ficlatuzumab.'}, {'drugbank-id': 'DB11685', 'name': 'Figitumumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Figitumumab.'}, {'drugbank-id': 'DB11714', 'name': 'Durvalumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Durvalumab.'}, {'drugbank-id': 'DB11715', 'name': 'Bapineuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Bapineuzumab.'}, {'drugbank-id': 'DB11731', 'name': 'Depatuxizumab mafodotin', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Depatuxizumab mafodotin.'}, {'drugbank-id': 'DB11746', 'name': 'Onartuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Onartuzumab.'}, {'drugbank-id': 'DB11756', 'name': 'Solanezumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Solanezumab.'}, {'drugbank-id': 'DB11767', 'name': 'Sarilumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Sarilumab.'}, {'drugbank-id': 'DB11771', 'name': 'Tremelimumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Tremelimumab.'}, {'drugbank-id': 'DB11776', 'name': 'Brodalumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Brodalumab.'}, {'drugbank-id': 'DB11803', 'name': 'Sirukumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Sirukumab.'}, {'drugbank-id': 'DB11826', 'name': 'Lampalizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Lampalizumab.'}, {'drugbank-id': 'DB11834', 'name': 'Guselkumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Guselkumab.'}, {'drugbank-id': 'DB11840', 'name': 'Dalotuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Dalotuzumab.'}, {'drugbank-id': 'DB11849', 'name': 'Emibetuzumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Emibetuzumab.'}, {'drugbank-id': 'DB11850', 'name': 'Ublituximab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Ublituximab.'}, {'drugbank-id': 'DB11856', 'name': 'Ligelizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Ligelizumab.'}, {'drugbank-id': 'DB11857', 'name': 'Seribantumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Seribantumab.'}, {'drugbank-id': 'DB11862', 'name': 'Landogrozumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Landogrozumab.'}, {'drugbank-id': 'DB11866', 'name': 'Romosozumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Romosozumab.'}, {'drugbank-id': 'DB11884', 'name': 'Vadastuximab talirine', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Vadastuximab talirine.'}, {'drugbank-id': 'DB11914', 'name': 'Lebrikizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Lebrikizumab.'}, {'drugbank-id': 'DB11930', 'name': 'Varlilumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Varlilumab.'}, {'drugbank-id': 'DB11945', 'name': 'Avelumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Avelumab.'}, {'drugbank-id': 'DB11959', 'name': 'Crenezumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Crenezumab.'}, {'drugbank-id': 'DB11972', 'name': 'Rilotumumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Rilotumumab.'}, {'drugbank-id': 'DB11976', 'name': 'Anifrolumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Anifrolumab.'}, {'drugbank-id': 'DB11988', 'name': 'Ocrelizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Ocrelizumab.'}, {'drugbank-id': 'DB12023', 'name': 'Benralizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Benralizumab.'}, {'drugbank-id': 'DB12034', 'name': 'Gantenerumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Gantenerumab.'}, {'drugbank-id': 'DB12053', 'name': 'Visilizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Visilizumab.'}, {'drugbank-id': 'DB12077', 'name': 'Urelumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Urelumab.'}, {'drugbank-id': 'DB12089', 'name': 'Lorvotuzumab mertansine', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Lorvotuzumab mertansine.'}, {'drugbank-id': 'DB12090', 'name': 'Patritumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Patritumab.'}, {'drugbank-id': 'DB12102', 'name': 'Fulranumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Fulranumab.'}, {'drugbank-id': 'DB12104', 'name': 'Tarextumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Tarextumab.'}, {'drugbank-id': 'DB12118', 'name': 'Sotatercept', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Sotatercept.'}, {'drugbank-id': 'DB12119', 'name': 'Gevokizumab', 'description': 'The risk or severity of adverse effects can be increased when Cetuximab is combined with Gevokizumab.'}, {'drugbank-id': 'DB12142', 'name': '\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                NaN\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     {'drug-interaction': [{'drugbank-id': 'DB00012', 'name': 'Darbepoetin alfa', 'description': 'The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Denileukin diftitox.'}, {'drugbank-id': 'DB00016', 'name': 'Erythropoietin', 'description': 'The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Denileukin diftitox.'}, {'drugbank-id': 'DB08894', 'name': 'Peginesatide', 'description': 'The risk or severity of Thrombosis can be increased when Peginesatide is combined with Denileukin diftitox.'}, {'drugbank-id': 'DB09107', 'name': 'Methoxy polyethylene glycol-epoetin beta', 'description': 'The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Denileukin diftitox.'}, {'drugbank-id': 'DB00281', 'name': 'Lidocaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Lidocaine.'}, {'drugbank-id': 'DB00296', 'name': 'Ropivacaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Ropivacaine.'}, {'drugbank-id': 'DB00297', 'name': 'Bupivacaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Bupivacaine.'}, {'drugbank-id': 'DB00527', 'name': 'Cinchocaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Cinchocaine.'}, {'drugbank-id': 'DB00645', 'name': 'Dyclonine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Dyclonine.'}, {'drugbank-id': 'DB00721', 'name': 'Procaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Procaine.'}, {'drugbank-id': 'DB00750', 'name': 'Prilocaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Prilocaine.'}, {'drugbank-id': 'DB00807', 'name': 'Proparacaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Proparacaine.'}, {'drugbank-id': 'DB00814', 'name': 'Meloxicam', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Meloxicam.'}, {'drugbank-id': 'DB00892', 'name': 'Oxybuprocaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Oxybuprocaine.'}, {'drugbank-id': 'DB00907', 'name': 'Cocaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Cocaine.'}, {'drugbank-id': 'DB00961', 'name': 'Mepivacaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Mepivacaine.'}, {'drugbank-id': 'DB01002', 'name': 'Levobupivacaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Levobupivacaine.'}, {'drugbank-id': 'DB01075', 'name': 'Diphenhydramine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Diphenhydramine.'}, {'drugbank-id': 'DB01086', 'name': 'Benzocaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Benzocaine.'}, {'drugbank-id': 'DB01161', 'name': 'Chloroprocaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Chloroprocaine.'}, {'drugbank-id': 'DB03255', 'name': 'Phenol', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Phenol.'}, {'drugbank-id': 'DB05232', 'name': 'Tetrodotoxin', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Tetrodotoxin.'}, {'drugbank-id': 'DB06770', 'name': 'Benzyl alcohol', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Benzyl alcohol.'}, {'drugbank-id': 'DB06774', 'name': 'Capsaicin', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Capsaicin.'}, {'drugbank-id': 'DB08987', 'name': 'Etidocaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Etidocaine.'}, {'drugbank-id': 'DB09009', 'name': 'Articaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Articaine.'}, {'drugbank-id': 'DB09085', 'name': 'Tetracaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Tetracaine.'}, {'drugbank-id': 'DB09342', 'name': 'Propoxycaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Propoxycaine.'}, {'drugbank-id': 'DB09345', 'name': 'Pramocaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Pramocaine.'}, {'drugbank-id': 'DB11148', 'name': 'Butamben', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Butamben.'}, {'drugbank-id': 'DB11502', 'name': 'Butacaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Butacaine.'}, {'drugbank-id': 'DB12532', 'name': 'Oxetacaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Oxetacaine.'}, {'drugbank-id': 'DB13259', 'name': 'Ethyl chloride', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Ethyl chloride.'}, {'drugbank-id': 'DB13328', 'name': 'Butanilicaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Butanilicaine.'}, {'drugbank-id': 'DB13578', 'name': 'Metabutethamine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Metabutethamine.'}, {'drugbank-id': 'DB13683', 'name': 'Quinisocaine', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Quinisocaine.'}, {'drugbank-id': 'DB06742', 'name': 'Ambroxol', 'description': 'The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Ambroxol.'}, {'drugbank-id': 'DB14766', 'name': 'Etrasimod', 'description': 'The risk or severity of immunosuppression can be increased when Denileukin diftitox is combined with Etrasimod.'}]}\n",
      "4    {'drug-interaction': [{'drugbank-id': 'DB08879', 'name': 'Belimumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Belimumab.'}, {'drugbank-id': 'DB00531', 'name': 'Cyclophosphamide', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Cyclophosphamide.'}, {'drugbank-id': 'DB06643', 'name': 'Denosumab', 'description': 'The risk or severity of adverse effects can be increased when Denosumab is combined with Etanercept.'}, {'drugbank-id': 'DB00065', 'name': 'Infliximab', 'description': 'Etanercept may increase the immunosuppressive activities of Infliximab.'}, {'drugbank-id': 'DB00008', 'name': 'Peginterferon alfa-2a', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Peginterferon alfa-2a.'}, {'drugbank-id': 'DB00011', 'name': 'Interferon alfa-n1', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-n1.'}, {'drugbank-id': 'DB00018', 'name': 'Interferon alfa-n3', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-n3.'}, {'drugbank-id': 'DB00022', 'name': 'Peginterferon alfa-2b', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Peginterferon alfa-2b.'}, {'drugbank-id': 'DB00033', 'name': 'Interferon gamma-1b', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon gamma-1b.'}, {'drugbank-id': 'DB00034', 'name': 'Interferon alfa-2a', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-2a.'}, {'drugbank-id': 'DB00041', 'name': 'Aldesleukin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Aldesleukin.'}, {'drugbank-id': 'DB00051', 'name': 'Adalimumab', 'description': 'The risk or severity of infection can be increased when Adalimumab is combined with Etanercept.'}, {'drugbank-id': 'DB00056', 'name': 'Gemtuzumab ozogamicin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Gemtuzumab ozogamicin.'}, {'drugbank-id': 'DB00059', 'name': 'Pegaspargase', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Pegaspargase.'}, {'drugbank-id': 'DB00068', 'name': 'Interferon beta-1b', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon beta-1b.'}, {'drugbank-id': 'DB00069', 'name': 'Interferon alfacon-1', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfacon-1.'}, {'drugbank-id': 'DB00073', 'name': 'Rituximab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Rituximab.'}, {'drugbank-id': 'DB00074', 'name': 'Basiliximab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Basiliximab.'}, {'drugbank-id': 'DB00075', 'name': 'Muromonab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Muromonab.'}, {'drugbank-id': 'DB00078', 'name': 'Ibritumomab tiuxetan', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Ibritumomab tiuxetan.'}, {'drugbank-id': 'DB00081', 'name': 'Tositumomab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Tositumomab.'}, {'drugbank-id': 'DB00087', 'name': 'Alemtuzumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Alemtuzumab.'}, {'drugbank-id': 'DB00092', 'name': 'Alefacept', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Alefacept.'}, {'drugbank-id': 'DB00095', 'name': 'Efalizumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Efalizumab.'}, {'drugbank-id': 'DB00098', 'name': 'Antithymocyte immunoglobulin (rabbit)', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Antithymocyte immunoglobulin (rabbit).'}, {'drugbank-id': 'DB00105', 'name': 'Interferon alfa-2b', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-2b.'}, {'drugbank-id': 'DB00111', 'name': 'Daclizumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Daclizumab.'}, {'drugbank-id': 'DB00120', 'name': 'Phenylalanine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Phenylalanine.'}, {'drugbank-id': 'DB00242', 'name': 'Cladribine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Cladribine.'}, {'drugbank-id': 'DB00276', 'name': 'Amsacrine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Amsacrine.'}, {'drugbank-id': 'DB00290', 'name': 'Bleomycin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Bleomycin.'}, {'drugbank-id': 'DB00291', 'name': 'Chlorambucil', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Chlorambucil.'}, {'drugbank-id': 'DB00293', 'name': 'Raltitrexed', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Raltitrexed.'}, {'drugbank-id': 'DB00305', 'name': 'Mitomycin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Mitomycin.'}, {'drugbank-id': 'DB00322', 'name': 'Floxuridine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Floxuridine.'}, {'drugbank-id': 'DB00352', 'name': 'Tioguanine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Tioguanine.'}, {'drugbank-id': 'DB00380', 'name': 'Dexrazoxane', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Dexrazoxane.'}, {'drugbank-id': 'DB00428', 'name': 'Streptozocin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Streptozocin.'}, {'drugbank-id': 'DB00432', 'name': 'Trifluridine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Trifluridine.'}, {'drugbank-id': 'DB00441', 'name': 'Gemcitabine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Gemcitabine.'}, {'drugbank-id': 'DB00445', 'name': 'Epirubicin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Epirubicin.'}, {'drugbank-id': 'DB00446', 'name': 'Chloramphenicol', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Chloramphenicol.'}, {'drugbank-id': 'DB00480', 'name': 'Lenalidomide', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Lenalidomide.'}, {'drugbank-id': 'DB00488', 'name': 'Altretamine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Altretamine.'}, {'drugbank-id': 'DB00515', 'name': 'Cisplatin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Cisplatin.'}, {'drugbank-id': 'DB00526', 'name': 'Oxaliplatin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Oxaliplatin.'}, {'drugbank-id': 'DB00550', 'name': 'Propylthiouracil', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Propylthiouracil.'}, {'drugbank-id': 'DB00552', 'name': 'Pentostatin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Pentostatin.'}, {'drugbank-id': 'DB00601', 'name': 'Linezolid', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Linezolid.'}, {'drugbank-id': 'DB00631', 'name': 'Clofarabine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Clofarabine.'}, {'drugbank-id': 'DB00763', 'name': 'Methimazole', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Methimazole.'}, {'drugbank-id': 'DB00853', 'name': 'Temozolomide', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Temozolomide.'}, {'drugbank-id': 'DB00859', 'name': 'Penicillamine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Penicillamine.'}, {'drugbank-id': 'DB00888', 'name': 'Mechlorethamine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Mechlorethamine.'}, {'drugbank-id': 'DB00928', 'name': 'Azacitidine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Azacitidine.'}, {'drugbank-id': 'DB00958', 'name': 'Carboplatin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Carboplatin.'}, {'drugbank-id': 'DB00970', 'name': 'Dactinomycin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Dactinomycin.'}, {'drugbank-id': 'DB01005', 'name': 'Hydroxyurea', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Hydroxyurea.'}, {'drugbank-id': 'DB01024', 'name': 'Mycophenolic acid', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Mycophenolic acid.'}, {'drugbank-id': 'DB01030', 'name': 'Topotecan', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Topotecan.'}, {'drugbank-id': 'DB01033', 'name': 'Mercaptopurine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Mercaptopurine.'}, {'drugbank-id': 'DB01042', 'name': 'Melphalan', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Melphalan.'}, {'drugbank-id': 'DB01073', 'name': 'Fludarabine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Fludarabine.'}, {'drugbank-id': 'DB01099', 'name': 'Flucytosine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Flucytosine.'}, {'drugbank-id': 'DB01168', 'name': 'Procarbazine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Procarbazine.'}, {'drugbank-id': 'DB01169', 'name': 'Arsenic trioxide', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Arsenic trioxide.'}, {'drugbank-id': 'DB01204', 'name': 'Mitoxantrone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Mitoxantrone.'}, {'drugbank-id': 'DB01206', 'name': 'Lomustine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Lomustine.'}, {'drugbank-id': 'DB01257', 'name': 'Eculizumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Eculizumab.'}, {'drugbank-id': 'DB01262', 'name': 'Decitabine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Decitabine.'}, {'drugbank-id': 'DB01280', 'name': 'Nelarabine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Nelarabine.'}, {'drugbank-id': 'DB01423', 'name': 'Stepronin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Stepronin.'}, {'drugbank-id': 'DB01816', 'name': 'Castanospermine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Castanospermine.'}, {'drugbank-id': 'DB02546', 'name': 'Vorinostat', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Vorinostat.'}, {'drugbank-id': 'DB02806', 'name': '2-Methoxyethanol', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with 2-Methoxyethanol.'}, {'drugbank-id': 'DB03523', 'name': 'Brequinar', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Brequinar.'}, {'drugbank-id': 'DB04956', 'name': 'Afelimomab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Afelimomab.'}, {'drugbank-id': 'DB05258', 'name': 'Interferon alfa', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa.'}, {'drugbank-id': 'DB05259', 'name': 'Glatiramer', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Glatiramer.'}, {'drugbank-id': 'DB05459', 'name': 'Briakinumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Briakinumab.'}, {'drugbank-id': 'DB05472', 'name': 'Human interferon omega-1', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Human interferon omega-1.'}, {'drugbank-id': 'DB06612', 'name': 'Mepolizumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Mepolizumab.'}, {'drugbank-id': 'DB06662', 'name': 'Abetimus', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Abetimus.'}, {'drugbank-id': 'DB06674', 'name': 'Golimumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Golimumab.'}, {'drugbank-id': 'DB06681', 'name': 'Belatacept', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Belatacept.'}, {'drugbank-id': 'DB06813', 'name': 'Pralatrexate', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Pralatrexate.'}, {'drugbank-id': 'DB08059', 'name': 'Wortmannin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Wortmannin.'}, {'drugbank-id': 'DB08871', 'name': 'Eribulin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Eribulin.'}, {'drugbank-id': 'DB08880', 'name': 'Teriflunomide', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Teriflunomide.'}, {'drugbank-id': 'DB08889', 'name': 'Carfilzomib', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Carfilzomib.'}, {'drugbank-id': 'DB08908', 'name': 'Dimethyl fumarate', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Dimethyl fumarate.'}, {'drugbank-id': 'DB08935', 'name': 'Obinutuzumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Obinutuzumab.'}, {'drugbank-id': 'DB09029', 'name': 'Secukinumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Secukinumab.'}, {'drugbank-id': 'DB09036', 'name': 'Siltuximab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Siltuximab.'}, {'drugbank-id': 'DB09052', 'name': 'Blinatumomab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Blinatumomab.'}, {'drugbank-id': 'DB09077', 'name': 'Dinutuximab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Dinutuximab.'}, {'drugbank-id': 'DB09091', 'name': 'Tixocortol', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Tixocortol.'}, {'drugbank-id': 'DB09122', 'name': 'Peginterferon beta-1a', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Peginterferon beta-1a.'}, {'drugbank-id': 'DB09312', 'name': 'Antilymphocyte immunoglobulin (horse)', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Antilymphocyte immunoglobulin (horse).'}, {'drugbank-id': 'DB11466', 'name': 'Tepoxalin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Tepoxalin.'}, {'drugbank-id': 'DB11569', 'name': 'Ixekizumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Ixekizumab.'}, {'drugbank-id': 'DB11580', 'name': 'Ravulizumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Ravulizumab.'}, {'drugbank-id': 'DB11616', 'name': 'Pirarubicin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Pirarubicin.'}, {'drugbank-id': 'DB11693', 'name': 'Voclosporin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Voclosporin.'}, {'drugbank-id': 'DB11708', 'name': 'Peficitinib', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Peficitinib.'}, {'drugbank-id': 'DB11767', 'name': 'Sarilumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Sarilumab.'}, {'drugbank-id': 'DB11776', 'name': 'Brodalumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Brodalumab.'}, {'drugbank-id': 'DB11803', 'name': 'Sirukumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Sirukumab.'}, {'drugbank-id': 'DB11834', 'name': 'Guselkumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Guselkumab.'}, {'drugbank-id': 'DB11988', 'name': 'Ocrelizumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Ocrelizumab.'}, {'drugbank-id': 'DB12025', 'name': 'Triptolide', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Triptolide.'}, {'drugbank-id': 'DB12612', 'name': 'Ozanimod', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Ozanimod.'}, {'drugbank-id': 'DB12617', 'name': 'Mizoribine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Mizoribine.'}, {'drugbank-id': 'DB12692', 'name': 'Gusperimus', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Gusperimus.'}, {'drugbank-id': 'DB12814', 'name': 'Cepeginterferon alfa-2B', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Cepeginterferon alfa-2B.'}, {'drugbank-id': 'DB12902', 'name': 'Trofosfamide', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Trofosfamide.'}, {'drugbank-id': 'DB12947', 'name': 'Doxifluridine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Doxifluridine.'}, {'drugbank-id': 'DB12991', 'name': 'Deoxyspergualin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Deoxyspergualin.'}, {'drugbank-id': 'DB12996', 'name': 'Acteoside', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Acteoside.'}, {'drugbank-id': 'DB13003', 'name': 'Cortivazol', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Cortivazol.'}, {'drugbank-id': 'DB13014', 'name': 'Hypericin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Hypericin.'}, {'drugbank-id': 'DB13068', 'name': '9-(N-methyl-L-isoleucine)-cyclosporin A', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.'}, {'drugbank-id': 'DB13223', 'name': 'Fluocortin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocortin.'}, {'drugbank-id': 'DB13241', 'name': 'Begelomab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Begelomab.'}, {'drugbank-id': 'DB13491', 'name': 'Fluperolone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Fluperolone.'}, {'drugbank-id': 'DB13843', 'name': 'Cloprednol', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Cloprednol.'}, {'drugbank-id': 'DB13856', 'name': 'Fluclorolone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Fluclorolone.'}, {'drugbank-id': 'DB14219', 'name': 'Monomethyl fumarate', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Monomethyl fumarate.'}, {'drugbank-id': 'DB14724', 'name': 'Emapalumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Emapalumab.'}, {'drugbank-id': 'DB14762', 'name': 'Risankizumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Risankizumab.'}, {'drugbank-id': 'DB14919', 'name': 'Rozanolixizumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Rozanolixizumab.'}, {'drugbank-id': 'DB15253', 'name': 'Bleselumab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Bleselumab.'}, {'drugbank-id': 'DB00180', 'name': 'Flunisolide', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Flunisolide.'}, {'drugbank-id': 'DB00394', 'name': 'Beclomethasone dipropionate', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Beclomethasone dipropionate.'}, {'drugbank-id': 'DB00443', 'name': 'Betamethasone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Betamethasone.'}, {'drugbank-id': 'DB00591', 'name': 'Fluocinolone acetonide', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocinolone acetonide.'}, {'drugbank-id': 'DB00635', 'name': 'Prednisone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Prednisone.'}, {'drugbank-id': 'DB00687', 'name': 'Fludrocortisone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Fludrocortisone.'}, {'drugbank-id': 'DB00860', 'name': 'Prednisolone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Prednisolone.'}, {'drugbank-id': 'DB00959', 'name': 'Methylprednisolone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Methylprednisolone.'}, {'drugbank-id': 'DB01196', 'name': 'Estramustine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Estramustine.'}, {'drugbank-id': 'DB01285', 'name': 'Corticotropin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Corticotropin.'}, {'drugbank-id': 'DB01380', 'name': 'Cortisone acetate', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Cortisone acetate.'}, {'drugbank-id': 'DB01384', 'name': 'Paramethasone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Paramethasone.'}, {'drugbank-id': 'DB04630', 'name': 'Aldosterone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Aldosterone.'}, {'drugbank-id': 'DB08970', 'name': 'Fluprednidene', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Fluprednidene.'}, {'drugbank-id': 'DB09082', 'name': 'Vilanterol', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Vilanterol.'}, {'drugbank-id': 'DB09378', 'name': 'Fluprednisolone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Fluprednisolone.'}, {'drugbank-id': 'DB09383', 'name': 'Meprednisone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Meprednisone.'}, {'drugbank-id': 'DB11487', 'name': 'Dexamethasone isonicotinate', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Dexamethasone isonicotinate.'}, {'drugbank-id': 'DB11529', 'name': 'Melengestrol', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Melengestrol.'}, {'drugbank-id': 'DB11921', 'name': 'Deflazacort', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Deflazacort.'}, {'drugbank-id': 'DB13208', 'name': 'Prednylidene', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Prednylidene.'}, {'drugbank-id': 'DB14066', 'name': 'Tetrandrine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Tetrandrine.'}, {'drugbank-id': 'DB14512', 'name': 'Mometasone furoate', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Mometasone furoate.'}, {'drugbank-id': 'DB14545', 'name': 'Hydrocortisone succinate', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Hydrocortisone succinate.'}, {'drugbank-id': 'DB01222', 'name': 'Budesonide', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Budesonide.'}, {'drugbank-id': 'DB00694', 'name': 'Daunorubicin', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Daunorubicin.'}, {'drugbank-id': 'DB00987', 'name': 'Cytarabine', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Cytarabine.'}, {'drugbank-id': 'DB01108', 'name': 'Trilostane', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Trilostane.'}, {'drugbank-id': 'DB05015', 'name': 'Belinostat', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Belinostat.'}, {'drugbank-id': 'DB01013', 'name': 'Clobetasol propionate', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Clobetasol propionate.'}, {'drugbank-id': 'DB01047', 'name': 'Fluocinonide', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocinonide.'}, {'drugbank-id': 'DB00547', 'name': 'Desoximetasone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Desoximetasone.'}, {'drugbank-id': 'DB00764', 'name': 'Mometasone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Mometasone.'}, {'drugbank-id': 'DB08971', 'name': 'Fluocortolone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocortolone.'}, {'drugbank-id': 'DB00324', 'name': 'Fluorometholone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Fluorometholone.'}, {'drugbank-id': 'DB09095', 'name': 'Difluocortolone', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Difluocortolone.'}, {'drugbank-id': 'DB15091', 'name': 'Upadacitinib', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Upadacitinib.'}, {'drugbank-id': 'DB03451', 'name': 'Lexacalcitol', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Lexacalcitol.'}, {'drugbank-id': 'DB15628', 'name': 'Inolimomab', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Inolimomab.'}, {'drugbank-id': 'DB15646', 'name': 'Fasitibant', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Fasitibant.'}, {'drugbank-id': 'DB00026', 'name': 'Anakinra', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Anakinra.'}, {'drugbank-id': 'DB01281', 'name': 'Abatacept', 'description': 'The risk or severity of infection can be increased when Etanercept is combined with Abatacept.'}, {'drugbank-id': 'DB06168', 'name': 'Canakinumab', 'description': 'The risk or severity of infection and neutropenia can be increased when Etanercept is combined with Canakinumab.'}, {'drugbank-id': 'DB06273', 'name': 'Tocilizumab', 'description': 'Tocilizumab may increase the immunosuppressive activities of Etanercept.'}, {'drugbank-id': 'DB06372', 'name': 'Rilonacept', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Rilonacept.'}, {'drugbank-id': 'DB08904', 'name': 'Certolizumab pegol', 'description': 'The risk or severity of infection can be increased when Etanercept is combined with Certolizumab pegol.'}, {'drugbank-id': 'DB09033', 'name': 'Vedolizumab', 'description': 'The risk or severity of infection can be increased when Etanercept is combined with Vedolizumab.'}, {'drugbank-id': 'DB00108', 'name': 'Natalizumab', 'description': 'The risk or severity of immunosuppression can be increased when Etanercept is combined with Natalizumab.'}, {'drugbank-id': 'DB00337', 'name': 'Pimecrolimus', 'description': 'The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etanercept.'}, {'drugbank-id': 'DB01656', 'name': 'Roflumilast', 'description': 'Roflumilast may increase the immunosuppressive activities of Etanercept.'}, {'drugbank-id': 'DB06688', 'name': 'Sipuleucel-T', 'description': 'The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Etanercept.'}, {'drugbank-id': 'DB01015', 'name': 'Sulfamethoxazole', 'description': 'The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Etanercept.'}, {'drugbank-id': 'DB01097', 'name': 'Leflunomide', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Leflunomide.'}, {'drugbank-id': 'DB08895', 'name': 'Tofacitinib', 'description': 'The risk or severity of adverse effects can be increased when Etanercept is combined with Tofacitinib.'}, {'drugbank-id': 'DB00072', 'name': 'Trastuzumab', 'description': 'The risk or severity of neutropenia can be increased when Trastuzumab is combined with Etanercept.'}, {'drugbank-id'\n",
      "Name: drug-interactions, dtype: object\n",
      "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              {'sequence': {'@format': 'FASTA', '#text': '>DB00001 sequence\\nLTYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIP\\nEEYLQ'}}\n",
      "1    {'sequence': [{'@format': 'FASTA', '#text': '>Cetuximab heavy chain\\nQVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYN\\nTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAA\\nSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG\\nLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP\\nSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS\\nTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL\\nTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ\\nQGNVFSCSVMHEALHNHYTQKSLSLSPGK'}, {'@format': 'FASTA', '#text': '>Cetuximab light chain\\nDILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPS\\nRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPP\\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC'}]}\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                {'sequence': {'@format': 'FASTA', '#text': '>Dornase alfa sequence\\nLKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAP\\nDTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFS\\nRFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQ\\nWSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYG\\nLSDQLAQAISDHYPVEVMLK'}}\n",
      "3                                                                                                                                                                                                                        {'sequence': {'@format': 'FASTA', '#text': '>DB00004 sequence\\nMGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNK\\nYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVG\\nTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMY\\nEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVS\\nEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEK\\nTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYN\\nFVESIINLFQVVHNSYNRPAYSPGHKTHAPTSSSTKKTQLQLEHLLLDLQMILNGINNYK\\nNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVI\\nVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT'}}\n",
      "4                                                                                                                                                                                                                                                                            {'sequence': {'@format': 'FASTA', '#text': '> Etanercept Sequence\\nLPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDST\\nYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRK\\nCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTS\\nTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSC\\nDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD\\nGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK\\nGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS\\nDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK'}}\n",
      "Name: sequences, dtype: object\n",
      "0    {'property': [{'kind': 'Water Solubility', 'value': 'Soluble', 'source': 'Health Canada drug label'}, {'kind': 'Melting Point', 'value': '65 °C', 'source': 'Otto, A. & Seckler, R. Eur. J. Biochem. 202:67-73 (1991)'}, {'kind': 'Isoelectric Point', 'value': '3.7', 'source': 'Health Canada drug label'}, {'kind': 'Molecular Weight', 'value': '6979.0', 'source': None}, {'kind': 'Molecular Formula', 'value': 'C287H440N80O111S6', 'source': None}]}\n",
      "1     {'property': [{'kind': 'Melting Point', 'value': '61 °C (FAB fragment), 71 °C (whole mAb)', 'source': 'Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)'}, {'kind': 'Hydrophobicity', 'value': '-0.413', 'source': None}, {'kind': 'Isoelectric Point', 'value': '8.48', 'source': None}, {'kind': 'Molecular Weight', 'value': '145781.6', 'source': None}, {'kind': 'Molecular Formula', 'value': 'C6484H10042N1732O2023S36', 'source': None}]}\n",
      "2                                                       {'property': [{'kind': 'Melting Point', 'value': '67 °C', 'source': 'Chan, H.K. et al., Pharm Res. 13:756-761 (1996)'}, {'kind': 'Hydrophobicity', 'value': '-0.083', 'source': None}, {'kind': 'Isoelectric Point', 'value': '4.58', 'source': None}, {'kind': 'Molecular Weight', 'value': '29253.9', 'source': None}, {'kind': 'Molecular Formula', 'value': 'C1321H1999N339O396S9', 'source': None}]}\n",
      "3                                                                                                                                                                {'property': [{'kind': 'Hydrophobicity', 'value': '-0.301', 'source': None}, {'kind': 'Isoelectric Point', 'value': '5.45', 'source': None}, {'kind': 'Molecular Weight', 'value': '57647.3', 'source': None}, {'kind': 'Molecular Formula', 'value': 'C2560H4042N678O799S17', 'source': None}]}\n",
      "4                               {'property': [{'kind': 'Melting Point', 'value': '71 °C (whole mAb)', 'source': 'Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)'}, {'kind': 'Hydrophobicity', 'value': '-0.529', 'source': None}, {'kind': 'Isoelectric Point', 'value': '7.89', 'source': None}, {'kind': 'Molecular Weight', 'value': '51234.9', 'source': None}, {'kind': 'Molecular Formula', 'value': 'C2224H3475N621O698S36', 'source': None}]}\n",
      "Name: experimental-properties, dtype: object\n",
      "0                                                                                                             {'external-identifier': [{'resource': 'Drugs Product Database (DPD)', 'identifier': '11916'}, {'resource': 'PubChem Substance', 'identifier': '46507011'}, {'resource': 'KEGG Drug', 'identifier': 'D06880'}, {'resource': 'PharmGKB', 'identifier': 'PA450195'}, {'resource': 'UniProtKB', 'identifier': 'P01050'}, {'resource': 'Therapeutic Targets Database', 'identifier': 'DAP000541'}, {'resource': 'Wikipedia', 'identifier': 'Lepirudin'}, {'resource': 'ChEMBL', 'identifier': 'CHEMBL1201666'}, {'resource': 'RxCUI', 'identifier': '237057'}]}\n",
      "1                                                                                                                {'external-identifier': [{'resource': 'Drugs Product Database (DPD)', 'identifier': '13175'}, {'resource': 'PubChem Substance', 'identifier': '46507042'}, {'resource': 'KEGG Drug', 'identifier': 'D03455'}, {'resource': 'GenBank', 'identifier': 'J00228'}, {'resource': 'PharmGKB', 'identifier': 'PA10040'}, {'resource': 'Therapeutic Targets Database', 'identifier': 'DNC000788'}, {'resource': 'Wikipedia', 'identifier': 'Cetuximab'}, {'resource': 'ChEMBL', 'identifier': 'CHEMBL1201577'}, {'resource': 'RxCUI', 'identifier': '318341'}]}\n",
      "2                                                                                                               {'external-identifier': [{'resource': 'Drugs Product Database (DPD)', 'identifier': '650'}, {'resource': 'PubChem Substance', 'identifier': '46507792'}, {'resource': 'GenBank', 'identifier': 'M55983'}, {'resource': 'PharmGKB', 'identifier': 'PA10318'}, {'resource': 'UniProtKB', 'identifier': 'P24855'}, {'resource': 'Therapeutic Targets Database', 'identifier': 'DAP000981'}, {'resource': 'Wikipedia', 'identifier': 'Dornase_alfa'}, {'resource': 'ChEMBL', 'identifier': 'CHEMBL1201431'}, {'resource': 'RxCUI', 'identifier': '337623'}]}\n",
      "3                                                                                                                                                                       {'external-identifier': [{'resource': 'PubChem Substance', 'identifier': '46506950'}, {'resource': 'GenBank', 'identifier': 'V01536'}, {'resource': 'PharmGKB', 'identifier': 'PA164750594'}, {'resource': 'UniProtKB', 'identifier': 'P00587'}, {'resource': 'Therapeutic Targets Database', 'identifier': 'DAP001098'}, {'resource': 'Wikipedia', 'identifier': 'Denileukin_diftitox'}, {'resource': 'ChEMBL', 'identifier': 'CHEMBL1201550'}, {'resource': 'RxCUI', 'identifier': '214470'}]}\n",
      "4    {'external-identifier': [{'resource': 'Drugs Product Database (DPD)', 'identifier': '12032'}, {'resource': 'PubChem Substance', 'identifier': '46506732'}, {'resource': 'KEGG Compound', 'identifier': 'C07897'}, {'resource': 'KEGG Drug', 'identifier': 'D00742'}, {'resource': 'GenBank', 'identifier': 'M32315'}, {'resource': 'PharmGKB', 'identifier': 'PA449515'}, {'resource': 'UniProtKB', 'identifier': 'P20333'}, {'resource': 'Therapeutic Targets Database', 'identifier': 'DNC000605'}, {'resource': 'Wikipedia', 'identifier': 'Etanercept'}, {'resource': 'ChEMBL', 'identifier': 'CHEMBL1201572'}, {'resource': 'RxCUI', 'identifier': '214555'}]}\n",
      "Name: external-identifiers, dtype: object\n",
      "0                {'external-link': [{'resource': 'RxList', 'url': 'http://www.rxlist.com/cgi/generic/lepirudin.htm'}, {'resource': 'Drugs.com', 'url': 'http://www.drugs.com/cdi/lepirudin.html'}]}\n",
      "1                 {'external-link': [{'resource': 'RxList', 'url': 'http://www.rxlist.com/cgi/generic3/erbitux.htm'}, {'resource': 'Drugs.com', 'url': 'http://www.drugs.com/cdi/cetuximab.html'}]}\n",
      "2             {'external-link': [{'resource': 'RxList', 'url': 'http://www.rxlist.com/cgi/generic/pulmozyme.htm'}, {'resource': 'Drugs.com', 'url': 'http://www.drugs.com/cdi/dornase-alfa.html'}]}\n",
      "3    {'external-link': [{'resource': 'RxList', 'url': 'http://www.rxlist.com/cgi/generic2/denileukin.htm'}, {'resource': 'Drugs.com', 'url': 'http://www.drugs.com/cdi/denileukin-diftitox.html'}]}\n",
      "4              {'external-link': [{'resource': 'RxList', 'url': 'http://www.rxlist.com/cgi/generic/etanercept.htm'}, {'resource': 'Drugs.com', 'url': 'http://www.drugs.com/cdi/etanercept.html'}]}\n",
      "Name: external-links, dtype: object\n",
      "0    {'pathway': {'smpdb-id': 'SMP0000278', 'name': 'Lepirudin Action Pathway', 'category': 'drug_action', 'drugs': {'drug': [{'drugbank-id': 'DB00001', 'name': 'Lepirudin'}, {'drugbank-id': 'DB01022', 'name': 'Phylloquinone'}, {'drugbank-id': 'DB01373', 'name': 'Calcium'}]}, 'enzymes': {'uniprot-id': ['P00734', 'P00748', 'P02452', 'P03952', 'P03951', 'P00740', 'P00451', 'P12259', 'P00742', 'P02671', 'P02675', 'P02679', 'P00488', 'P05160', 'P00747', 'P00750', 'P08709', 'P13726', 'Q9BQB6', 'P38435']}}}\n",
      "1                                                                                                                                                                                                                                                                                                          {'pathway': {'smpdb-id': 'SMP0000474', 'name': 'Cetuximab Action Pathway', 'category': 'drug_action', 'drugs': {'drug': {'drugbank-id': 'DB00002', 'name': 'Cetuximab'}}, 'enzymes': {'uniprot-id': 'P00533'}}}\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NaN\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NaN\n",
      "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NaN\n",
      "Name: pathways, dtype: object\n",
      "0    {'reaction': [{'sequence': '1', 'left-element': {'drugbank-id': 'DB00001', 'name': 'Lepirudin'}, 'right-element': {'drugbank-id': 'DBMET03462', 'name': 'M1 (1-64)'}, 'enzymes': None}, {'sequence': '2', 'left-element': {'drugbank-id': 'DBMET03462', 'name': 'M1 (1-64)'}, 'right-element': {'drugbank-id': 'DBMET03463', 'name': 'M2 (1-63)'}, 'enzymes': None}, {'sequence': '3', 'left-element': {'drugbank-id': 'DBMET03463', 'name': 'M2 (1-63)'}, 'right-element': {'drugbank-id': 'DBMET03464', 'name': 'M3 (1-62)'}, 'enzymes': None}, {'sequence': '4', 'left-element': {'drugbank-id': 'DBMET03464', 'name': 'M3 (1-62)'}, 'right-element': {'drugbank-id': 'DBMET03465', 'name': 'M4 (1-61)'}, 'enzymes': None}]}\n",
      "1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                NaN\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                NaN\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                NaN\n",
      "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                NaN\n",
      "Name: reactions, dtype: object\n",
      "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NaN\n",
      "1    {'effect': [{'protein-name': 'Low affinity immunoglobulin gamma Fc region receptor II-a', 'gene-symbol': 'FCGR2A', 'uniprot-id': 'P12318', 'rs-id': 'rs1801274', 'allele': None, 'defining-change': 'H allelle', 'description': 'Patients with this genotype may have increased progression-free survival time when using cetuximab to treat colorectal cancer.', 'pubmed-id': '17704420'}, {'protein-name': 'Low affinity immunoglobulin gamma Fc region receptor III-A', 'gene-symbol': 'FCGR3A', 'uniprot-id': 'P08637', 'rs-id': 'rs396991', 'allele': None, 'defining-change': 'G > T', 'description': 'Patients with this genotype have increased progression-free survival time when using cetuximab to treat colorectal cancer.', 'pubmed-id': '17704420'}]}\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NaN\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NaN\n",
      "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     NaN\n",
      "Name: snp-effects, dtype: object\n",
      "0    NaN\n",
      "1    NaN\n",
      "2    NaN\n",
      "3    NaN\n",
      "4    NaN\n",
      "Name: snp-adverse-drug-reactions, dtype: object\n",
      "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 {'target': {'@position': '1', 'id': 'BE0000048', 'name': 'Prothrombin', 'organism': 'Humans', 'actions': {'action': 'inhibitor'}, 'references': {'articles': {'article': [{'ref-id': 'A1703', 'pubmed-id': '10505536', 'citation': 'Turpie AG: Anticoagulants in acute coronary syndromes. Am J Cardiol. 1999 Sep 2;84(5A):2M-6M.'}, {'ref-id': 'A1705', 'pubmed-id': '10912644', 'citation': 'Warkentin TE: Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm Med. 2000 Jul;6(4):343-51.'}, {'ref-id': 'A1707', 'pubmed-id': '11055889', 'citation': 'Eriksson BI: New therapeutic options in deep vein thrombosis prophylaxis. Semin Hematol. 2000 Jul;37(3 Suppl 5):7-9.'}, {'ref-id': 'A1709', 'pubmed-id': '11467439', 'citation': 'Fabrizio MC: Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra Corpor Technol. 2001 May;33(2):117-25.'}, {'ref-id': 'A1711', 'pubmed-id': '11807012', 'citation': 'Szaba FM, Smiley ST: Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002 Feb 1;99(3):1053-9.'}]}, 'textbooks': None, 'links': {'link': {'ref-id': 'L41539', 'title': 'Health Canada Approved Drug Products: Refludan (lepirudin) lyophilized powder for intravenous injection', 'url': 'https://pdf.hres.ca/dpd_pm/00004023.PDF'}}, 'attachments': None}, 'known-action': 'yes', 'polypeptide': {'@id': 'P00734', '@source': 'Swiss-Prot', 'name': 'Prothrombin', 'general-function': 'Thrombospondin receptor activity', 'specific-function': 'Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.', 'gene-name': 'F2', 'locus': '11p11-q12', 'cellular-location': 'Secreted', 'transmembrane-regions': None, 'signal-regions': '1-24', 'theoretical-pi': '5.7', 'molecular-weight': '70036.295', 'chromosome-location': '11', 'organism': {'@ncbi-taxonomy-id': '9606', '#text': 'Humans'}, 'external-identifiers': {'external-identifier': [{'resource': 'HUGO Gene Nomenclature Committee (HGNC)', 'identifier': 'HGNC:3535'}, {'resource': 'GenAtlas', 'identifier': 'F2'}, {'resource': 'GenBank Gene Database', 'identifier': 'M17262'}, {'resource': 'GenBank Protein Database', 'identifier': '339641'}, {'resource': 'Guide to Pharmacology', 'identifier': '2362'}, {'resource': 'UniProtKB', 'identifier': 'P00734'}, {'resource': 'UniProt Accession', 'identifier': 'THRB_HUMAN'}]}, 'synonyms': {'synonym': ['3.4.21.5', 'Coagulation factor II']}, 'amino-acid-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0016004|Prothrombin\\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\\nVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\\nNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\\nCSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\\nQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\\nDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\\nDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\\nDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\\nVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\\nRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\\nGFYTHVFRLKKWIQKVIDQFGE'}, 'gene-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0016005|Prothrombin (F2)\\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC\\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG\\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\\nGGAGAGTAG'}, 'pfams': {'pfam': [{'identifier': 'PF00594', 'name': 'Gla'}, {'identifier': 'PF00051', 'name': 'Kringle'}, {'identifier': 'PF00089', 'name': 'Trypsin'}, {'identifier': 'PF09396', 'name': 'Thrombin_light'}]}, 'go-classifiers': {'go-classifier': [{'category': 'component', 'description': 'blood microparticle'}, {'category': 'component', 'description': 'cytosol'}, {'category': 'component', 'description': 'endoplasmic reticulum lumen'}, {'category': 'component', 'description': 'extracellular exosome'}, {'category': 'component', 'description': 'extracellular matrix'}, {'category': 'component', 'description': 'extracellular region'}, {'category': 'component', 'description': 'extracellular space'}, {'category': 'component', 'description': 'Golgi lumen'}, {'category': 'component', 'description': 'plasma membrane'}, {'category': 'function', 'description': 'calcium ion binding'}, {'category': 'function', 'description': 'growth factor activity'}, {'category': 'function', 'description': 'receptor binding'}, {'category': 'function', 'description': 'serine-type endopeptidase activity'}, {'category': 'function', 'description': 'thrombospondin receptor activity'}, {'category': 'process', 'description': 'acute-phase response'}, {'category': 'process', 'description': 'blood coagulation'}, {'category': 'process', 'description': 'blood coagulation, intrinsic pathway'}, {'category': 'process', 'description': 'cell surface receptor signaling pathway'}, {'category': 'process', 'description': 'cellular protein metabolic process'}, {'category': 'process', 'description': 'cellular response to mechanical stimulus'}, {'category': 'process', 'description': 'cytosolic calcium ion homeostasis'}, {'category': 'process', 'description': 'fibrinolysis'}, {'category': 'process', 'description': 'leukocyte migration'}, {'category': 'process', 'description': 'multicellular organismal development'}, {'category': 'process', 'description': 'negative regulation of astrocyte differentiation'}, {'category': 'process', 'description': 'negative regulation of fibrinolysis'}, {'category': 'process', 'description': 'negative regulation of platelet activation'}, {'category': 'process', 'description': 'negative regulation of proteolysis'}, {'category': 'process', 'description': 'peptidyl-glutamic acid carboxylation'}, {'category': 'process', 'description': 'platelet activation'}, {'category': 'process', 'description': 'positive regulation of blood coagulation'}, {'category': 'process', 'description': 'positive regulation of cell growth'}, {'category': 'process', 'description': 'positive regulation of cell proliferation'}, {'category': 'process', 'description': 'positive regulation of collagen biosynthetic process'}, {'category': 'process', 'description': 'positive regulation of phosphatidylinositol 3-kinase signaling'}, {'category': 'process', 'description': 'positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway'}, {'category': 'process', 'description': 'positive regulation of protein phosphorylation'}, {'category': 'process', 'description': 'positive regulation of reactive oxygen species metabolic process'}, {'category': 'process', 'description': 'positive regulation of release of sequestered calcium ion into cytosol'}, {'category': 'process', 'description': 'post-translational protein modification'}, {'category': 'process', 'description': 'proteolysis'}, {'category': 'process', 'description': 'regulation of blood coagulation'}, {'category': 'process', 'description': 'regulation of cell shape'}, {'category': 'process', 'description': 'regulation of gene expression'}, {'category': 'process', 'description': 'response to inactivity'}, {'category': 'process', 'description': 'response to wounding'}]}}}}\n",
      "1    {'target': [{'@position': '1', 'id': 'BE0000767', 'name': 'Epidermal growth factor receptor', 'organism': 'Humans', 'actions': {'action': 'binder'}, 'references': {'articles': {'article': [{'ref-id': 'A9', 'pubmed-id': '11752352', 'citation': 'Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.'}, {'ref-id': 'A227973', 'pubmed-id': '15821783', 'citation': 'Harding J, Burtness B: Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc). 2005 Feb;41(2):107-27. doi: 10.1358/dot.2005.41.2.882662.'}]}, 'textbooks': None, 'links': None, 'attachments': None}, 'known-action': 'yes', 'polypeptide': {'@id': 'P00533', '@source': 'Swiss-Prot', 'name': 'Epidermal growth factor receptor', 'general-function': 'Ubiquitin protein ligase binding', 'specific-function': 'Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.Isoform 2 may act as an antagonist of EGF action.', 'gene-name': 'EGFR', 'locus': '7p12', 'cellular-location': 'Cell membrane', 'transmembrane-regions': '646-668', 'signal-regions': '1-24', 'theoretical-pi': '6.67', 'molecular-weight': '134276.185', 'chromosome-location': '7', 'organism': {'@ncbi-taxonomy-id': '9606', '#text': 'Humans'}, 'external-identifiers': {'external-identifier': [{'resource': 'HUGO Gene Nomenclature Committee (HGNC)', 'identifier': 'HGNC:3236'}, {'resource': 'GenAtlas', 'identifier': 'EGFR'}, {'resource': 'GenBank Gene Database', 'identifier': 'X00588'}, {'resource': 'GenBank Protein Database', 'identifier': '757924'}, {'resource': 'Guide to Pharmacology', 'identifier': '1797'}, {'resource': 'UniProtKB', 'identifier': 'P00533'}, {'resource': 'UniProt Accession', 'identifier': 'EGFR_HUMAN'}]}, 'synonyms': {'synonym': ['2.7.10.1', 'ERBB', 'ERBB1', 'HER1', 'Proto-oncogene c-ErbB-1', 'Receptor tyrosine-protein kinase erbB-1']}, 'amino-acid-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0001530|Epidermal growth factor receptor\\nMRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV\\nVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA\\nVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF\\nQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC\\nTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV\\nVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK\\nNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF\\nENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL\\nFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN\\nLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM\\nGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV\\nALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS\\nGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI\\nCLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA\\nRNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY\\nGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK\\nFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ\\nQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED\\nSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN\\nTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV\\nAPQSSEFIGA'}, 'gene-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0019007|Epidermal growth factor receptor (EGFR)\\nATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCG\\nGCGAGTCGGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAG\\nTTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTG\\nGTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAG\\nACCATCCAGGAGGTGGCTGGTTATGTCCTCATTGCCCTCAACACAGTGGAGCGAATTCCT\\nTTGGAAAACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTATGCCTTAGCA\\nGTCTTATCTAACTATGATGCAAATAAAACCGGACTGAAGGAGCTGCCCATGAGAAATTTA\\nCAGGAAATCCTGCATGGCGCCGTGCGGTTCAGCAACAACCCTGCCCTGTGCAACGTGGAG\\nAGCATCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGCAACATGTCGATGGACTTC\\nCAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAATGGGAGCTGCTGG\\nGGTGCAGGAGAGGAGAACTGCCAGAAACTGACCAAAATCATCTGTGCCCAGCAGTGCTCC\\nGGGCGCTGCCGTGGCAAGTCCCCCAGTGACTGCTGCCACAACCAGTGTGCTGCAGGCTGC\\nACAGGCCCCCGGGAGAGCGACTGCCTGGTCTGCCGCAAATTCCGAGACGAAGCCACGTGC\\nAAGGACACCTGCCCCCCACTCATGCTCTACAACCCCACCACGTACCAGATGGATGTGAAC\\nCCCGAGGGCAAATACAGCTTTGGTGCCACCTGCGTGAAGAAGTGTCCCCGTAATTATGTG\\nGTGACAGATCACGGCTCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGATGGAGGAA\\nGACGGCGTCCGCAAGTGTAAGAAGTGCGAAGGGCCTTGCCGCAAAGTGTGTAACGGAATA\\nGGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTAAACACTTCAAA\\nAACTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCC\\nTTCACACATACTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAA\\nATCACAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTT\\nGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTCTTGCAGTC\\nGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGATAAGTGATGGAGAT\\nGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATACAATAAACTGGAAAAAACTG\\nTTTGGGACCTCCGGTCAGAAAACCAAAATTATAAGCAACAGAGGTGAAAACAGCTGCAAG\\nGCCACAGGCCAGGTCTGCCATGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCC\\nAGGGACTGCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAAC\\nCTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCA\\nGAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC\\nCAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGAGTCATG\\nGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGC\\nCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGG\\nCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTG\\nGCCCTGGGGATCGGCCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGG\\nAGGCTGCTGCAGGAGAGGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAAC\\nCAAGCTCTCTTGAGGATCTTGAAGGAAACTGAATTCAAAAAGATCAAAGTGCTGGGCTCC\\nGGTGCGTTCGGCACGGTGTATAAGGGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATT\\nCCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTC\\nGATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTGGGCATC\\nTGCCTCACCTCCACCGTGCAGCTCATCACGCAGCTCATGCCCTTCGGCTGCCTCCTGGAC\\nTATGTCCGGGAACACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAG\\nATCGCAAAGGGCATGAACTACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCC\\nAGGAACGTACTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAA\\nCTGCTGGGTGCGGAAGAGAAAGAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGG\\nATGGCATTGGAATCAATTTTACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTAC\\nGGGGTGACCGTTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCC\\nAGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATATGTACC\\nATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAG\\nTTCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTC\\nATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCTACCGTGCC\\nCTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAG\\nCAGGGCTTCTTCAGCAGCCCCTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCA\\nACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATC\\nAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGAC\\nAGCATAGACGACACCTTCCTCCCAGTGCCTGAATACATAAACCAGTCCGTTCCCAAAAGG\\nCCCGCTGGCTCTGTGCAGAATCCTGTCTATCACAATCAGCCTCTGAACCCCGCGCCCAGC\\nAGAGACCCACACTACCAGGACCCCCACAGCACTGCAGTGGGCAACCCCGAGTATCTCAAC\\nACTGTCCAGCCCACCTGTGTCAACAGCACATTCGACAGCCCTGCCCACTGGGCCCAGAAA\\nGGCAGCCACCAAATTAGCCTGGACAACCCTGACTACCAGCAGGACTTCTTTCCCAAGGAA\\nGCCAAGCCAAATGGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAATACCTAAGGGTC\\nGCGCCACAAAGCAGTGAATTTATTGGAGCATGA'}, 'pfams': {'pfam': [{'identifier': 'PF07714', 'name': 'PK_Tyr_Ser-Thr'}, {'identifier': 'PF00757', 'name': 'Furin-like'}, {'identifier': 'PF01030', 'name': 'Recep_L_domain'}, {'identifier': 'PF14843', 'name': 'GF_recep_IV'}]}, 'go-classifiers': {'go-classifier': [{'category': 'component', 'description': 'basolateral plasma membrane'}, {'category': 'component', 'description': 'cell surface'}, {'category': 'component', 'description': 'cytoplasm'}, {'category': 'component', 'description': 'early endosome membrane'}, {'category': 'component', 'description': 'endocytic vesicle'}, {'category': 'component', 'description': 'endoplasmic reticulum membrane'}, {'category': 'component', 'description': 'endosome'}, {'category': 'component', 'description': 'endosome membrane'}, {'category': 'component', 'description': 'extracellular space'}, {'category': 'component', 'description': 'focal adhesion'}, {'category': 'component', 'description': 'Golgi membrane'}, {'category': 'component', 'description': 'integral component of membrane'}, {'category': 'component', 'description': 'membrane'}, {'category': 'component', 'description': 'membrane raft'}, {'category': 'component', 'description': 'multivesicular body, internal vesicle lumen'}, {'category': 'component', 'description': 'nuclear membrane'}, {'category': 'component', 'description': 'nucleus'}, {'category': 'component', 'description': 'perinuclear region of cytoplasm'}, {'category': 'component', 'description': 'plasma membrane'}, {'category': 'component', 'description': 'receptor complex'}, {'category': 'component', 'description': 'Shc-EGFR complex'}, {'category': 'function', 'description': 'actin filament binding'}, {'category': 'function', 'description': 'ATP binding'}, {'category': 'function', 'description': 'chromatin binding'}, {'category': 'function', 'description': 'double-stranded DNA binding'}, {'category': 'function', 'description': 'enzyme binding'}, {'category': 'function', 'description': 'epidermal growth factor-activated receptor activity'}, {'category': 'function', 'description': 'identical protein binding'}, {'category': 'function', 'description': 'MAP kinase kinase kinase activity'}, {'category': 'function', 'description': 'protein heterodimerization activity'}, {'category': 'function', 'description': 'protein phosphatase binding'}, {'category': 'function', 'description': 'protein tyrosine kinase activity'}, {'category': 'function', 'description': 'receptor signaling protein tyrosine kinase activity'}, {'category': 'function', 'description': 'transmembrane receptor protein tyrosine kinase activity'}, {'category': 'function', 'description': 'transmembrane signaling receptor activity'}, {'category': 'function', 'description': 'ubiquitin protein ligase binding'}, {'category': 'process', 'description': 'activation of MAPKK activity'}, {'category': 'process', 'description': 'activation of phospholipase A2 activity by calcium-mediated signaling'}, {'category': 'process', 'description': 'activation of phospholipase C activity'}, {'category': 'process', 'description': 'axon guidance'}, {'category': 'process', 'description': 'cell proliferation'}, {'category': 'process', 'description': 'cell surface receptor signaling pathway'}, {'category': 'process', 'description': 'cellular response to amino acid stimulus'}, {'category': 'process', 'description': 'cellular response to epidermal growth factor stimulus'}, {'category': 'process', 'description': 'cellular response to estradiol stimulus'}, {'category': 'process', 'description': 'cerebral cortex cell migration'}, {'category': 'process', 'description': 'digestive tract morphogenesis'}, {'category': 'process', 'description': 'embryonic placenta development'}, {'category': 'process', 'description': 'epidermal growth factor receptor signaling pathway'}, {'category': 'process', 'description': 'Fc-epsilon receptor signaling pathway'}, {'category': 'process', 'description': 'fibroblast growth factor receptor signaling pathway'}, {'category': 'process', 'description': 'hair follicle development'}, {'category': 'process', 'description': 'innate immune response'}, {'category': 'process', 'description': 'insulin receptor signaling pathway'}, {'category': 'process', 'description': 'learning or memory'}, {'category': 'process', 'description': 'MAPK cascade'}, {'category': 'process', 'description': 'morphogenesis of an epithelial fold'}, {'category': 'process', 'description': 'negative regulation of apoptotic process'}, {'category': 'process', 'description': 'negative regulation of epidermal growth factor receptor signaling pathway'}, {'category': 'process', 'description': 'negative regulation of protein catabolic process'}, {'category': 'process', 'description': 'neurotrophin TRK receptor signaling pathway'}, {'category': 'process', 'description': 'ossification'}, {'category': 'process', 'description': 'peptidyl-tyrosine phosphorylation'}, {'category': 'process', 'description': 'phosphatidylinositol-mediated signaling'}, {'category': 'process', 'description': 'positive regulation of catenin import into nucleus'}, {'category': 'process', 'description': 'positive regulation of cell migration'}, {'category': 'process', 'description': 'positive regulation of cell proliferation'}, {'category': 'process', 'description': 'positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle'}, {'category': 'process', 'description': 'positive regulation of DNA repair'}, {'category': 'process', 'description': 'positive regulation of DNA replication'}, {'category': 'process', 'description': 'positive regulation of epithelial cell proliferation'}, {'category': 'process', 'description': 'positive regulation of ERK1 and ERK2 cascade'}, {'category': 'process', 'description': 'positive regulation of fibroblast proliferation'}, {'category': 'process', 'description': 'positive regulation of MAP kinase activity'}, {'category': 'process', 'description': 'positive regulation of nitric oxide biosynthetic process'}, {'category': 'process', 'description': 'positive regulation of phosphorylation'}, {'category': 'process', 'description': 'positive regulation of protein kinase B signaling'}, {'category': 'process', 'description': 'positive regulation of protein phosphorylation'}, {'category': 'process', 'description': 'positive regulation of transcription from RNA polymerase II promoter'}, {'category': 'process', 'description': 'protein autophosphorylation'}, {'category': 'process', 'description': 'protein insertion into membrane'}, {'category': 'process', 'description': 'Ras protein signal transduction'}, {'category': 'process', 'description': 'regulation of nitric-oxide synthase activity'}, {'category': 'process', 'description': 'regulation of peptidyl-tyrosine phosphorylation'}, {'category': 'process', 'description': 'response to stress'}, {'category': 'process', 'description': 'response to UV-A'}, {'category': 'process', 'description': 'salivary gland morphogenesis'}, {'category': 'process', 'description': 'signal transduction'}, {'category': 'process', 'description': 'single organismal cell-cell adhesion'}, {'category': 'process', 'description': 'small GTPase mediated signal transduction'}, {'category': 'process', 'description': 'vascular endothelial growth factor receptor signaling pathway'}]}}}, {'@position': '2', 'id': 'BE0000901', 'name': 'Low affinity immunoglobulin gamma Fc region receptor III-B', 'organism': 'Humans', 'actions': {'action': 'binder'}, 'references': {'articles': {'article': {'ref-id': 'A11', 'pubmed-id': '16336752', 'citation': 'Snyder LC, Astsaturov I, Weiner LM: Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80.'}}, 'textbooks': None, 'links': None, 'attachments': None}, 'known-action': 'unknown', 'polypeptide': {'@id': 'O75015', '@source': 'Swiss-Prot', 'name': 'Low affinity immunoglobulin gamma Fc region receptor III-B', 'general-function': None, 'specific-function': 'Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.', 'gene-name': 'FCGR3B', 'locus': '1q23', 'cellular-location': 'Cell membrane', 'transmembrane-regions': None, 'signal-regions': '1-16', 'theoretical-pi': '6.71', 'molecular-weight': '26215.64', 'chromosome-location': '1', 'organism': {'@ncbi-taxonomy-id': '9606', '#text': 'Humans'}, 'external-identifiers': {'external-identifier': [{'resource': 'HUGO Gene Nomenclature Committee (HGNC)', 'identifier': 'HGNC:3620'}, {'resource': 'GenAtlas', 'identifier': 'FCGR3B'}, {'resource': 'GenBank Gene Database', 'identifier': 'X16863'}, {'resource': 'GenBank Protein Database', 'identifier': '31322'}, {'resource': 'UniProtKB', 'identifier': 'O75015'}, {'resource': 'UniProt Accession', 'identifier': 'FCG3B_HUMAN'}]}, 'synonyms': {'synonym': ['CD16B', 'Fc-gamma RIII', 'Fc-gamma RIII-beta', 'Fc-gamma RIIIb', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIb', 'IGFR3', 'IgG Fc receptor III-1']}, 'amino-acid-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B\\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI'}, 'gene-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)\\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\\nTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA'}, 'pfams': {'pfam': {'identifier': 'PF13895', 'name': 'Ig_2'}}, 'go-classifiers': {'go-classifier': [{'category': 'component', 'description': 'anchored component of membrane'}, {'category': 'component', 'description': 'extracellular exosome'}, {'category': 'component', 'description': 'plasma membrane'}, {'category': 'process', 'description': 'immune response'}, {'category': 'process', 'description': 'mitophagy in response to mitochondrial depolarization'}, {'category': 'process', 'description': 'positive regulation of defense response to virus by host'}, {'category': 'process', 'description': 'xenophagy'}]}}}, {'@position': '3', 'id': 'BE0002094', 'name': 'Complement C1q subcomponent subunit A', 'organism': 'Humans', 'actions': {'action': 'binder'}, 'references': {'articles': {'article': {'ref-id': 'A202103', 'pubmed-id': '32117299', 'citation': 'Deveuve Q, Lajoie L, Barrault B, Thibault G: The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass. Front Immunol. 2020 Feb 11;11:168. doi: 10.3389/fimmu.2020.00168. eCollection 2020.'}}, 'textbooks': None, 'links': None, 'attachments': None}, 'known-action': 'unknown', 'polypeptide': {'@id': 'P02745', '@source': 'Swiss-Prot', 'name': 'Complement C1q subcomponent subunit A', 'general-function': None, 'specific-function': 'C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.', 'gene-name': 'C1QA', 'locus': '1p36.12', 'cellular-location': 'Secreted', 'transmembrane-regions': None, 'signal-regions': '1-22', 'theoretical-pi': '9.45', 'molecular-weight': '26016.47', 'chromosome-location': '1', 'organism': {'@ncbi-taxonomy-id': '9606', '#text': 'Humans'}, 'external-identifiers': {'external-identifier': [{'resource': 'HUGO Gene Nomenclature Committee (HGNC)', 'identifier': 'HGNC:1241'}, {'resource': 'GenAtlas', 'identifier': 'C1QA'}, {'resource': 'GenBank Gene Database', 'identifier': 'AF135157'}, {'resource': 'GenBank Protein Database', 'identifier': '4894854'}, {'resource': 'UniProtKB', 'identifier': 'P02745'}, {'resource': 'UniProt Accession', 'identifier': 'C1QA_HUMAN'}]}, 'synonyms': {'synonym': 'Complement C1q subcomponent subunit A precursor'}, 'amino-acid-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0016678|Complement C1q subcomponent subunit A\\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\\nIFPSA'}, 'gene-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0016679|Complement C1q subcomponent subunit A (C1QA)\\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGAGCCCGTGGCATCCCGGGAATTAAA\\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\\nATCTTCCCATCTGCCTGA'}, 'pfams': {'pfam': [{'identifier': 'PF01391', 'name': 'Collagen'}, {'identifier': 'PF00386', 'name': 'C1q'}]}, 'go-classifiers': {'go-classifier': [{'category': 'component', 'description': 'collagen trimer'}, {'category': 'component', 'description': 'complement component C1 complex'}, {'category': 'component', 'description': 'extracellular exosome'}, {'category': 'component', 'description': 'extracellular region'}, {'category': 'process', 'description': 'cell-cell signaling'}, {'category': 'process', 'description': 'complement activation'}, {'category': 'process', 'description': 'complement activation, classical pathway'}, {'category': 'process', 'description': 'innate immune response'}]}}}, {'@position': '4', 'id': 'BE0002095', 'name': 'Complement C1q subcomponent subunit B', 'organism': 'Humans', 'actions': {'action': 'binder'}, 'references': {'articles': {'article': {'ref-id': 'A202103', 'pubmed-id': '32117299', 'citation': 'Deveuve Q, Lajoie L, Barrault B, Thibault G: The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass. Front Immunol. 2020 Feb 11;11:168. doi: 10.3389/fimmu.2020.00168. eCollection 2020.'}}, 'textbooks': None, 'links': None, 'attachments': None}, 'known-action': 'unknown', 'polypeptide': {'@id': 'P02746', '@source': 'Swiss-Prot', 'name': 'Complement C1q subcomponent subunit B', 'general-function': None, 'specific-function': 'C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.', 'gene-name': 'C1QB', 'locus': '1p36.12', 'cellular-location': 'Secreted', 'transmembrane-regions': None, 'signal-regions': '1-27', 'theoretical-pi': '8.87', 'molecular-weight': '26721.62', 'chromosome-location': '1', 'organism': {'@ncbi-taxonomy-id': '9606', '#text': 'Humans'}, 'external-identifiers': {'external-identifier': [{'resource': 'HUGO Gene Nomenclature Committee (HGNC)', 'identifier': 'HGNC:1242'}, {'resource': 'GenAtlas', 'identifier': 'C1QB'}, {'resource': 'GenBank Gene Database', 'identifier': 'X03084'}, {'resource': 'GenBank Protein Database', 'identifier': '573114'}, {'resource': 'UniProtKB', 'identifier': 'P02746'}, {'resource': 'UniProt Accession', 'identifier': 'C1QB_HUMAN'}]}, 'synonyms': {'synonym': 'Complement C1q subcomponent subunit B precursor'}, 'amino-acid-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0016676|Complement C1q subcomponent subunit B\\nMMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKG\\nEKGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQ\\nKIAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNL\\nCVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANS\\nIFSGFLLFPDMEA'}, 'gene-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0016677|Complement C1q subcomponent subunit B (C1QB)\\nATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGC\\nCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATC\\nCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGA\\nGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCA\\nGGGATTCCTGGGAATCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGC\\nCCAGGGGCCCCTGGAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAG\\nAAAATCGCCTTCTCTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATC\\nCGCTTCGACCACGTGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTC\\nACCTGCAAGGTGCCCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTG\\nTGCGTGAACCTCATGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTAT\\nGCCTACAACACCTTCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAG\\nAACGTCTTCCTGCAGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGC\\nATCTTTTCCGGGTTCCTGCTCTTTCCAGATATGGAGGCCTGA'}, 'pfams': {'pfam': [{'identifier': 'PF01391', 'name': 'Collagen'}, {'identifier': 'PF00386', 'name': 'C1q'}]}, 'go-classifiers': {'go-classifier': [{'category': 'component', 'description': 'blood microparticle'}, {'category': 'component', 'description': 'collagen trimer'}, {'category': 'component', 'description': 'complement component C1 complex'}, {'category': 'component', 'description': 'extracellular exosome'}, {'category': 'component', 'description': 'extracellular region'}, {'category': 'process', 'description': 'complement activation'}, {'category': 'process', 'description': 'complement activation, classical pathway'}, {'category': 'process', 'description': 'innate immune response'}, {'category': 'process', 'description': 'inner ear development'}]}}}, {'@position': '5', 'id': 'BE0002096', 'name': 'Complement C1q subcomponent subunit C', 'organism': 'Humans', 'actions': {'action': 'binder'}, 'references': {'articles': {'article': {'ref-id': 'A202103', 'pubmed-id': '32117299', 'citation': 'Deveuve Q, Lajoie L, Barrault B, Thibault G: The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass. Front Immunol. 2020 Feb 11;11:168. doi: 10.3389/fimmu.2020.00168. eCollection 2020.'}}, 'textbooks': None, 'links': None, 'attachments': None}, 'known-action': 'unknown', 'polypeptide': {'@id': 'P02747', '@source': 'Swiss-Prot', 'name': 'Complement C1q subcomponent subunit C', 'general-function': None, 'specific-function': 'C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.', 'gene-name': 'C1QC', 'locus': '1p36.11', 'cellular-location': 'Secreted', 'transmembrane-regions': None, 'signal-regions': '1-28', 'theoretical-pi': '8.58', 'molecular-weight': '25773.56', 'chromosome-location': '1', 'organism': {'@ncbi-taxonomy-id': '9606', '#text': 'Humans'}, 'external-identifiers': {'external-identifier': [{'resource': 'HUGO Gene Nomenclature Committee (HGNC)', 'identifier': 'HGNC:1245'}, {'resource': 'GenAtlas', 'identifier': 'C1QC'}, {'resource': 'GenBank Gene Database', 'identifier': 'AF087892'}, {'resource': 'GenBank Protein Database', 'identifier': '33150626'}, {'resource': 'UniProtKB', 'identifier': 'P02747'}, {'resource': 'UniProt Accession', 'identifier': 'C1QC_HUMAN'}]}, 'synonyms': {'synonym': 'C1QG'}, 'amino-acid-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0011520|Complement C1q subcomponent subunit C\\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\\nLLFPD'}, 'gene-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0011521|Complement C1q subcomponent subunit C (C1QC)\\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\\nCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\\nCCCATGGGCATCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\\nAACGCGGTCCTCACCAACCCGCAGGGAGATTATGACACGAGCACTGGCAAGTTCACCTGC\\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\\nCTGCTCTTCCCCGACTAG'}, 'pfams': {'pfam': [{'identifier': 'PF01391', 'name': 'Collagen'}, {'identifier': 'PF00386', 'name': 'C1q'}]}, 'go-classifiers': {'go-classifier': [{'category': 'component', 'description': 'blood microparticle'}, {'category': 'component', 'description': 'collagen trimer'}, {'category': 'component', 'description': 'extracellular exosome'}, {'category': 'component', 'description': 'extracellular region'}, {'category': 'component', 'description': 'extracellular space'}, {'category': 'process', 'description': 'complement activation'}, {'category': 'process', 'description': 'complement activation, classical pathway'}, {'category': 'process', 'description': 'immune response'}, {'category': 'process', 'description': 'innate immune response'}, {'category': 'process', 'description': 'negative regulation of granulocyte differentiation'}, {'category': 'process', 'description': 'negative regulation of macrophage differentiation'}]}}}, {'@position': '6', 'id': 'BE0002097', 'name': 'Low affinity immunoglobulin gamma Fc region receptor III-A', 'organism': 'Humans', 'actions': {'action': 'binder'}, 'references': {'articles': {'article': [{'ref-id': 'A1713', 'pubmed-id': '17139284', 'citation': 'Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.'}, {'ref-id': 'A1715', 'pubmed-id': '17016423', 'citation': 'Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.'}, {'ref-id': 'A13078', 'pubmed-id': '17704420', 'citation': 'Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8.'}]}, 'textbooks': None, 'links': None, 'attachments': None}, 'known-action': 'unknown', 'polypeptide': {'@id': 'P08637', '@source': 'Swiss-Prot', 'name': 'Low affinity immunoglobulin gamma Fc region receptor III-A', 'general-function': None, 'specific-function': 'Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.', 'gene-name': 'FCGR3A', 'locus': '1q23', 'cellular-location': 'Cell membrane', 'transmembrane-regions': '209-229', 'signal-regions': '1-16', 'theoretical-pi': '8.21', 'molecular-weight': '29088.895', 'chromosome-location': '1', 'organism': {'@ncbi-taxonomy-id': '9606', '#text': 'Humans'}, 'external-identifiers': {'ex\n",
      "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               {'target': {'@position': '1', 'id': 'BE0004796', 'name': 'DNA', 'organism': 'Humans', 'actions': None, 'references': {'articles': {'article': {'ref-id': 'A12', 'pubmed-id': '8792953', 'citation': 'Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61.'}}, 'textbooks': None, 'links': None, 'attachments': None}, 'known-action': 'yes'}}\n",
      "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             {'target': [{'@position': '1', 'id': 'BE0000658', 'name': 'Interleukin-2 receptor subunit alpha', 'organism': 'Humans', 'actions': {'action': 'binder'}, 'references': {'articles': {'article': [{'ref-id': 'A1717', 'pubmed-id': '2786749', 'citation': 'Kiyokawa T, Shirono K, Hattori T, Nishimura H, Yamaguchi K, Nichols JC, Strom TB, Murphy JR, Takatsuki K: Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res. 1989 Jul 15;49(14):4042-6.'}, {'ref-id': 'A1719', 'pubmed-id': '3124610', 'citation': 'Murphy JR, Kelley VE, Strom TB: Interleukin 2 toxin: a step toward selective immunomodulation. Am J Kidney Dis. 1988 Feb;11(2):159-62.'}, {'ref-id': 'A1721', 'pubmed-id': '18684057', 'citation': 'Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. doi: 10.2217/14796694.4.4.457.'}, {'ref-id': 'A15', 'pubmed-id': '17187516', 'citation': 'Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7.'}]}, 'textbooks': None, 'links': None, 'attachments': None}, 'known-action': 'yes', 'polypeptide': {'@id': 'P01589', '@source': 'Swiss-Prot', 'name': 'Interleukin-2 receptor subunit alpha', 'general-function': 'Interleukin-2 receptor activity', 'specific-function': 'Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T cells.', 'gene-name': 'IL2RA', 'locus': '10p15-p14', 'cellular-location': 'Membrane', 'transmembrane-regions': '241-259', 'signal-regions': '1-21', 'theoretical-pi': '6.49', 'molecular-weight': '30818.915', 'chromosome-location': '10', 'organism': {'@ncbi-taxonomy-id': '9606', '#text': 'Humans'}, 'external-identifiers': {'external-identifier': [{'resource': 'HUGO Gene Nomenclature Committee (HGNC)', 'identifier': 'HGNC:6008'}, {'resource': 'GenAtlas', 'identifier': 'IL2RA'}, {'resource': 'GenBank Gene Database', 'identifier': 'X01057'}, {'resource': 'GenBank Protein Database', 'identifier': '33813'}, {'resource': 'Guide to Pharmacology', 'identifier': '1695'}, {'resource': 'UniProtKB', 'identifier': 'P01589'}, {'resource': 'UniProt Accession', 'identifier': 'IL2RA_HUMAN'}]}, 'synonyms': {'synonym': ['IL-2 receptor subunit alpha', 'p55', 'TAC antigen']}, 'amino-acid-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0018991|Interleukin-2 receptor subunit alpha\\nMDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKS\\nGSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQAS\\nLPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQP\\nQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQ\\nVAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI'}, 'gene-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0018992|Interleukin-2 receptor subunit alpha (IL2RA)\\nATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAG\\nGCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCC\\nTACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGC\\nGGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGT\\nCAATGCACAAGCTCTGCCACTCGGAACACAACGAAACAAGTGACACCTCAACCTGAAGAA\\nCAGAAAGAAAGGAAAACCACAGAAATGCAAAGTCCAATGCAGCCAGTGGACCAAGCGAGC\\nCTTCCAGGTCACTGCAGGGAACCTCCACCATGGGAAAATGAAGCCACAGAGAGAATTTAT\\nCATTTCGTGGTGGGGCAGATGGTTTATTATCAGTGCGTCCAGGGATACAGGGCTCTACAC\\nAGAGGTCCTGCTGAGAGCGTCTGCAAAATGACCCACGGGAAGACAAGGTGGACCCAGCCC\\nCAGCTCATATGCACAGGTGAAATGGAGACCAGTCAGTTTCCAGGTGAAGAGAAGCCTCAG\\nGCAAGCCCCGAAGGCCGTCCTGAGAGTGAGACTTCCTGCCTCGTCACAACAACAGATTTT\\nCAAATACAGACAGAAATGGCTGCAACCATGGAGACGTCCATATTTACAACAGAGTACCAG\\nGTAGCAGTGGCCGGCTGTGTTTTCCTGCTGATCAGCGTCCTCCTCCTGAGTGGGCTCACC\\nTGGCAGCGGAGACAGAGGAAGAGTAGAAGAACAATCTAG'}, 'pfams': {'pfam': {'identifier': 'PF00084', 'name': 'Sushi'}}, 'go-classifiers': {'go-classifier': [{'category': 'component', 'description': 'external side of plasma membrane'}, {'category': 'component', 'description': 'integral component of membrane'}, {'category': 'component', 'description': 'intracellular'}, {'category': 'component', 'description': 'plasma membrane'}, {'category': 'function', 'description': 'drug binding'}, {'category': 'function', 'description': 'interleukin-2 binding'}, {'category': 'function', 'description': 'interleukin-2 receptor activity'}, {'category': 'process', 'description': 'activation of MAPKK activity'}, {'category': 'process', 'description': 'activation-induced cell death of T cells'}, {'category': 'process', 'description': 'apoptotic process'}, {'category': 'process', 'description': 'axon guidance'}, {'category': 'process', 'description': 'cell proliferation'}, {'category': 'process', 'description': 'cell surface receptor signaling pathway'}, {'category': 'process', 'description': 'epidermal growth factor receptor signaling pathway'}, {'category': 'process', 'description': 'Fc-epsilon receptor signaling pathway'}, {'category': 'process', 'description': 'fibroblast growth factor receptor signaling pathway'}, {'category': 'process', 'description': 'immune response'}, {'category': 'process', 'description': 'inflammatory response'}, {'category': 'process', 'description': 'inflammatory response to antigenic stimulus'}, {'category': 'process', 'description': 'innate immune response'}, {'category': 'process', 'description': 'insulin receptor signaling pathway'}, {'category': 'process', 'description': 'MAPK cascade'}, {'category': 'process', 'description': 'negative regulation of defense response to virus'}, {'category': 'process', 'description': 'negative regulation of immune response'}, {'category': 'process', 'description': 'negative regulation of inflammatory response'}, {'category': 'process', 'description': 'negative regulation of T cell proliferation'}, {'category': 'process', 'description': 'neurotrophin TRK receptor signaling pathway'}, {'category': 'process', 'description': 'Notch signaling pathway'}, {'category': 'process', 'description': 'positive regulation of activated T cell proliferation'}, {'category': 'process', 'description': 'positive regulation of T cell differentiation'}, {'category': 'process', 'description': 'Ras protein signal transduction'}, {'category': 'process', 'description': 'regulation of T cell homeostatic proliferation'}, {'category': 'process', 'description': 'regulation of T cell tolerance induction'}, {'category': 'process', 'description': 'small GTPase mediated signal transduction'}, {'category': 'process', 'description': 'vascular endothelial growth factor receptor signaling pathway'}]}}}, {'@position': '2', 'id': 'BE0000651', 'name': 'Interleukin-2 receptor subunit beta', 'organism': 'Humans', 'actions': {'action': 'agonist'}, 'references': {'articles': {'article': [{'ref-id': 'A13080', 'pubmed-id': '15811959', 'citation': 'Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5.'}, {'ref-id': 'A13081', 'pubmed-id': '16516670', 'citation': 'Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6.'}, {'ref-id': 'A1721', 'pubmed-id': '18684057', 'citation': 'Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. doi: 10.2217/14796694.4.4.457.'}, {'ref-id': 'A15', 'pubmed-id': '17187516', 'citation': 'Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7.'}, {'ref-id': 'A9', 'pubmed-id': '11752352', 'citation': 'Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.'}]}, 'textbooks': None, 'links': None, 'attachments': None}, 'known-action': 'yes', 'polypeptide': {'@id': 'P14784', '@source': 'Swiss-Prot', 'name': 'Interleukin-2 receptor subunit beta', 'general-function': 'Interleukin-2 receptor activity', 'specific-function': 'Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.', 'gene-name': 'IL2RB', 'locus': '22q13|22q13.1', 'cellular-location': 'Membrane', 'transmembrane-regions': '241-265', 'signal-regions': '1-26', 'theoretical-pi': '4.68', 'molecular-weight': '61116.59', 'chromosome-location': '22', 'organism': {'@ncbi-taxonomy-id': '9606', '#text': 'Humans'}, 'external-identifiers': {'external-identifier': [{'resource': 'HUGO Gene Nomenclature Committee (HGNC)', 'identifier': 'HGNC:6009'}, {'resource': 'GenAtlas', 'identifier': 'IL2RB'}, {'resource': 'GenBank Gene Database', 'identifier': 'M26062'}, {'resource': 'GenBank Protein Database', 'identifier': '307048'}, {'resource': 'UniProtKB', 'identifier': 'P14784'}, {'resource': 'UniProt Accession', 'identifier': 'IL2RB_HUMAN'}]}, 'synonyms': {'synonym': ['High affinity IL-2 receptor subunit beta', 'IL-2 receptor subunit beta', 'p70-75', 'p75']}, 'amino-acid-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0016166|Interleukin-2 receptor subunit beta\\nMAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQ\\nVHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMA\\nIQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEE\\nAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDT\\nIPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDV\\nQKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFT\\nNQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCT\\nFPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVP\\nDLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQ\\nELQGQDPTHLV'}, 'gene-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0016167|Interleukin-2 receptor subunit beta (IL2RB)\\nATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCT\\nACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCG\\nAGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAA\\nGTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGT\\nCAAGCATCCTGGGCCTGCAACCTGATCCTCGGAGCCCCAGATTCTCAGAAACTGACCACA\\nGTTGACATCGTCACCCTGAGGGTGCTGTGCCGTGAGGGGGTGCGATGGAGGGTGATGGCC\\nATCCAGGACTTCAAGCCCTTTGAGAACCTTCGCCTGATGGCCCCCATCTCCCTCCAAGTT\\nGTCCACGTGGAGACCCACAGATGCAACATAAGCTGGGAAATCTCCCAAGCCTCCCACTAC\\nTTTGAAAGACACCTGGAGTTCGAGGCCCGGACGCTGTCCCCAGGCCACACCTGGGAGGAG\\nGCCCCCCTGCTGACTCTCAAGCAGAAGCAGGAATGGATCTGCCTGGAGACGCTCACCCCA\\nGACACCCAGTATGAGTTTCAGGTGCGGGTCAAGCCTCTGCAAGGCGAGTTCACGACCTGG\\nAGCCCCTGGAGCCAGCCCCTGGCCTTCAGGACAAAGCCTGCAGCCCTTGGGAAGGACACC\\nATTCCGTGGCTCGGCCACCTCCTCGTGGGCCTCAGCGGGGCTTTTGGCTTCATCATCTTA\\nGTGTACTTGCTGATCAACTGCAGGAACACCGGGCCATGGCTGAAGAAGGTCCTGAAGTGT\\nAACACCCCAGACCCCTCGAAGTTCTTTTCCCAGCTGAGCTCAGAGCATGGAGGAGACGTC\\nCAGAAGTGGCTCTCTTCGCCCTTCCCCTCATCGTCCTTCAGCCCTGGCGGCCTGGCACCT\\nGAGATCTCGCCACTAGAAGTGCTGGAGAGGGACAAGGTGACGCAGCTGCTCCTGCAGCAG\\nGACAAGGTGCCTGAGCCCGCATCCTTAAGCAGCAACCACTCGCTGACCAGCTGCTTCACC\\nAACCAGGGTTACTTCTTCTTCCACCTCCCGGATGCCTTGGAGATAGAGGCCTGCCAGGTG\\nTACTTTACTTACGACCCCTACTCAGAGGAAGACCCTGATGAGGGTGTGGCCGGGGCACCC\\nACAGGGTCTTCCCCCCAACCCCTGCAGCCTCTGTCAGGGGAGGACGACGCCTACTGCACC\\nTTCCCCTCCAGGGATGACCTGCTGCTCTTCTCCCCCAGTCTCCTCGGTGGCCCCAGCCCC\\nCCAAGCACTGCCCCTGGGGGCAGTGGGGCCGGTGAAGAGAGGATGCCCCCTTCTTTGCAA\\nGAAAGAGTCCCCAGAGACTGGGACCCCCAGCCCCTGGGGCCTCCCACCCCAGGAGTCCCA\\nGACCTGGTGGATTTTCAGCCACCCCCTGAGCTGGTGCTGCGAGAGGCTGGGGAGGAGGTC\\nCCTGACGCTGGCCCCAGGGAGGGAGTCAGTTTCCCCTGGTCCAGGCCTCCTGGGCAGGGG\\nGAGTTCAGGGCCCTTAATGCTCGCCTGCCCCTGAACACTGATGCCTACTTGTCCCTCCAA\\nGAACTCCAGGGTCAGGACCCAACTCACTTGGTGTAG'}, 'pfams': None, 'go-classifiers': {'go-classifier': [{'category': 'component', 'description': 'external side of plasma membrane'}, {'category': 'component', 'description': 'integral component of plasma membrane'}, {'category': 'component', 'description': 'intracellular'}, {'category': 'component', 'description': 'membrane'}, {'category': 'component', 'description': 'plasma membrane'}, {'category': 'function', 'description': 'interleukin-2 binding'}, {'category': 'function', 'description': 'interleukin-2 receptor activity'}, {'category': 'process', 'description': 'activation of MAPKK activity'}, {'category': 'process', 'description': 'axon guidance'}, {'category': 'process', 'description': 'cytokine-mediated signaling pathway'}, {'category': 'process', 'description': 'epidermal growth factor receptor signaling pathway'}, {'category': 'process', 'description': 'Fc-epsilon receptor signaling pathway'}, {'category': 'process', 'description': 'fibroblast growth factor receptor signaling pathway'}, {'category': 'process', 'description': 'innate immune response'}, {'category': 'process', 'description': 'insulin receptor signaling pathway'}, {'category': 'process', 'description': 'interleukin-2-mediated signaling pathway'}, {'category': 'process', 'description': 'MAPK cascade'}, {'category': 'process', 'description': 'negative regulation of apoptotic process'}, {'category': 'process', 'description': 'neurotrophin TRK receptor signaling pathway'}, {'category': 'process', 'description': 'protein complex assembly'}, {'category': 'process', 'description': 'Ras protein signal transduction'}, {'category': 'process', 'description': 'signal transduction'}, {'category': 'process', 'description': 'small GTPase mediated signal transduction'}, {'category': 'process', 'description': 'vascular endothelial growth factor receptor signaling pathway'}, {'category': 'process', 'description': 'viral process'}]}}}, {'@position': '3', 'id': 'BE0002102', 'name': 'Cytokine receptor common subunit gamma', 'organism': 'Humans', 'actions': None, 'references': {'articles': {'article': [{'ref-id': 'A13080', 'pubmed-id': '15811959', 'citation': 'Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5.'}, {'ref-id': 'A13081', 'pubmed-id': '16516670', 'citation': 'Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6.'}, {'ref-id': 'A13082', 'pubmed-id': '11707860', 'citation': 'Foss FM: DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma. 2000 Nov;1 Suppl 1:S27-31.'}]}, 'textbooks': None, 'links': None, 'attachments': None}, 'known-action': 'unknown', 'polypeptide': {'@id': 'P31785', '@source': 'Swiss-Prot', 'name': 'Cytokine receptor common subunit gamma', 'general-function': 'Interleukin-2 binding', 'specific-function': 'Common subunit for the receptors for a variety of interleukins.', 'gene-name': 'IL2RG', 'locus': 'Xq13.1', 'cellular-location': 'Membrane', 'transmembrane-regions': '263-283', 'signal-regions': '1-22', 'theoretical-pi': '6.31', 'molecular-weight': '42286.68', 'chromosome-location': 'X', 'organism': {'@ncbi-taxonomy-id': '9606', '#text': 'Humans'}, 'external-identifiers': {'external-identifier': [{'resource': 'HUGO Gene Nomenclature Committee (HGNC)', 'identifier': 'HGNC:6010'}, {'resource': 'GenAtlas', 'identifier': 'IL2RG'}, {'resource': 'GenBank Gene Database', 'identifier': 'D11086'}, {'resource': 'GenBank Protein Database', 'identifier': '219890'}, {'resource': 'UniProtKB', 'identifier': 'P31785'}, {'resource': 'UniProt Accession', 'identifier': 'IL2RG_HUMAN'}]}, 'synonyms': {'synonym': ['gammaC', 'IL-2 receptor subunit gamma', 'IL-2R subunit gamma', 'IL-2RG', 'Interleukin-2 receptor subunit gamma', 'p64']}, 'amino-acid-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0004122|Cytokine receptor common subunit gamma\\nMLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEV\\nQCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKK\\nEIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLN\\nHCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEW\\nSHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLV\\nTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAP\\nPCYTLKPET'}, 'gene-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0016682|Cytokine receptor common subunit gamma (IL2RG)\\nATGTTGAAGCCATCATTACCATTCACATCCCTCTTATTCCTGCAGCTGCCCCTGCTGGGA\\nGTGGGGCTGAACACGACAATTCTGACGCCCAATGGGAATGAAGACACCACAGCTGATTTC\\nTTCCTGACCACTATGCCCACTGACTCCCTCAGTGTTTCCACTCTGCCCCTCCCAGAGGTT\\nCAGTGTTTTGTGTTCAATGTCGAGTACATGAATTGCACTTGGAACAGCAGCTCTGAGCCC\\nCAGCCTACCAACCTCACTCTGCATTATTGGTACAAGAACTCGGATAATGATAAAGTCCAG\\nAAGTGCAGCCACTATCTATTCTCTGAAGAAATCACTTCTGGCTGTCAGTTGCAAAAAAAG\\nGAGATCCACCTCTACCAAACATTTGTTGTTCAGCTCCAGGACCCACGGGAACCCAGGAGA\\nCAGGCCACACAGATGCTAAAACTGCAGAATCTGGTGATCCCCTGGGCTCCAGAGAACCTA\\nACACTTCACAAACTGAGTGAATCCCAGCTAGAACTGAACTGGAACAACAGATTCTTGAAC\\nCACTGTTTGGAGCACTTGGTGCAGTACCGGACTGACTGGGACCACAGCTGGACTGAACAA\\nTCAGTGGATTATAGACATAAGTTCTCCTTGCCTAGTGTGGATGGGCAGAAACGCTACACG\\nTTTCGTGTTCGGAGCCGCTTTAACCCACTCTGTGGAAGTGCTCAGCATTGGAGTGAATGG\\nAGCCACCCAATCCACTGGGGGAGCAATACTTCAAAAGAGAATCCTTTCCTGTTTGCATTG\\nGAAGCCGTGGTTATCTCTGTTGGCTCCATGGGATTGATTATCAGCCTTCTCTGTGTGTAT\\nTTCTGGCTGGAACGGACGATGCCCCGAATTCCCACCCTGAAGAACCTAGAGGATCTTGTT\\nACTGAATACCACGGGAACTTTTCGGCCTGGAGTGGTGTGTCTAAGGGACTGGCTGAGAGT\\nCTGCAGCCAGACTACAGTGAACGACTCTGCCTCGTCAGTGAGATTCCCCCAAAAGGAGGG\\nGCCCTTGGGGAGGGGCCTGGGGCCTCCCCATGCAACCAGCATAGCCCCTACTGGGCCCCC\\nCCATGTTACACCCTAAAGCCTGAAACCTGA'}, 'pfams': {'pfam': [{'identifier': 'PF00041', 'name': 'fn3'}, {'identifier': 'PF09240', 'name': 'IL6Ra-bind'}]}, 'go-classifiers': {'go-classifier': [{'category': 'component', 'description': 'external side of plasma membrane'}, {'category': 'component', 'description': 'integral component of plasma membrane'}, {'category': 'component', 'description': 'intracellular'}, {'category': 'component', 'description': 'membrane'}, {'category': 'component', 'description': 'plasma membrane'}, {'category': 'function', 'description': 'cytokine receptor activity'}, {'category': 'function', 'description': 'interleukin-2 binding'}, {'category': 'process', 'description': 'activation of MAPKK activity'}, {'category': 'process', 'description': 'axon guidance'}, {'category': 'process', 'description': 'epidermal growth factor receptor signaling pathway'}, {'category': 'process', 'description': 'Fc-epsilon receptor signaling pathway'}, {'category': 'process', 'description': 'fibroblast growth factor receptor signaling pathway'}, {'category': 'process', 'description': 'immune response'}, {'category': 'process', 'description': 'innate immune response'}, {'category': 'process', 'description': 'insulin receptor signaling pathway'}, {'category': 'process', 'description': 'interleukin-2-mediated signaling pathway'}, {'category': 'process', 'description': 'interleukin-4-mediated signaling pathway'}, {'category': 'process', 'description': 'interleukin-7-mediated signaling pathway'}, {'category': 'process', 'description': 'MAPK cascade'}, {'category': 'process', 'description': 'neurotrophin TRK receptor signaling pathway'}, {'category': 'process', 'description': 'Ras protein signal transduction'}, {'category': 'process', 'description': 'signal transduction'}, {'category': 'process', 'description': 'small GTPase mediated signal transduction'}, {'category': 'process', 'description': 'vascular endothelial growth factor receptor signaling pathway'}, {'category': 'process', 'description': 'viral process'}]}}}]}\n",
      "4    {'target': [{'@position': '1', 'id': 'BE0000704', 'name': 'Tumor necrosis factor', 'organism': 'Humans', 'actions': {'action': ['inhibitor', 'antibody']}, 'references': {'articles': {'article': [{'ref-id': 'A1723', 'pubmed-id': '10206649', 'citation': 'Park YC, Burkitt V, Villa AR, Tong L, Wu H: Structural basis for self-association and receptor recognition of human TRAF2. Nature. 1999 Apr 8;398(6727):533-8.'}, {'ref-id': 'A1725', 'pubmed-id': '10338381', 'citation': 'Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May;5(2):119-33.'}, {'ref-id': 'A1727', 'pubmed-id': '10357816', 'citation': 'Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, Huang DC, Wu Lee YH, Durkop H, Engelmann H, Scheurich P, Wajant H, Strasser A: Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J. 1999 Jun 1;18(11):3034-43.'}, {'ref-id': 'A1729', 'pubmed-id': '10375846', 'citation': 'Moreland LW: Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve Clin J Med. 1999 Jun;66(6):367-74.'}, {'ref-id': 'A1731', 'pubmed-id': '10405518', 'citation': 'Calabrese LH: Rheumatoid arthritis and primary care: the case for early diagnosis and treatment. J Am Osteopath Assoc. 1999 Jun;99(6):313-21.'}, {'ref-id': 'A9', 'pubmed-id': '11752352', 'citation': 'Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.'}, {'ref-id': 'A247970', 'pubmed-id': '31092047', 'citation': 'Clark IA, Vissel B: Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective - a Commentary. Expert Rev Neurother. 2019 Jun;19(6):535-543. doi: 10.1080/14737175.2019.1618710. Epub 2019 May 24.'}]}, 'textbooks': None, 'links': None, 'attachments': None}, 'known-action': 'yes', 'polypeptide': {'@id': 'P01375', '@source': 'Swiss-Prot', 'name': 'Tumor necrosis factor', 'general-function': 'Tumor necrosis factor receptor binding', 'specific-function': \"Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208). Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line (PubMed:22517918).The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells.\", 'gene-name': 'TNF', 'locus': '6p21.3', 'cellular-location': 'Cell membrane', 'transmembrane-regions': '36-56', 'signal-regions': None, 'theoretical-pi': '6.92', 'molecular-weight': '25644.15', 'chromosome-location': '6', 'organism': {'@ncbi-taxonomy-id': '9606', '#text': 'Humans'}, 'external-identifiers': {'external-identifier': [{'resource': 'HUGO Gene Nomenclature Committee (HGNC)', 'identifier': 'HGNC:11892'}, {'resource': 'GenAtlas', 'identifier': 'TNF'}, {'resource': 'GenBank Gene Database', 'identifier': 'M16441'}, {'resource': 'GenBank Protein Database', 'identifier': '339741'}, {'resource': 'Guide to Pharmacology', 'identifier': '2635'}, {'resource': 'UniProtKB', 'identifier': 'P01375'}, {'resource': 'UniProt Accession', 'identifier': 'TNFA_HUMAN'}]}, 'synonyms': {'synonym': ['Cachectin', 'TNF-a', 'TNF-alpha', 'TNFA', 'TNFSF2', 'Tumor necrosis factor ligand superfamily member 2']}, 'amino-acid-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0001404|Tumor necrosis factor\\nMSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR\\nEEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELR\\nDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRE\\nTPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL'}, 'gene-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0021837|Tumor necrosis factor (TNF)\\nATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAG\\nACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATC\\nGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGG\\nGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCT\\nTCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGGGG\\nCAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGA\\nGATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTC\\nAAGGGCCAAGGCTGCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCC\\nGTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCAGAGGGAG\\nACCCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTC\\nCAGCTGGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTT\\nGCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA'}, 'pfams': {'pfam': {'identifier': 'PF00229', 'name': 'TNF'}}, 'go-classifiers': {'go-classifier': [{'category': 'component', 'description': 'cell surface'}, {'category': 'component', 'description': 'external side of plasma membrane'}, {'category': 'component', 'description': 'extracellular region'}, {'category': 'component', 'description': 'extracellular space'}, {'category': 'component', 'description': 'integral component of plasma membrane'}, {'category': 'component', 'description': 'membrane raft'}, {'category': 'component', 'description': 'phagocytic cup'}, {'category': 'component', 'description': 'plasma membrane'}, {'category': 'component', 'description': 'recycling endosome'}, {'category': 'function', 'description': 'cytokine activity'}, {'category': 'function', 'description': 'identical protein binding'}, {'category': 'function', 'description': 'protease binding'}, {'category': 'function', 'description': 'transcription regulatory region DNA binding'}, {'category': 'function', 'description': 'tumor necrosis factor receptor binding'}, {'category': 'process', 'description': 'activation of cysteine-type endopeptidase activity involved in apoptotic process'}, {'category': 'process', 'description': 'activation of MAPK activity'}, {'category': 'process', 'description': 'activation of MAPKKK activity'}, {'category': 'process', 'description': 'cell surface receptor signaling pathway'}, {'category': 'process', 'description': 'cellular response to amino acid stimulus'}, {'category': 'process', 'description': 'cellular response to nicotine'}, {'category': 'process', 'description': 'cellular response to organic cyclic compound'}, {'category': 'process', 'description': 'chronic inflammatory response to antigenic stimulus'}, {'category': 'process', 'description': 'cortical actin cytoskeleton organization'}, {'category': 'process', 'description': 'death-inducing signaling complex assembly'}, {'category': 'process', 'description': 'defense response to Gram-positive bacterium'}, {'category': 'process', 'description': 'embryonic digestive tract development'}, {'category': 'process', 'description': 'epithelial cell proliferation involved in salivary gland morphogenesis'}, {'category': 'process', 'description': 'establishment of protein localization to plasma membrane'}, {'category': 'process', 'description': 'extracellular matrix organization'}, {'category': 'process', 'description': 'extrinsic apoptotic signaling pathway'}, {'category': 'process', 'description': 'extrinsic apoptotic signaling pathway via death domain receptors'}, {'category': 'process', 'description': 'glucose metabolic process'}, {'category': 'process', 'description': 'humoral immune response'}, {'category': 'process', 'description': 'I-kappaB kinase/NF-kappaB signaling'}, {'category': 'process', 'description': 'inflammatory response'}, {'category': 'process', 'description': 'intrinsic apoptotic signaling pathway in response to DNA damage'}, {'category': 'process', 'description': 'JNK cascade'}, {'category': 'process', 'description': 'leukocyte tethering or rolling'}, {'category': 'process', 'description': 'lipopolysaccharide-mediated signaling pathway'}, {'category': 'process', 'description': 'MAPK cascade'}, {'category': 'process', 'description': 'necroptotic signaling pathway'}, {'category': 'process', 'description': 'negative regulation of alkaline phosphatase activity'}, {'category': 'process', 'description': 'negative regulation of bicellular tight junction assembly'}, {'category': 'process', 'description': 'negative regulation of branching involved in lung morphogenesis'}, {'category': 'process', 'description': 'negative regulation of cytokine secretion involved in immune response'}, {'category': 'process', 'description': 'negative regulation of extrinsic apoptotic signaling pathway in absence of ligand'}, {'category': 'process', 'description': 'negative regulation of fat cell differentiation'}, {'category': 'process', 'description': 'negative regulation of gene expression'}, {'category': 'process', 'description': 'negative regulation of glucose import'}, {'category': 'process', 'description': 'negative regulation of growth of symbiont in host'}, {'category': 'process', 'description': 'negative regulation of interleukin-6 production'}, {'category': 'process', 'description': 'negative regulation of lipid catabolic process'}, {'category': 'process', 'description': 'negative regulation of lipid storage'}, {'category': 'process', 'description': 'negative regulation of myoblast differentiation'}, {'category': 'process', 'description': 'negative regulation of myosin-light-chain-phosphatase activity'}, {'category': 'process', 'description': 'negative regulation of osteoblast differentiation'}, {'category': 'process', 'description': 'negative regulation of protein complex disassembly'}, {'category': 'process', 'description': 'negative regulation of transcription from RNA polymerase II promoter'}, {'category': 'process', 'description': 'negative regulation of transcription, DNA-templated'}, {'category': 'process', 'description': 'negative regulation of viral genome replication'}, {'category': 'process', 'description': 'osteoclast differentiation'}, {'category': 'process', 'description': 'positive regulation of apoptotic process'}, {'category': 'process', 'description': 'positive regulation of calcidiol 1-monooxygenase activity'}, {'category': 'process', 'description': 'positive regulation of cell adhesion'}, {'category': 'process', 'description': 'positive regulation of ceramide biosynthetic process'}, {'category': 'process', 'description': 'positive regulation of chemokine (C-X-C motif) ligand 2 production'}, {'category': 'process', 'description': 'positive regulation of chemokine biosynthetic process'}, {'category': 'process', 'description': 'positive regulation of chemokine production'}, {'category': 'process', 'description': 'positive regulation of chronic inflammatory response to antigenic stimulus'}, {'category': 'process', 'description': 'positive regulation of cysteine-type endopeptidase activity involved in apoptotic process'}, {'category': 'process', 'description': 'positive regulation of cytokine production'}, {'category': 'process', 'description': 'positive regulation of cytokine secretion'}, {'category': 'process', 'description': 'positive regulation of ERK1 and ERK2 cascade'}, {'category': 'process', 'description': 'positive regulation of fever generation'}, {'category': 'process', 'description': 'positive regulation of gene expression'}, {'category': 'process', 'description': 'positive regulation of hair follicle development'}, {'category': 'process', 'description': 'positive regulation of heterotypic cell-cell adhesion'}, {'category': 'process', 'description': 'positive regulation of humoral immune response mediated by circulating immunoglobulin'}, {'category': 'process', 'description': 'positive regulation of I-kappaB kinase/NF-kappaB signaling'}, {'category': 'process', 'description': 'positive regulation of interferon-gamma production'}, {'category': 'process', 'description': 'positive regulation of interleukin-6 production'}, {'category': 'process', 'description': 'positive regulation of interleukin-8 biosynthetic process'}, {'category': 'process', 'description': 'positive regulation of interleukin-8 production'}, {'category': 'process', 'description': 'positive regulation of JUN kinase activity'}, {'category': 'process', 'description': 'positive regulation of MAP kinase activity'}, {'category': 'process', 'description': 'positive regulation of membrane protein ectodomain proteolysis'}, {'category': 'process', 'description': 'positive regulation of mononuclear cell migration'}, {'category': 'process', 'description': 'positive regulation of NF-kappaB import into nucleus'}, {'category': 'process', 'description': 'positive regulation of NF-kappaB transcription factor activity'}, {'category': 'process', 'description': 'positive regulation of NFAT protein import into nucleus'}, {'category': 'process', 'description': 'positive regulation of NIK/NF-kappaB signaling'}, {'category': 'process', 'description': 'positive regulation of nitric oxide biosynthetic process'}, {'category': 'process', 'description': 'positive regulation of osteoclast differentiation'}, {'category': 'process', 'description': 'positive regulation of peptidyl-serine phosphorylation'}, {'category': 'process', 'description': 'positive regulation of phagocytosis'}, {'category': 'process', 'description': 'positive regulation of podosome assembly'}, {'category': 'process', 'description': 'positive regulation of programmed cell death'}, {'category': 'process', 'description': 'positive regulation of protein complex assembly'}, {'category': 'process', 'description': 'positive regulation of protein complex disassembly'}, {'category': 'process', 'description': 'positive regulation of protein kinase activity'}, {'category': 'process', 'description': 'positive regulation of protein kinase B signaling'}, {'category': 'process', 'description': 'positive regulation of protein localization to cell surface'}, {'category': 'process', 'description': 'positive regulation of protein phosphorylation'}, {'category': 'process', 'description': 'positive regulation of protein transport'}, {'category': 'process', 'description': 'positive regulation of sequence-specific DNA binding transcription factor activity'}, {'category': 'process', 'description': 'positive regulation of smooth muscle cell proliferation'}, {'category': 'process', 'description': 'positive regulation of transcription from RNA polymerase II promoter'}, {'category': 'process', 'description': 'positive regulation of transcription, DNA-templated'}, {'category': 'process', 'description': 'positive regulation of translational initiation by iron'}, {'category': 'process', 'description': 'positive regulation of vitamin D biosynthetic process'}, {'category': 'process', 'description': 'protein import into nucleus, translocation'}, {'category': 'process', 'description': 'protein kinase B signaling'}, {'category': 'process', 'description': 'receptor biosynthetic process'}, {'category': 'process', 'description': 'regulation of branching involved in salivary gland morphogenesis'}, {'category': 'process', 'description': 'regulation of establishment of endothelial barrier'}, {'category': 'process', 'description': 'regulation of I-kappaB kinase/NF-kappaB signaling'}, {'category': 'process', 'description': 'regulation of immunoglobulin secretion'}, {'category': 'process', 'description': 'regulation of insulin secretion'}, {'category': 'process', 'description': 'regulation of tumor necrosis factor-mediated signaling pathway'}, {'category': 'process', 'description': 'response to glucocorticoid'}, {'category': 'process', 'description': 'response to salt stress'}, {'category': 'process', 'description': 'response to virus'}, {'category': 'process', 'description': 'sequestering of triglyceride'}, {'category': 'process', 'description': 'transformed cell apoptotic process'}, {'category': 'process', 'description': 'tumor necrosis factor-mediated signaling pathway'}]}}}, {'@position': '2', 'id': 'BE0001087', 'name': 'Lymphotoxin-alpha', 'organism': 'Humans', 'actions': {'action': 'antibody'}, 'references': {'articles': {'article': [{'ref-id': 'A11581', 'pubmed-id': '11302411', 'citation': 'Johnson CJ, Reilly KM, Murray KM: Etanercept in juvenile rheumatoid arthritis. Ann Pharmacother. 2001 Apr;35(4):464-71.'}, {'ref-id': 'A11583', 'pubmed-id': '15005015', 'citation': 'Gudbrandsdottir S, Larsen R, Sorensen LK, Nielsen S, Hansen MB, Svenson M, Bendtzen K, Muller K: TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004 Jan-Feb;22(1):118-24.'}, {'ref-id': 'A11584', 'pubmed-id': '15033655', 'citation': 'Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P: True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis. 2004 Oct;63(10):1344-6. Epub 2004 Mar 19.'}]}, 'textbooks': None, 'links': {'link': {'ref-id': 'L4237', 'title': 'Enbrel (Etanercept) FDA Label', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103795s5503lbl.pdf'}}, 'attachments': None}, 'known-action': 'yes', 'polypeptide': {'@id': 'P01374', '@source': 'Swiss-Prot', 'name': 'Lymphotoxin-alpha', 'general-function': 'Receptor binding', 'specific-function': 'Cytokine that in its homotrimeric form binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM. In its heterotrimeric form with LTB binds to TNFRSF3/LTBR. Lymphotoxin is produced by lymphocytes and cytotoxic for a wide range of tumor cells in vitro and in vivo.', 'gene-name': 'LTA', 'locus': '6p21.3', 'cellular-location': 'Secreted', 'transmembrane-regions': None, 'signal-regions': '1-34', 'theoretical-pi': '9.36', 'molecular-weight': '22296.57', 'chromosome-location': '6', 'organism': {'@ncbi-taxonomy-id': '9606', '#text': 'Humans'}, 'external-identifiers': {'external-identifier': [{'resource': 'HUGO Gene Nomenclature Committee (HGNC)', 'identifier': 'HGNC:6709'}, {'resource': 'GenAtlas', 'identifier': 'LTA'}, {'resource': 'GenBank Gene Database', 'identifier': 'X01393'}, {'resource': 'GenBank Protein Database', 'identifier': '34445'}, {'resource': 'UniProtKB', 'identifier': 'P01374'}, {'resource': 'UniProt Accession', 'identifier': 'TNFB_HUMAN'}]}, 'synonyms': {'synonym': ['LT-alpha', 'TNF-beta', 'TNFB', 'TNFSF1', 'Tumor necrosis factor ligand superfamily member 1']}, 'amino-acid-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0010761|Lymphotoxin-alpha\\nMTPPERLFLPRVCGTTLHLLLLGLLLVLLPGAQGLPGVGLTPSAAQTARQHPKMHLAHST\\nLKPAAHLIGDPSKQNSLLWRANTDRAFLQDGFSLSNNSLLVPTSGIYFVYSQVVFSGKAY\\nSPKATSSPLYLAHEVQLFSSQYPFHVPLLSSQKMVYPGLQEPWLHSMYHGAAFQLTQGDQ\\nLSTHTDGIPHLVLSPSTVFFGAFAL'}, 'gene-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0010762|Lymphotoxin-alpha (LTA)\\nATGACACCACCTGAACGTCTCTTCCTCCCAAGGGTGTGTGGCACCACCCTACACCTCCTC\\nCTTCTGGGGCTGCTGCTGGTTCTGCTGCCTGGGGCCCAGGGGCTCCCTGGTGTTGGCCTC\\nACACCTTCAGCTGCCCAGACTGCCCGTCAGCACCCCAAGATGCATCTTGCCCACAGCACC\\nCTCAAACCTGCTGCTCACCTCATTGGAGACCCCAGCAAGCAGAACTCACTGCTCTGGAGA\\nGCAAACACGGACCGTGCCTTCCTCCAGGATGGTTTCTCCTTGAGCAACAATTCTCTCCTG\\nGTCCCCACCAGTGGCATCTACTTCGTCTACTCCCAGGTGGTCTTCTCTGGGAAAGCCTAC\\nTCTCCCAAGGCCACCTCCTCCCCACTCTACCTGGCCCATGAGGTCCAGCTCTTCTCCTCC\\nCAGTACCCCTTCCATGTGCCTCTCCTCAGCTCCCAGAAGATGGTGTATCCAGGGCTGCAG\\nGAACCCTGGCTGCACTCGATGTACCACGGGGCTGCGTTCCAGCTCACCCAGGGAGACCAG\\nCTATCCACCCACACAGATGGCATCCCCCACCTAGTCCTCAGCCCTAGTACTGTCTTCTTT\\nGGAGCCTTCGCTCTGTAG'}, 'pfams': {'pfam': {'identifier': 'PF00229', 'name': 'TNF'}}, 'go-classifiers': {'go-classifier': [{'category': 'component', 'description': 'extracellular space'}, {'category': 'component', 'description': 'plasma membrane'}, {'category': 'function', 'description': 'receptor binding'}, {'category': 'process', 'description': 'apoptotic process'}, {'category': 'process', 'description': 'cell-cell signaling'}, {'category': 'process', 'description': 'defense response to Gram-positive bacterium'}, {'category': 'process', 'description': 'humoral immune response'}, {'category': 'process', 'description': 'lymph node development'}, {'category': 'process', 'description': 'negative regulation of fibroblast proliferation'}, {'category': 'process', 'description': 'negative regulation of growth of symbiont in host'}, {'category': 'process', 'description': 'positive regulation of apoptotic process'}, {'category': 'process', 'description': 'positive regulation of chronic inflammatory response to antigenic stimulus'}, {'category': 'process', 'description': 'positive regulation of glial cell proliferation'}, {'category': 'process', 'description': 'positive regulation of humoral immune response mediated by circulating immunoglobulin'}, {'category': 'process', 'description': 'positive regulation of interferon-gamma production'}, {'category': 'process', 'description': 'response to drug'}, {'category': 'process', 'description': 'response to hypoxia'}, {'category': 'process', 'description': 'response to lipopolysaccharide'}, {'category': 'process', 'description': 'response to nutrient'}, {'category': 'process', 'description': 'signal transduction'}, {'category': 'process', 'description': 'tumor necrosis factor-mediated signaling pathway'}]}}}, {'@position': '3', 'id': 'BE0000710', 'name': 'High affinity immunoglobulin gamma Fc receptor I', 'organism': 'Humans', 'actions': {'action': 'ligand'}, 'references': {'articles': {'article': [{'ref-id': 'A202010', 'pubmed-id': '27463856', 'citation': 'Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.'}, {'ref-id': 'A203909', 'pubmed-id': '19128982', 'citation': 'Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.'}]}, 'textbooks': None, 'links': None, 'attachments': None}, 'known-action': 'unknown', 'polypeptide': {'@id': 'P12314', '@source': 'Swiss-Prot', 'name': 'High affinity immunoglobulin gamma Fc receptor I', 'general-function': 'Receptor signaling protein activity', 'specific-function': 'High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.', 'gene-name': 'FCGR1A', 'locus': '1q21.2-q21.3', 'cellular-location': 'Cell membrane', 'transmembrane-regions': '293-313', 'signal-regions': '1-15', 'theoretical-pi': '8.08', 'molecular-weight': '42631.525', 'chromosome-location': '1', 'organism': {'@ncbi-taxonomy-id': '9606', '#text': 'Humans'}, 'external-identifiers': {'external-identifier': [{'resource': 'HUGO Gene Nomenclature Committee (HGNC)', 'identifier': 'HGNC:3613'}, {'resource': 'GenAtlas', 'identifier': 'FCGR1A'}, {'resource': 'GenBank Gene Database', 'identifier': 'X14356'}, {'resource': 'GenBank Protein Database', 'identifier': '31332'}, {'resource': 'UniProtKB', 'identifier': 'P12314'}, {'resource': 'UniProt Accession', 'identifier': 'FCGR1_HUMAN'}]}, 'synonyms': {'synonym': ['Fc-gamma RI', 'Fc-gamma RIA', 'FCG1', 'FcgammaRIa', 'FCGR1', 'FcRI', 'IGFR1', 'IgG Fc receptor I']}, 'amino-acid-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I\\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\\nLQEGVHRKEPQGAT'}, 'gene-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)\\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\\nAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC\\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG'}, 'pfams': {'pfam': [{'identifier': 'PF00047', 'name': 'ig'}, {'identifier': 'PF13895', 'name': 'Ig_2'}]}, 'go-classifiers': {'go-classifier': [{'category': 'component', 'description': 'clathrin-coated endocytic vesicle membrane'}, {'category': 'component', 'description': 'early endosome membrane'}, {'category': 'component', 'description': 'integral component of membrane'}, {'category': 'component', 'description': 'plasma membrane'}, {'category': 'function', 'description': 'receptor signaling protein activity'}, {'category': 'process', 'description': 'antigen processing and presentation of exogenous peptide antigen via MHC class I'}, {'category': 'process', 'description': 'antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent'}, {'category': 'process', 'description': 'antigen processing and presentation of peptide antigen via MHC class I'}, {'category': 'process', 'description': 'cytokine-mediated signaling pathway'}, {'category': 'process', 'description': 'Fc-gamma receptor signaling pathway involved in phagocytosis'}, {'category': 'process', 'description': 'immune response'}, {'category': 'process', 'description': 'innate immune response'}, {'category': 'process', 'description': 'interferon-gamma-mediated signaling pathway'}, {'category': 'process', 'description': 'intracellular signal transduction'}, {'category': 'process', 'description': 'phagocytosis, engulfment'}, {'category': 'process', 'description': 'regulation of immune response'}, {'category': 'process', 'description': 'signal transduction'}]}}}, {'@position': '4', 'id': 'BE0002098', 'name': 'Low affinity immunoglobulin gamma Fc region receptor II-a', 'organism': 'Humans', 'actions': {'action': 'ligand'}, 'references': {'articles': {'article': [{'ref-id': 'A13085', 'pubmed-id': '15457442', 'citation': 'Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6.'}, {'ref-id': 'A13086', 'pubmed-id': '15526004', 'citation': 'Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7.'}, {'ref-id': 'A202010', 'pubmed-id': '27463856', 'citation': 'Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.'}, {'ref-id': 'A203909', 'pubmed-id': '19128982', 'citation': 'Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.'}]}, 'textbooks': None, 'links': None, 'attachments': None}, 'known-action': 'unknown', 'polypeptide': {'@id': 'P12318', '@source': 'Swiss-Prot', 'name': 'Low affinity immunoglobulin gamma Fc region receptor II-a', 'general-function': None, 'specific-function': 'Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.', 'gene-name': 'FCGR2A', 'locus': '1q23', 'cellular-location': 'Cell membrane', 'transmembrane-regions': '218-240', 'signal-regions': '1-33', 'theoretical-pi': '6.78', 'molecular-weight': '35000.42', 'chromosome-location': '1', 'organism': {'@ncbi-taxonomy-id': '9606', '#text': 'Humans'}, 'external-identifiers': {'external-identifier': [{'resource': 'HUGO Gene Nomenclature Committee (HGNC)', 'identifier': 'HGNC:3616'}, {'resource': 'GenAtlas', 'identifier': 'FCGR2A'}, {'resource': 'GenBank Gene Database', 'identifier': 'M31932'}, {'resource': 'GenBank Protein Database', 'identifier': '182474'}, {'resource': 'UniProtKB', 'identifier': 'P12318'}, {'resource': 'UniProt Accession', 'identifier': 'FCG2A_HUMAN'}]}, 'synonyms': {'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-a', 'Fc-gamma-RIIa', 'FCG2', 'FCGR2A1', 'FcRII-a', 'IGFR2', 'IgG Fc receptor II-a']}, 'amino-acid-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0037156|Low affinity immunoglobulin gamma Fc region receptor II-a\\nMTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHS\\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\\nKNIYLTLPPNDHVNSNN'}, 'gene-sequence': {'@format': 'FASTA', '#text': '>lcl|BSEQ0019233|Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)\\nATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\\nAAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA'}, 'pfams': {'pfam': {'identifier': 'PF13895', 'name': 'Ig_2'}}, 'go-classifiers': {'go-classifier': [{'category': 'component', 'description': 'extracellular exosome'}, {'category': 'component', 'description': 'integral component of membrane'}, {'category': 'component', 'description': 'plasma membrane'}, {'category': 'process', 'description': 'Fc-gamma receptor signaling pathway involved in phagocytosis'}, {'category': 'process', 'description': 'innate immune response'}]}}}, {'@position': '5', 'id': 'BE0002099', 'name': 'Low affinity immunoglobulin gamma Fc region receptor II-b', 'organism': 'Humans', 'actions': {'action': 'ligand'}, 'references': {'articles': {'article': [{'ref-id': 'A202010', 'pubmed-id': '27463856', 'citation': 'Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.'}, {'ref-id': 'A203909', 'pubmed-id': '19128982', 'citation': 'Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens\n",
      "Name: targets, dtype: object\n",
      "0    NaN\n",
      "1    NaN\n",
      "2    NaN\n",
      "3    NaN\n",
      "4    NaN\n",
      "Name: enzymes, dtype: object\n",
      "0    NaN\n",
      "1    NaN\n",
      "2    NaN\n",
      "3    NaN\n",
      "4    NaN\n",
      "Name: carriers, dtype: object\n",
      "0    NaN\n",
      "1    NaN\n",
      "2    NaN\n",
      "3    NaN\n",
      "4    NaN\n",
      "Name: transporters, dtype: object\n",
      "0                                                                        NaN\n",
      "1    //s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00002.pdf?1265922813\n",
      "2    //s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00003.pdf?1410715221\n",
      "3    //s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00004.pdf?1265922800\n",
      "4                                                                        NaN\n",
      "Name: fda-label, dtype: object\n",
      "0                                                                  NaN\n",
      "1    //s3-us-west-2.amazonaws.com/drugbank/msds/DB00002.pdf?1458412933\n",
      "2    //s3-us-west-2.amazonaws.com/drugbank/msds/DB00003.pdf?1410714694\n",
      "3                                                                  NaN\n",
      "4                                                                  NaN\n",
      "Name: msds, dtype: object\n",
      "0   NaN\n",
      "1   NaN\n",
      "2   NaN\n",
      "3   NaN\n",
      "4   NaN\n",
      "Name: average-mass, dtype: float64\n",
      "0   NaN\n",
      "1   NaN\n",
      "2   NaN\n",
      "3   NaN\n",
      "4   NaN\n",
      "Name: monoisotopic-mass, dtype: float64\n",
      "0    NaN\n",
      "1    NaN\n",
      "2    NaN\n",
      "3    NaN\n",
      "4    NaN\n",
      "Name: calculated-properties, dtype: object\n"
     ]
    }
   ],
   "execution_count": 7
  },
  {
   "metadata": {},
   "cell_type": "code",
   "outputs": [],
   "execution_count": null,
   "source": "",
   "id": "cf6b5826289594e"
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
